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ABSTRACT 
Cancer is one of the most serious global diseases. We have focused on 
cancer immunoprevention. My thesis projects include developing a prophylactic 
primary and metastatic cancer vaccines, early cancer detection and investigation 
of genes involved in tumor development. These studies were focused on frame-
shift (FS) antigens. The FS antigens are generated by genomic mutations or 
abnormal RNA processing, which cause a portion of a normal protein to be 
translated out of frame. 
The concept of the prophylactic cancer vaccine is to develop a general 
cancer vaccine that could prevent healthy people from developing different types 
of cancer. We have discovered a set of cancer specific FS antigens. One of the FS 
candidates, structural maintenance of chromosomes protein 1A (SMC1A) FS, 
could start to accumulate at early stages of tumor and be specifically exposed to 
the immune system by tumor cells. Prophylactic immunization with SMC1A-FS 
could significantly inhibit primary tumor development in different murine tumor 
models and also has the potential to inhibit tumor metastasis.  
The SMC1A-FS transcript was detected in the plasma of the 4T1/BALB/c 
mouse tumor model. The tumor size was correlated with the transcript ratio of the 
SMC1A-FS verses the WT in plasma, which could be measured by regular RT-
PCR. This unique cancer biomarker has a practical potential for a large population 
cancer screen, as well as clinical tumor monitoring.  
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With a set of mimotope peptides, antibodies against SMC1A-FS peptide 
were detected in different cancer patients, including breast cancer, pancreas 
cancer and lung cancer with a 53.8%, 56.5% and 12.5% positive rate respectively. 
This suggested that the FS antibody could be a biomarker for early cancer 
detection. 
The characterization of SMC1A suggested that: First, the deficiency of the 
SMC1A is common in different tumors and able to promote tumor initiation and 
development; second, the FS truncated protein may have nucleolus function in 
normal cells. Mis-control of this protein may promote tumor development.  
In summary, we developed a systematic general cancer prevention strategy 
through the variety immunological and molecular methods. The results gathered 
suggest the SMC1A-FS may be useful for the detection and prevention of cancer.  
         
 
 
 
 
 
 
 
 
 
 
iii
ACKNOWLEDGEMENTS 
This thesis is a summary of my research life as a Ph.D student, which is an 
unforgettable experience for me. After finished all of the scientific writings, it is 
really a pleasure to express my thanks to all people those support me over the 
seven years and made this thesis possible.  
First of all, I would like to thank my advisor, Dr. Stephen Albert Johnston. 
The major projector of my thesis, prophylactic cancer vaccine development, was 
decided at the first time I met with Dr. Johnston face to face at August, 2005. 
Ever since, he has supported me on my research with his patience, ambitions and 
brilliant and innovative suggestions through the rough road to finish this thesis 
and will continuously support my post doctoral research. The most important 
training I learned during these seven years from Dr. Johnston is how to be an 
innovative scientist.  
I would also like to acknowledge my committee: Dr. Yung Chang, Dr. 
Bertram Jacobs, Dr. Laurence Miller and Dr. Kathryn Sykes, for their insightful 
comments and encouragement of all these years. I’d like to thank Dr. Laurence 
Miller for his kindly offering primary tumor samples for the prophylactic cancer 
vaccine project. I also really appreciate to Dr. Kathryn Sykes for her lots of 
detailed suggestions on my studies. She is always welcome to my questions.  
It is my pleasure to work with the prophylactic cancer vaccine project 
team in the Center for Innovations in Medicine in Biodesign Institute at ASU. I’d 
like to thank them for their effort on the project and help with my study: Dr. Jose 
 
iv
Cano Buendia, Dr. Tricia Carrigan, Felicia Craciunescu, Kristen Day, Hu Duan, 
Dr. Douglas Lake, Dr. Hojoon Lee, Danielle Lussier, Kari Kotlarczyk, Dr. Cheryl 
Myers, Dr. John-Charles Rodenberry, Yvette Ruiz and Kurt Whittemore. I also 
want to thank administrators in CIM: Pattie Madjidi, Penny Gwynne, Preston 
Hunter and Kevin Brown. Especially, I want to thank Kurt and Danielle for their 
help with my thesis writing.  
At last, I really want to thank my family. My parents and parents in law 
supported me in every aspect of my life. I also want to thank my wife, Yang Xue, 
for supporting my research and taking care everyone in the family all these years. 
Of course, I want to thank my daughter, Elly Mijia Shen. She was always quiet 
when I was writing. 
 
 
 
 
 
 
 
 
 
 
 
 
v
TABLE OF CONTENTS 
                                                                                                                           Page 
LIST OF TABLE ................................................................................................... xi 
LIST OF FIGUES................................................................................................. xii 
CHAPTER 
1 INTRODUCTION ............................................................................................... 1 
1.1 Cancer Statistics............................................................................................ 1 
1.2 Cancer treatment ........................................................................................... 2 
1.3 Cancer Prevention......................................................................................... 5 
1.4 Dynamic Interaction between immune system and tumor............................ 6 
1.4.1 Cancer Immune Surveillance ................................................................. 6 
1.4.2 Cancer Immune Evolving ...................................................................... 8 
1.4.2.1 Cancer Immune Escape................................................................... 9 
1.4.2.2 Cancer Immune Suppression ........................................................ 10 
1.5 Limitations of Current Therapeutic Cancer Vaccine.................................. 16 
1.6 Cancer Immunoprevention ......................................................................... 21 
1.7 Prophylactic Cancer Vaccine...................................................................... 22 
1.7.1 Introduction.......................................................................................... 22 
1.7.2 Advantages in Eliciting Efficient Immune Response .......................... 24 
1.7.3 Disadvantages of Autoimmune Disease Risk ...................................... 27 
1.7.4 Discussion of strategy for prophylactic cancer vaccine development . 28 
 
 
 
vi
CHAPTER                                                                                                          Page 
1.7.5 Prophylactic cancer vaccine and metastasis cancer vaccine based on the 
Frame Shifted antigens ................................................................................. 32 
1.8 Preventing tumor development by innate stimulation of the immune system
.......................................................................................................................... 41 
1.9 Cancer Detection......................................................................................... 45 
2 PROPHYLACTIC CANCER VACCINE DEVELOPMENT........................... 48 
2.1 Introduction................................................................................................. 48 
2.2 Results......................................................................................................... 51 
2.2.1Detection of SMC1A FS....................................................................... 51 
2.2.1.1 Detection of SMC1A FS transcript............................................... 51 
2.2.1.2 Analysis of SMC1A gene in Panc1 cell line................................. 56 
2.2.1.3 Detection of the immune response to SMC1A FS peptide in tumor 
bearing mice.............................................................................................. 57 
2.2.2 Protection of immunization of SMC1A FS in mouse tumor models... 60 
2.2.2.1 Epitope prediction......................................................................... 60 
2.2.2.2 Optimization of Immunization...................................................... 61 
2.2.2.3 Evaluation of primary tumor prevention....................................... 77 
2.2.3 Prevention of tumor development by innate stimulations of the immune 
response......................................................................................................... 99 
2.3 Materials and Methods.............................................................................. 102 
2.3.1 Mice ................................................................................................... 102 
 
vii
CHAPTER                                                                                                          Page 
2.3.2 Cell lines. ........................................................................................... 103 
2.3.3 Tumor samples and cDNAs samples ................................................. 103 
2.3.4 RT-PCR.............................................................................................. 103 
2.3.5 Quantitative PCR ............................................................................... 104 
2.3.6 ELISA ................................................................................................ 104 
2.3.7 IFN-γ ELISPOT ................................................................................. 105 
2.3.8 Genetic Immunization........................................................................ 105 
2.3.9 4T1 lung metastasis assay.................................................................. 107 
2.4 Discussion................................................................................................. 108 
3 CANCER DETECTION.................................................................................. 118 
3.1 Introduction............................................................................................... 118 
3.2 FS antibody as cancer biomarker.............................................................. 118 
3.2.1 Introduction........................................................................................ 118 
3.2.2 Results................................................................................................ 121 
3.2.2.1 Screen the mimotope of the SMC1A FS peptide........................ 121 
3.2.2.2 Validation of the mimotopes....................................................... 124 
3.2.2.3 Screen cancer patient serum with the mimotopes....................... 126 
3.2.3 Discussion .......................................................................................... 130 
3.3 Circulating FS transcript as cancer biomarker.......................................... 134 
3.3.1 Introduction........................................................................................ 134 
3.3.2 Result ................................................................................................. 136 
 
viii
CHAPTER                                                                                                          Page 
3.3.2.1 Discover the SMC1A WT and FS transcript in tumor bearing mice 
and healthy mice ..................................................................................... 136 
3.3.2.2 Correlation between tumor size and ratio of the WT and FS 
transcript by regular RT-PCR of the circulating RNA ........................... 138 
3.3.3 Discussion .......................................................................................... 140 
3.4 Materials and Methods.............................................................................. 143 
3.4.1 Rabbit SMC1fs Serum ....................................................................... 143 
3.4.2 Antibody absorption........................................................................... 143 
3.4.3 Random peptide array printing .......................................................... 144 
3.4.4 Customized peptide array .................................................................. 145 
3.4.5 Application of serum to random peptide array .................................. 145 
3.4.6 Scanning and analysis of array .......................................................... 145 
3.4.7 Antibody purification......................................................................... 145 
3.4.8 Human serum samples ....................................................................... 146 
3.4.9 Circulating RNA extraction and RT-PCR ......................................... 146 
3.4.10 Gel electrophoresis and quantifing the intensity of the PCR products
..................................................................................................................... 147 
4 SMC1A AND TUMORIGENICITY............................................................... 148 
4.1 Introduction............................................................................................... 148 
4.2 Result ........................................................................................................ 153 
 
 
ix
CHAPTER                                                                                                          Page 
4.2.1 Detection of the alternative splicing of SMC1A in tumor ................. 153 
4.2.2 The SMC1A WT is down regulated and the FS is up regulated in 
pancreatic tumors ........................................................................................ 155 
4.2.3 Transient knock down of the expression of the WT SMC1A could not 
induce the tumorigenicity of the HPED6 cell. ............................................ 156 
4.2.5 Detection of the SMC1A FS truncated protein.................................. 160 
4.2.6 The truncated protein encoded by the SMC1A FS transcript is located 
in the nucleolus ........................................................................................... 167 
4.2.7 Evolutionary evidence of the truncated SMC1A FS protein may have 
function in normal cells .............................................................................. 170 
4.3 Materials and Methods.............................................................................. 173 
4.3.1 Quantitative PCR ............................................................................... 173 
4.3.2 siRNA assay....................................................................................... 173 
4.3.3 shRNA assay...................................................................................... 174 
4.3.4 Anchorage independent growth assay................................................ 175 
4.3.5 Enzymatic deglycolyzation assay ...................................................... 176 
4.3.4 Chemical Deglycosylation with Trifluoromethanesulfonic Acid 
(TFMS) ....................................................................................................... 176 
4.4 Discussion................................................................................................. 176 
5 SUMMARY..................................................................................................... 181 
 
 
 
x
                                                                                                                            Page 
REFERENCES ................................................................................................... 186 
APPENDIX                                                                                                        
APPENDIX 1 FS ANTIGEN DISCOVERY BY PROTEOMICS ANALYSIS 210 
APPENDIX 2 RT-PCR ANALYSIS OF FS TRANSCRIPTS........................... 215 
APPENDIX 3 INSTITUTIONAL REVIEW BOARD (IRB) ............................ 220 
APPENDIX 4 INSTITUTIONAL ANIMAL CARE & USE COMMITTEE .... 228 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi
LIST OF TABLE 
Table                                                                                                                   Page 
1. 1 Alignment of mouse and human SMC1A exon 4.. ........................................ 52 
3. 1 Screen cancer patient’s sera.. ....................................................................... 127 
3. 2 MHC II epitope prediction of human SMC1A FS peptide and mimotopes. 129 
3. 3 HLA-A*02:01 epitope prediction of human SMC1A FS peptide and 
mimotopes................................................................................................... 130 
4. 1 Conservation analysis of the SMC1A DNA sequence ................................ 170 
4. 2 Conservation analysis of peptides encoded by different reading frames the 
SMC1A DNA fragments............................................................................. 173 
AP1. 1 FS peptides identify from LC/MS analysis of CRLC of 12B1 cell ........ 213 
AP1. 2 T cell epitope prediction of three FS peptides ........................................ 214 
 
 
 
 
 
 
 
 
 
 
 
xii
LIST OF FIGUES 
Figure                                                                                                                 Page 
1. 1 Model of FS antigen presentation during tumor development ...................... 37 
1. 2 Strategy of prophylactic cancer vaccine based on FS antigens ..................... 39 
1. 3 Strategy of prophylactic cancer metastasis vaccine....................................... 40 
1. 4 Strategy of innate stimulation to prevent tumor development....................... 43 
2. 1 SMC1A WT and FS....................................................................................... 51 
2. 2  RT-PCR and Q-PCR analysis of SMC1A transcript in human primary brease 
tumors and normal mammary glands............................................................ 54 
2. 3  RT-PCR analysis of SMC1A FS transcript in mouse normal tissues and 
tumors. .......................................................................................................... 55 
2. 4  RT-PCR analysis of SMC1A FS transcript in dog primary tumors and 
normal tissues................................................................................................ 55 
2. 5 RT-PCR analysis of SMC1A FS transcript in normal mammary gland and 
breast tumors of FVB/N-NeuT ..................................................................... 56 
2. 6  Analysis of SMC1A gene in Panc 1 tumor cell line. .................................... 57 
2. 7  ELISA analysis of IgG activity to mouse SMC1A FS 27aa......................... 59 
2. 8  ELISPOT analysis of IFN-gamma release splenocytes. .............................. 59 
2. 9  Dosage optimization of FS antigen............................................................... 65 
2. 10  Comparing different immunization regimen. ............................................. 66 
2. 11  Optimization of SMC1A FS antigen........................................................... 67 
2. 12  Optimization of genetic adjuvant................................................................ 68 
 
xiii
Figure                                                                                                                 Page 
2. 13  ELISA analysis of IgG activity against SMC1 FS 17mer peptide in mice 
immunized SMC1 FS with different adjuvants. ........................................... 69 
2. 14  Experimental plan for immunization optimization. .................................... 69 
2. 15  Individual tumor volume at 13 days after tumor inoculation. .................... 70 
2. 16  ELISA analysis of IgG subtype activity against SMC1A FS peptide of 
pooled endpoint serum of each group........................................................... 72 
2. 17  ELISPOT analysis of IFN-gamma release splenocytes. ............................. 72 
2. 18  Detail of experimental plan for adjuvant optimization. .............................. 73 
2. 19  ELISA analysis of IgG subtype activity against SMC1A FS 27mer. ......... 74 
2. 20  Detail subtype IgG analysis against SMC1A FS 27mer of two groups...... 74 
2. 21 Summarize of IFN-gamma release splenocyte ELISPOT analysis of SMC1A 
FS and CPV172 immunization with different regimens............................... 75 
2. 22  Detail experimental plan for protection evaluation of FS antigens in 
B16F10/C57BL6 mouse melanoma tumor model ........................................ 78 
2. 23  Tumor size measurement. ........................................................................... 78 
2. 24  Detail experimental plan for protection evaluation of FS antigens in 
4T1/BALB/c mouse breast tumor model...................................................... 79 
2. 25  Protection analysis of 4T1/BALB/c mouse breast tumor model. .............. 80 
2. 26  Detail experimental plan for protection evaluation of FS antigens in 
4T1/BALB/c mouse breast tumor model...................................................... 81 
 
 
 
xiv
Figure                                                                                                                 Page 
2. 27  Tumor growth curve of each group ............................................................ 81 
2. 28  Detail experimental plan for protection evaluation of FS antigens in 
FVB/N-NeuT mouse breast tumor model..................................................... 83 
2. 29  Tumor free curve of different group in FVB/N-NeuT model..................... 84 
2. 30  Tumor multiplicity curve of different groups of FVB/N-NeuT model....... 84 
2. 31  Detail experimental plan for immunization regimen optimization of 
SMC1A FS in BALB-NeuT mouse breast tumor model .............................. 85 
2. 32  Tumor multiplicity curve of different groups with different immunization 
regimens........................................................................................................ 86 
2. 33  Detail experimental plan for immunization regimen optimization of 
SMC1A FS in BALB-NeuT mouse breast tumor model with CpG plus B2L 
as adjuvant .................................................................................................... 86 
2. 34  Tumor multiplicity curve of SMC1A group and CPV172 group with CpG 
plus B2L as adjuvant..................................................................................... 87 
2. 35  Detail experimental plan for protection evaluation of SMC1A FS in BALB-
NeuT mouse breast tumor model.................................................................. 88 
2. 36  Tumor development in different immunization groups.. ............................ 88 
2. 37  Tumor multiplicity curve of SMC1A group, negative group and no-treated 
group in BALB-NeuT model ........................................................................ 89 
2. 38  ELISPOT analysis of IFN-gamma release splenocyte in SMC1A 
immunized mice............................................................................................ 90 
 
 
xv
Figure                                                                                                                 Page 
2. 39  ELISA analysis of subtype IgG activity to SMC1A FS 27mer in SMC1A 
FS immunized mice (11mice). ...................................................................... 90 
2. 40  Correlation analysis of tumor progression time and IgG activity............... 91 
2. 41  Detail experimental plan for additive protection of FS antigens in 
B16F10/C57BL6 mouse melanoma tumor model ........................................ 92 
2. 42  Tumor growth curve of different groups .................................................... 92 
2. 43  Detail experimental plan for additive protection of FS antigens in 
B16F10/C57BL6 mouse melanoma tumor model ........................................ 93 
2. 44  Tumor growth curve of different groups .................................................... 94 
2. 45  Comparison of tumor growth curves from different experiment with the 
same immunization regimen. ........................................................................ 95 
2. 46  Comparison of the bullets preparation of two individual experiments....... 95 
2. 47  Detail experimental plan for anti-metastasis evaluation of SMC1A FS 
antigen in 4T1/BALB/c mouse breast tumor model ..................................... 96 
2. 48  Protection evaluation against primary tumor development. ....................... 97 
2. 49  4T1 lung metastasis assay. A. pictures of the 4T1 lung metastasis clones. 98 
2. 50  Correlation analysis of over all tumor size and lung metastasis colon 
number .......................................................................................................... 98 
2. 51  Influenza infection of BALB-NeuT mice. ................................................ 100 
2. 52  CpG plus GMCSF treatment of BALB-NeuT breast tumor model.. ........ 101 
2. 53  B2L treatment of BALB-NeuT mouse breast tumor model. .................... 102 
 
xvi
Figure                                                                                                                 Page 
3. 1 Strategy for mimotope screen. s................................................................... 121 
3. 2 ELISA vilification of absorbed anti-serum samples.................................... 122 
3. 3 Heat map of intensities exhibited by peptides specific for anti-SMC1A FS 
antibodies. ................................................................................................... 123 
3. 4  ELISA analysis of the specificity of the mimotop candidates.................... 123 
3. 5 ELISA analysis of antibody that were affinity purified by different peptide 
against hSMC1A-27mer and KLH protein ................................................. 125 
3. 6 Cross reaction of antibody that were affinity purified by different peptides125 
3. 7 Process of the analysis of the circulating SMC1A FS and WT transcript. .. 136 
3. 8 Gel electrophoresis of the RT-PCR products of the circulating RNA from the 
blood. .......................................................................................................... 137 
3. 9 Analysis of the circulating SMC1A FS and WT transcripts with 4T1-BALB/c 
mouse breast tumor model .......................................................................... 138 
3. 10 Correlation between tumor development and the PCR products ratio of the 
FS and WT transcripts ................................................................................ 140 
4. 1 Detection of alternative splicing of the SMC1A.......................................... 153 
4. 2 Sequence analysis of the alternative splicing of the SMC1A...................... 154 
4. 3 q-PCR analysis of the WT and FS isoforms expression in pancreas tumors 
and the normal adjacent tissues................................................................... 155 
4. 4 RT-PCR analysis of the SMC1A knock down in HPDE6 with siRNA....... 159 
4. 5 Anchorage independent growth assayd. ...................................................... 160 
 
xvii
Figure                                                                                                                 Page 
4. 6 RT-PCR analysis of the expression SMC1A stable knock down in BALB-
3T3 cell.. ..................................................................................................... 161 
4. 7 Anchorage independent growth assay. ........................................................ 161 
4. 8 Analysis of cross reaction of rabbit anti-human SMC1A FS peptide anti-
serum to mouse SMC1A FS peptide........................................................... 162 
4. 9 WB of human and mouse tumor cell lysate with affinity purified rabbit anti-
human SMC1A FS antibody....................................................................... 162 
4. 10 WB of human breast tumor cell CRL2351 lysate with the commercial rabbit 
anti-human wild type SMC1A N-terminal antibody. ................................. 163 
4. 11 WB of deglycosylation of B16F10 tumor cell lysate with the rabbit anti-
human SMC1A FS peptide antiserum. ....................................................... 164 
4. 12 WB of total B16F10 denatured lysate........................................................ 165 
4. 13 WB of B16F10 denatured lysate and normal C57BL6 tissues lysates ...... 166 
4. 14 Immunoehistiochemistry analysis of formalin-fixed human normal tissues 
and primary tissues with rabbit anti-human MSC1A FS anti-serum.......... 168 
4. 15 IF assay of the cellular location of the truncated protein of the SMC1A FS 
isoform in U2OS cell .................................................................................. 169 
AP1. 1  Protection analysis in 12B1/BALB/c mouse model. ............................. 214 
AP2. 1 RT-PCR screen SMC1A FS transcript in human tumor cell lines.. ....... 216 
AP2. 2  RT-PCR detection SMC1A FS transcript in normal BALB/C splenocytes 
that were separated by mouse CD8+ T cell enrichment kit......................... 216 
 
xviii
Figure                                                                                                                 Page 
AP2. 3  RT-PCR detection of SMC1A, 6-21 and 1-78 FS transcripts in four dog 
melanoma cDNAs....................................................................................... 217 
AP2. 4 RT-PCR screen 6-21 FS transcript in C57BL6 mouse normal and B16F10 
melanoma cell ............................................................................................. 217 
AP2. 5  RT-PCR screen 6-21 and 1-78 FS transcript in spontaneous breast tumors 
from FVB/N-NeuT mice............................................................................. 218 
AP2. 6  RT-PCR detection of 6-21 transcript in human breast tumors tumor cell 
lines and MCF-10A cell.............................................................................. 218 
AP2. 7  RT-PCR detection of 6-21 transcript in human primary breast tumors 
tumors and normal mammary tissues.. ....................................................... 219 
AP2. 8 RT-PCR detection of 6-21 FS transcript in dog tumor cDNAs and normal 
tissues.......................................................................................................... 219 
  
 
 
1
CHAPTER 1  
INTRODUCTION 
1.1 Cancer Statistics 
Cancer is one of the most serious global diseases threatening human lives.  
It is one of the leading causes of death in both developing and developed 
countries. In developed countries, for example in the US, from 1999 to 2008, the 
cancer death rate is decreasing more than 1% per year. However the over all 
tumor incident rate is increasing in both male and female. In developing countries, 
although cancer incident rate is about half of the developed countries, the overall 
cancer death rate is at a similar level [1, 2]. There were over 12 million new cases 
of cancer diagnosis and 7.6 million deaths from cancer in the world in 2008. This 
is more than doubled in the past 30 years. What is worse, the global cancer burden 
will reach 27 million annual incidents and 17 million deaths by 2030[3].  
This rapidly increasing cancer burden hugely impacts public health and 
society. Cancer causes the highest economic loss of any disease in the world. The 
global economic impact of premature death and disability from cancer was $895 
billion in 2008, which is 1.5% of the world’s gross domestic product. This was 
not including the direct cost of the cancer treatment. In the US, the direct medical 
cost of cancer was estimated to be $103.8 billion in 2007 [4]. The global 
economic loss by cancer is projected to increase along with the increasing of the 
cancer incident and death. 
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This huge global cancer burden is mainly caused by the increase in the life 
expectancy of individuals and populations of the world. This is also caused by an 
increase in cancer risk behaviors, such as tobacco use, alcohol use, unhealthy diet 
and physical inactivity. For example, tobacco use causes 22% of cancer deaths 
and 71% lung cancer death in the world[3]. The regulation and education of the 
tobacco use steadily decreased the smoking rate in the US. The reduction of the 
smoking rate contributed to the decline of both incidence and mortality of lung 
cancer in men in the US starting in the 1990s. It has been estimated that about 
30% of cancer burden can be reduced by outreach programs focused on education  
of current cancer control knowledge and enforcement to modify or avoid these 
key cancer risk factors[3]. Therefore, more public education and regulation leads 
to great cancer incidence and survival control.  
1.2 Cancer treatment 
Cancer control through medical care could be simply classified into three 
areas: cancer treatment, cancer prevention and cancer detection.  
The traditional cancer treatment includes three main methods: surgery, 
radiotherapy and chemotherapy. More recently, cancer immunotherapy has started 
to show promise and become an important component for cancer treatment.  
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Surgery was and remains the first available method for cancer treatment 
by removing the tumor from the patients. This started at the beginning of the 19th 
century and fast developed after the introduction of anesthesia and antisepsis in 
the middle of the 19th century. Although few cancer patients could be cured by 
surgical treatment alone, surgery was the only option for most cancer patients 
until the development of radiotherapy by the middle of the 20th century.  
Cancer radiotherapy started at the end of the 19th century after the 
discovery of x-rays by Roentgen. Radiotherapy was further developed during the 
20th century, along with the development of new technologies, such as radiators 
and computer science. The cancer cure rate with surgery, radiotherapy or a 
combination was increased by about 30% in the 1950s[5].  
At the same time, the chemotherapy started to develop by screening 
chemicals to target cancer cells. By the middle of the 1960s, it was proven that 
combination chemotherapy could cure childhood leukemia and advanced 
Hodgkin’s lymphoma [6, 7]. Since then, more drugs were discovered to treat 
major cancers, such as breast, colorectal, lung cancers and melanoma.  
The first clinical trial of cancer immunotherapy started in 1891 by William 
Coley, who first developed ‘Coley’s toxins’ to treat developed erysipelas with live 
or inactive bacteria [8]. However, the efficacy of this type of treatment and other 
immunotherapy trials, including therapeutic cancer vaccines, was poor. Cancer 
immunotherapy was not accepted as the general clinical treatment until recent 
decades with the accumulation of the knowledge of the immune system and tumor 
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cells. For example, nine monoclonal antibodies have been approved for the 
treatment of solid tumors and lymphoma caner. These monoclonal antibodies 
target cancer associated proteins, such as epidermal growth factor receptors and 
vascular endothelial growth factors, and induce tumor cell apoptosis, antibody-
dependent cellular cytotoxicity and phagocytosis and may also elicit adaptive 
immune response against tumor cells [9]. More recently, the first therapeutic 
cancer vaccine was also approved by the US FDA to treat asymptomatic 
metastatic castrate-resistant prostate cancer. There are currently many cancer 
immunotherapies in clinical trials targeting a variety of pathways, such as 
pathways regulating immune checkpoints and targeting different tumor associated 
antigens. Cancer immunotherapy is becoming another effective method of cancer 
treatment.  
With the development of new cancer treatments, it is clear that the single 
cancer treatments could not effectively cure cancer. With a combination of 
different cancer treatments and improved diagnostic methods, the mortality rate of 
both breast and colorectal cancer was successfully decreased during past decades, 
especially in developed countries, which have advanced cancer treatment 
resources. However, the complex characteristic of cancer, such as metastasis and 
immune suppression, limit the efficacy of the current cancer treatments, especially 
for cancer at late stages.  Additionally, the costs of current efficient cancer 
treatments are expensive. This also limits the contributions of the advanced cancer 
treatments to the global cancer control efforts, especially in developing countries.   
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1.3 Cancer Prevention 
Although the developments of cancer treatment have successfully 
controlled the mortality of cancer in developed countries, the overall cancer 
incidence is still increasing since 1970s, even in developed countries. Despite the 
advanced achievements in cancer treatments, cancer prevention is still considered 
to be the most cost-effect long term goal for global cancer control. However, 
compared to the impressive developments in cancer treatment, the development of 
cancer prevention through medical care has made little advancements. There were 
only two notable successes in this area so far: chemoprevention and cancer related 
virus vaccines.  
It was clearly shown that the chemical drugs used for cancer treatment 
could also effectively prevent specific cancers, such as finasteride for prostate 
cancer prevention and antiestrogens for breast cancer prevention. Recently, 
colorectal cancer prevention by aspirin also has been demonstrated[10]. However, 
because of the potential for toxicity and serious side effects, current effective 
chemoprevention drugs cannot be widely used for cancer prevention in the 
healthy population.  
The development of vaccines against liver cancer related hepatitis B virus 
(HBV) and cervical cancer related human papilloma virus (HPV) are another two 
successful achievements of cancer prevention [11, 12]. These vaccines, so called 
prophylactic cancer vaccines, are actually traditional infectious disease vaccines. 
HBV vaccine has been proven to reduce 49% liver cancer incidence among 
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immunized children and 42% liver cancer risk of immunized adults. It has been 
estimated that about 17.8% cancer incidents are related to pathogen infections 
[13]. Therefore, the development of vaccines against cancer related virus is an 
important strategy for cancer prevention and needs to be further explored.  
1.4 Dynamic Interaction between immune system and tumor 
1.4.1 Cancer Immune Surveillance 
In 1909, Ehrlich proposed the original hypothesis that the immune system 
can also recognize and destroy nascent transformed cells in our body and prevent 
them from manifesting clinically[14]. Fifty years later, Burnet and Thomas 
revisited this idea and proposed a formal hypothesis of immune surveillance: 
thymus dependent cells constantly protect host from nascent transformed cells 
through effective immune response to tumor specific antigens [15, 16]. Based on 
this hypothesis, the tumor incident should increase with the deficiency of the 
immune system. However, this hypothesis was not supported by work which was 
performed by Stutman and others in the 1970s. They demonstrated that compared 
to normal mice, the tumor incidence did not increase in athymic-nude mice, mice 
with a genetic deficit causing failure of normal development of the thymus and 
therefore, are lacking mature T cells[17]. Now we know that the athymic-nude 
mice are not the appropriate model to test the hypothesis. The main hindrance of 
the athymice-nude mice is that they are not completely immunodeficient. Immune 
mechanisms, other than the mature T cells, involving cancer immune surveillance 
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are marginally distributed in these nude mice, such as innate immune response, 
and a few T cells could still mature even without a proper thymus environment. 
Therefore, the immune surveillance still could efficiently monitor tumor 
development and contribute to tumor prevention during the time periods of these 
experiments. On the other hand, these experiments suggest that efficacy of the 
immune surveillance in tumor prevention. Even the impaired immune system 
could efficiently prevent the tumor development for a relatively long time.  
However, this hypothesis was seriously challenged at that time.  
After the 1990s, the immune surveillance of cancer was validated with 
new technologies through a variety of well documented experiments using 
different systems, such as dysfunction of specific immune responses by 
modifying specific genes in mice, inhibition of different immunologic 
components by different monoclonal antibodies and stimulation of specific 
immune responses by different activators. For example, the treatment with 
monoclonal antibody against IFN-γ could block the LPS induced tumor rejection 
in both transplanted and chemical induced mouse tumor models[18]. The IFN-γ-/- 
C57BL6 mice and BALB/c mice displayed increased incidence of disseminated 
lymphomas and spontaneous lung adenocarcinomas respectively [19, 20]. IFN-γ 
is a critical cytokine for both innate and adaptive immune responses. Finally, the 
cancer immune surveillance was directly proven in the appropriate 
immunodeficient mouse models, such as BALB/c SCID mice, RAG-1-/- and 
RAG-2-/- mice [21-23]. The B cell, T cell and NKT cells in these mice were 
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dysfunctional by genetic modification. The chemical induced tumor incidents in 
these mice were significantly increased compared to wild type mice. The theory 
of cancer immune surveillance is also substantiated by the fact that both the innate 
and adaptive immune systems are involved in the immune surveillance of cancer.  
 1.4.2 Cancer Immune Evolving        
The immune surveillance hypothesis has now been supported for decades 
and suggests that the immune system can control tumor development. However, 
this still could not explain the fact that most cancers initiate in healthy people with 
proper immune systems that can still efficiently fight infections. The accumulated 
evidence suggests that the one dimensional description of the immune system 
inhibiting tumor development by the theory of immune surveillance is not 
sufficient. The refined theory is described as cancer immunoediting and 
regulation to reflect the dynamic interaction between the immune system and 
tumor: immune surveillance inhibits tumor development from tumor initiation, 
while the tumor develops under the immune surveillance and evolves different 
mechanisms to avoid and resistant the immune attack or suppress the immune 
surveillance through multiple pathways, allowing the tumors to develop [24, 25].  
Early studies had revealed that tumor cells from immunodeficient mice are more 
immunogenic than tumor cells from immunocompetent mice. For example, the 
chemical induced tumor cells from nude mice and SCID mice were more 
frequently rejected when transplanted into wild type mice, compared the chemical 
induced tumor cell from the wild type mice [26, 27]. This suggests that the 
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immune surveillance has the selective pressure contributing to tumor development 
and has forced tumor cells to evolve characteristics to escape the immune 
surveillance.  
1.4.2.1 Cancer Immune Escape 
The research on the molecular bases of tumor self-alteration revealed two 
major mechanisms: compromising of the antigen presentation pathway and 
resistance to apoptosis. Defects in MHC I antigen presentation are frequently 
found in mouse tumor models, as well as in 40%-90% of human tumor types [28, 
29]. The loss of MHC I expression is the most frequent mechanism, which could 
be derived by either immune pressure or the oncogenic process. Garcia-Lora 
showed that an H2 class I negative fibrosarcoma cell line could generate H-2 
negative lung metastasis in normal BALB/c mice, and generate H-2 class I 
positive lung metastasis in nude/nude mice [30-32]. This result reveals the 
selection of the immune surveillance. The loss of MHC I expression could be 
directly induced by tumor development, such as mutations or loss of 
heterozygosity (LOH) of MCH class genes with the genomic instability [33]and 
expression of oncogenes. It has been showed that over expression of HER2 could 
significantly reduce the expression of MHC class I in HER2 low expression 
human melanoma and breast carcinoma cell lines [34].  
Apoptosis resistance was found in a variety of tumors with over-
expression of anti-apoptosis proteins, such as FLICE-inhibitory proteins (FLIPs) 
and inhibitor of apoptosis proteins (IAPs)[35, 36]. For example, over-
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expression of FLIP was detected in human melanomas and mouse tumor models 
[37-39]. FLIP has been shown to interfere with the death receptor induced 
apoptosis. The tumors with high expression of FLIP have been shown to be 
resistant to the T cell mediated immunity in vivo. On the other hand, the tumor 
apoptosis resistance could also be produced by deficiency of proapoptotic 
pathways. Down regulation and mutation of the death receptor, such as FasR, 
TRAIL-R1/2, were widely detected in different tumors, such as hepatocellular 
carcinomas, melanomas and lung cancers [40-43].   
1.4.2.2 Cancer Immune Suppression 
Besides developing mechanisms to escape the attacking immune system, 
tumor cells also develop a variety of mechanisms to suppress the immune 
surveillance both locally and systemically. A list of tumor derived immune 
suppression factors has been identified. These factors could either directly inhibit 
the infiltrated immune cells or recruit tumor associated macrophages (TAMs), 
myeloid-derived suppressor cells (MDSCs) and Regulatory T cells (Tregs) to the 
tumor microenvironment. All of such mechanisms consequently induce the 
anergy or apoptosis of activated anti-tumor immune cells and produce systemic 
tumor specific tolerance.  
It has been found that the soluble Fas ligands (FasL) [44]and MHC class I 
polypeptide-related sequence A (MICA) [45]were increased in various tumors, 
such as lung, colon and breast tumors. The expression of soluble FasL in the 
tumor microenvironment could directly induce the filtrated T cell apoptosis 
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through the Fas receptor on the T cell surface. NKG2D is a receptor on NK cells 
and CD8 T cells. The soluble MICA could impair the NKG2D expression on the 
NK cell and T cell, and subsequently decrease the responsiveness of the tumor 
specific effector T cells [46]. The soluble MICA could not only suppress local T 
cells, but also impair the systemic T cell activity. The down regulation of the 
NKG2D on both tumor infiltrated T cells and peripheral blood T cells were 
observed in a variety of types of MICA positive cancer, including melanoma, 
breast, lung, ovarian and colon carcinomas [47, 48].  
There are other tumor derived factors that could inhibit the infiltrated 
immune cells. The tumor-derived TGF-β could directly inhibit cytotoxic T cells 
through repressing the transcription of the cytotoxic genes, such as perforin, 
granzyme A and B, Fas ligand and IFN-γ [49]. The over-expression of serine 
protease inhibitor PI-9/SPI-6 in a variety of tumors could also inhibit the 
perfoin/granzyme B pathway of the cytotoxic T cells [50, 51]. Recently, it was 
found that the expression of B7-H1 on tumor cell surface could promote T cell 
apoptosis through programmed death-1 signal pathway[52]. 
The cellular immune suppression that is induced by tumors is involved in 
three types of cells: TAMs, MDSCs and Tregs. They are recruited or induced by 
different tumor derived factors and amplify these factors to further enhance the 
immune suppression microenvironment. They also could produce their unique 
factors directly to inhibit the immune cells. 
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TAMs could be recruited and accumulated in tumor microenvironment by 
tumor derived chemokines and cytokines, such as CC chemokines, soluble 
vascular endothelial growth factor (VEGF) and M-CFS that was released by 
tumor cell [53]. The TAMs are M2 polarized macrophages. In the tumor 
microenvironment, TAMs produce and excrete different molecular proteins, such 
as cytokines, chemokines, matrix proteins and proteases. Some of these could 
promote tumor development, such as by directly stimulating tumor growth, 
enhancing neoangiogenesis, changing tumor matix architecture and promoting 
tumor metastasis[54]. With respect to immune suppression, the TAMs derived IL-
10, TGF-β and some of CC chemokines could inhibit the cytotoxic T cells and 
induce the Tregs by attracting naïve T cells to the tumor microenvironment [55, 
56].  
MDSCs recruited by tumor cells are highly heterogeneous, including 
immature granulocytes, macrophages and dendritic cells [57]. The heterogenous 
population of the MDSCs allows them to suppress the immune response with a 
variety of mechanisms. They could produce a similar set of the cytokines and 
chomkines as tumor cells or TAMs, such as IL-10, TGF-β, VEGF and CXCL5 
[58], which could either directly suppress immune cells or recruit more immune 
suppression cells. Monocytic and granulocytic MDCSs could produce their 
unique extracellular molecules, such as nitic oxide and reactive oxygen species 
respectively [59, 60], and directly inhibit T cells. MDSCs also deprive the 
environment of arginine and cysteine, which are two essential amino acids for T 
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cell activation [61, 62]. MDSCs also could over express B7-1 on their surface and 
directly bind to the CTLA-4 on the activated T cells to induce a signal pathway 
that inactivates T cells [63].       
Tregs are another important immune suppression cells for tumors to 
combat immune surveillance. The complex immune suppression factors in the 
tumor microenvironment could either attract Tregs or induce Tregs [64, 65]. 
Similar to MDSCs, Tregs also apply multiple mechanisms to broadly suppress the 
immune cells through contact dependent or independent pathways. Besides IL-10 
and TGF-β, the two common factors in the immune suppression mechanism, 
Tregs could produce other soluble factors to suppress immune cells. For example, 
galectin-1, a member of β-galactoside-binding proteins, could be released by 
Tregs as a homodimer and bind to CD45, CD43 and CD7 causing growth arrest, 
apoptosis and abrogation of proinflammatory cytokine production in activated T 
cells [66, 67]. Similar to MDSCs, Tregs also compete for cysteine with activated 
T cells [68, 69], and Tregs compete for IL-2 with the T cells as well [70, 71].  
Tregs also apply multiple mechanisms of contact dependent suppression. 
Tregs constitutively expresses both CTLA-4 [72, 73]and LAG-3[74]. The CTLA-
4 could bind to CD80 and CD86 on APCs surface and block the costimulatory 
signal transduction. The interaction between Tregs and DCs with CTLA-4/CD80 
or CD86 could also induce the enzyme indoleamine 2, 3-dioxygenase (IDO) in 
DCs and induce the immunosuppressive metabolites [75]. The LAG-3 could bind 
to MHC II on some APCs and are required for the maximal suppressive activity 
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[76]. Tregs also have a high level of cyclic adenosine monophosphate (cAMP) to 
maintain their anergic state [77]. By forming gap junctions between Tregs and 
effector T cells, cAMP in Tregs could diffuse into the T cells and suppress the T 
cell through the cAMP-protein kinase A type I-C terminal Src kinase inhibitory 
pathway [76]. Tregs also use perforin/granyme pathway to induce cytolysis of 
monocytes, DCs, B cells and T cells.  
After 100 years of exploring tumor immunology, the complex and 
dynamic interaction between immune system and tumor development has become 
clearer. This whole dynamic interaction could clearly be represented by the 
investigations of genetically modified mouse tumor models. In a mouse model 
with liver transfection of oncogene Nras through hydrodynamic injection, the 
expression of Nras could induce the senescence program in those Nras expressing 
hepatocytes. Immune surveillance was efficiently triggered and started to 
eradicate the senescent cells 6 days after the oncogene activation through the 
CD4+ T cell mediated adaptive immune response. 60 days after oncogene 
activation, all senescent cells were eradicated [78]. In some more aggressive 
tumor development models, such as oncogene derived transgenic mouse tumor 
models, both antigen-specific antibodies and T cells were elicited at early stage of 
tumor development [79-81]. However, the endogenous immune surveillance 
failed to inhibit the tumor development in any case. Although the titer of the 
specific antibody increased over time, the specific CD8+ T cells in both tumor 
host organs and tumor draining lymph nodes were increased at early stages of 
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tumor development and eventually declined at late stages. Those specific CD8+ T 
cells were not fully functional and anergic. The T cell tolerance may be induced 
by the enhanced TGF-β signaling of tumor draining lymph node T cells and 
increased Tregs in tumors [80].   
The endogenous immune surveillance consistently eradicates spontaneous 
nascent transformed cells through both innate and adaptive immune systems. The 
occasional tumor initiation event in cell, such as DNA damage and oncogene 
activation, always first triggers the cellular program to fix the problem or turn off 
the cell. In the case of oncogene derived tumors, the spontaneous aberrant 
activation of oncogene could trigger the cellular senescence program and cause 
cell cycle arrest. The senescence process also induces the cell to start secreting 
various cytokines and growth factors [82, 83]. This is the time point when the 
dynamic interaction between immune surveillance and tumor development starts. 
Depending on the cellular microenvironment, the secreted factors could promote 
the tumoregenesis, bypass the senescence and escape from the immune 
surveillance. In most case, with a health immune system, the secreted factors 
could trigger both the innate and adaptive immune response and efficiently 
eradicate these senescent cells. However, at some time point in an organism’s life, 
some nascent transformed cells survive by occasional event or/and accumulated 
factors that impair the immune surveillance, such as virus infection, chronic 
inflammation and aging [80, 81]. The surviving nascent transformed cells keep 
evolving under the immune surveillance, and develop multiple mechanisms to 
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both promote the development and escape the immune surveillance. Eventually, 
these cells successfully suppress the immune surveillance locally and/or 
systemically, and establish the primary tumor and metastatic tumors. 
Interestingly, almost all of the mechanisms that tumors utilize to escape and 
suppress the immune surveillance are the mechanisms to regulate the healthy 
immune system of the body or regulate the maternal-fetal interaction during the 
pregnancy. For example, IDO is released by placenta to prevent immune rejection 
of fetus and it is also released by tumor cells to suppress the anti-tumor immune 
responses [84-86].  Some of the mechanisms tumors utilize even are the 
mechanisms used to inhibit the tumor development at the beginning, such as 
TGF-β.  
In summary, with the 100 years of accumulated knowledge of the tumor 
immunology, we now much better understand the dynamic interaction between 
the immune system and tumor development. This reveals the pivotal role of the 
immune system in the tumor development and also suggests that the proper 
modulation of the immune system should have great potential to control the tumor 
development.  
1.5 Limitations of Current Therapeutic Cancer Vaccine  
Since the original hypothesis of immune surveillance was proposed, 
people have worked on cancer immunocontrol for more than one hundred years. 
This is the most clinically tested immunotherapy. Despite the dramatic 
development of this area, the clinical efficacy of the therapeutic cancer 
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vaccine is still limited. Only a few therapeutic cancer vaccines are currently 
available and are restrictive to relatively small groups of cancer patients. The 
major hindrance is current cancer vaccines could not elicit an efficient immune 
response to eradicate tumors.  With the current understanding of tumor 
immunology, there are two major causes for this limitation: immune suppression 
caused by the tumor and the low immunogenicity of the current tumor antigens in 
the vaccine.  
First is the immune suppression of the tumor. The most important criterion 
for any vaccine development is to induce an efficient immune response. In fact, 
the occasionally successful cases in those vaccine trials were associated with the 
relatively higher efficient anti-tumor immune responses directly or indirectly 
elicited by the vaccine [9, 87, 88]. However, as discussed above, an established 
tumor already develops a strong immune suppressing microenvironment, as well 
as the systemic immune suppression. Additionally, most of these clinical trials are 
in conjunction with other cancer treatments, which could further cause the 
impairment of their immune system. This is the most important hindrance specific 
for cancer immunotherapy.  
On the other hand, the immunization strategy in these early cancer vaccine 
trials were not specifically designed to overcome immune suppression factors, 
instead they were engineered to directly stimulate the immune response through 
pathways to enhance the antigen presentations, such as using different adjuvants, 
like GM-CSF and CpGs. Therefore, it is not surprising that most of these early 
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cancer vaccine trials failed, because of their inability to induce a sufficient anti-
tumor immune response, especially the T cell response. The most important 
reason for the success of the first FDA approved therapeutic cancer vaccine, 
Sipuleucel-T, is that the immunization strategy of this vaccine partially avoids the 
immune suppression factors [89, 90]. This vaccine applies the in vitro stimulated 
DC for the immunization and avoids the immune suppression during antigen 
processing. 66% of patients with Sipuleucel-T treatment showed an antibody 
response to the immunized antigen PA2024 and 28.5% showed antibody to 
prostatic acid phosphatase; and 73% patients and 27.3% patients showed the 
specific T cell response to these two antigens respectively. The higher antibody 
activity showed significant association with longer survival time. However, the 
median increase in survival with the Sipuleucel-T treatment was only 4.5 months. 
This indicated that without further control of the immune suppression, the 
therapeutic cancer vaccine still could not elicit meaningful clinical efficacy [89]. 
The second limitation of the current therapeutic cancer vaccine is the 
natural immune regulatory system that inhibits the immunogenicity of the antigen 
components in current vaccine development. The majority of tumor antigens in 
clinical trials are tumor associated antigens, which are self antigens that are over-
expressed in tumors [91-93]. This could be the fundamental hindrance for all of 
the self antigens as cancer vaccine candidates.  The low immune response to 
tumor antigens, such as breast tumor antigen Her2 and melanoma antigen gp100, 
has been well documented in both mouse models and clinical studies. For 
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example, peptide immunization of the T cell epitope gp100209-217 with different 
regimens had a minimal immune response in melanoma patients, as well as in a 
transgenic mouse model with the most common human MHC class I molecule, 
HLA-A2 [94-97]. This is the similar situation for breast tumor antigen Her2. Two 
T cell epitopes derived from Her2 could not elicit high avidity CD8+ T cell in 
A2/neu transgenic FVB/N mice, comparing to the A2 wide type mice [98]. 
Further investigations reveal two mechanisms that could cause the low affinity T 
cell-dominant immune response: the immune tolerance to those self antigens and 
instability of the peptide-MHC-1 complex. It has been clear that self antigens are 
naturally tolerant to the immune system. Central immune tolerance deletes most 
high avidity T cell and B cell against self antigens at thymus and bone marrow 
during the development. Those high self-avidity T/B cells that escape from central 
immune tolerance are still under the control of the peripheral tolerance, which are 
mainly operated by Tregs, as well as other regulatory leukocytes, such as DCs and 
NK cells. Therefore, the low avidity T cells to these self tumor antigens are 
dominant in the immune system and more frequently activated by immunization. 
The immunization of the NY-ESO-1, the cancer-testis antigen, elicited a high 
frequency of low affinity T cells in the ovarian cancer patients [99-101]. 
However, the high avidity T cells could be detected by in vitro stimulation 
without Tregs [102]. This indicated the low frequency and high avidity T cells are 
tightly controlled by the peripheral tolerance.  
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The instability of peptide-MHC-1 complex is another possible mechanism 
responsible for the low immune response.  The instability of the peptide-MHC-1 
complex could inefficiently present the T cell epitope to naïve T cells, therefore 
could inhibiting the eliciting of a strong immune response. The evidence for this 
mechanism comes from the observation of the low immune response elicited by 
the immunization of the gp100209-217 in the A2 transgenic mice whose gp100209-217 
was knocked out [96]. And faster rate of the dissociation of the epitope from the 
HLA-A*0201 was also confirmed through the biological and physical analysis. In 
any case, these self tumor antigens are not good immunogenic antigens.  
In summary, the inefficient immune response has been to date 
characteristic of the therapeutic cancer vaccine. Without strong antitumor immune 
responses, the therapeutic cancer vaccine could not achieve the sufficient clinical 
efficacy. However, with additional methods, such as combined treatment with 
immune modulators and modification of the antigens, the therapeutic cancer 
vaccine may overcome this hindrance. On the other hand, because most tumor 
antigens are self antigens, the risk of the autoimmune disease will increase with 
the improvement of the antitumor immune responses to these self antigens. With 
this catch-22, the contribution of the therapeutic cancer vaccine with self antigens 
may be limited for cancer control. Using tumor specific antigens for therapeutic 
vaccines may overcome the problem of auto-immunity and low avidity T cells, 
but would still be restricted by immune suppression initiated by tumor at early 
stages.  
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1.6 Cancer Immunoprevention 
Although cancer immunotherapy is the most tested strategy of cancer 
immunocontrol, cancer immunoprevention is the original suggestion of the cancer 
immune surveillance theory: Elicit efficient immune response to eliminate the 
nascent transformed cells and then eradicate the cancer. Mainly because of 
practical reasons, the strategy of cancer immunoprevention was neglected for a 
long time. The successes of the HPV and HBV vaccines in prevention of the 
related cancers, as well as the better understanding of tumor immunology, the idea 
of cancer immunoprevention is becoming more attractive. Especially, with the 
effort of Dr. Johnston and other initiatives, the National Breast Cancer Initiative 
has started the Artemis Project to develop a prophylactic breast cancer vaccine to 
prevent breast cancer.  
To date, the concept of cancer immunoprevention has been developed and 
replenished by multiples strategies. There are two major types of strategies: 1) 
removing the cancer risk factors, such as HPV and HBV vaccines and 2) 
eradicating nascent transformed cells through immunoprevention, such as 
prophylactic cancer vaccine. The fundamental difference between these two 
strategies is the targets. The first strategy targets the cancer risk factors and 
prevents initiation of the tumor cells. The second strategy targets the nascent 
transformed cells and prevents the further development of the initiated tumor cells 
[103]. These two strategies are not exclusive to each other. The combination of 
the two strategies may have better efficiency in preventing cancer.  
 
22
The first strategy has been partially realized with the development of the 
vaccines against cancer related viruses, such as HBV and HPV. Vaccines 
developed against cancer related infections have the potential to prevent about 
17.8% of cancer, which is the estimated percentage of the pathogen infection 
related cancer. Another part of this strategy is controlling chronic inflammation, 
which has been recently confirmed as one of the major risk factors of tumor 
initiation and development [104]. This could also be accomplished by chemical 
drugs, such as aspirin.  
The second strategy was directly suggested by the original concept of the 
cancer immune surveillance. However, all of the achievements in this area were 
still mainly limited in the animal models. The current strategies for this 
immunoprevention area are almost totally adopted from the cancer 
immunotherapy. This could be classified into two types: 1) prophylactic cancer 
vaccines that target tumor antigens; 2) enhancement of immune system by 
immune stimulators and immune modulators. However, some limitations of 
cancer immunotherapy also could be directly adopted by the immunoprevention, 
and even be enlarged, such as the risk of the autoimmune diseases. 
1.7 Prophylactic Cancer Vaccine     
1.7.1 Introduction        
The cancer vaccine was first inspired from the success of infectious 
disease vaccines, and then mainly focused on the development on the therapeutic 
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cancer vaccine to treat the cancer patient. However, there is no infectious disease 
vaccine, which efficiently controls the established infections alone. This is the 
same in the therapeutic cancer vaccine development. The prophylactic cancer 
vaccine gained popularity after the successes of the HBV and HPV vaccines in 
the prevention of related cancers. The concept of the prophylactic cancer vaccine 
is as simple and straight forward as the infectious disease vaccines: eliciting a 
sufficient and specific anti-tumor immune response in healthy people and 
eradicating nascent transformed cells whenever they emerge during the organism 
lifetime preventing cancer.  
It has been well clarified that the nascent transformed cells are completely 
different from the established tumor cells at all levels: genome, transcriptome and 
proteome. A nascent transformed cell needs to evolve in all these levels, and 
adopt the characteristic ten hall marks to become a fully developed tumor [105, 
106]. The tumors are very heterogeneous. There is no known cancer deriving 
genes found in all cancers, even in cancers in the same organ. For example, the 
Her2+ breast cancer only represents about 25% breast cancers. Recent deep tumor 
sequencing studies revealed that heterogeneity is typical in all types of tumors. 
Different tumor cells in the same tumor differ in mutation profile, which is 
accumulated as the tumor evolves under the different selecting suppression, such 
as growth suppression and immune suppression [107]. The evolution of tumor 
cells creates moving targets for the therapeutic cancer vaccine and fundamentally 
causes the inefficiency of these vaccine trials.  The lesson learned from the 
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failures of the therapeutic cancer vaccine suggests targeting the nascent 
transformed cells is a much more efficient way to prevent tumors.  
However, most current strategies in prophylactic cancer vaccine 
development are directly adopted from the therapeutic vaccines, as well as the 
limitations of the therapeutic cancer vaccines [103, 108-112]. Some of these 
limitations are decreased in the prophylactic setting, such as efficiency of eliciting 
immune response, while some are amplified, such as the risk of the autoimmune 
diseases. I will discuss some major advantages and disadvantages of current 
strategies for prophylactic cancer vaccine development compared to therapeutic 
cancer vaccines.           
1.7.2 Advantages in Eliciting Efficient Immune Response 
As discussed above, the biggest hindrance of the cancer immunotherapy is 
the immune suppression derived by the tumor or natural immune tolerance. This 
could inhibit the vaccine to induce a strong anti-tumor immune response. 
Compared to the therapeutic cancer vaccine, the main advantage of the 
prophylactic cancer vaccine is there is no tumor derived immune suppression in 
healthy people. Without the immune suppression, the prophylactic cancer vaccine 
could efficiently elicit strong immune responses. With advanced vaccine 
development strategies, both T cell and B cell immune responses against current 
tumor antigens could be robustly elicited in a variety of mouse models as well as 
in the clinical cancer vaccine trials. Even in the presence of tumor derived 
immune suppression, more than 50% of the immunized cancer patients still 
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could successfully elicit an immune responses against the vaccine antigens in the 
trial with Sipuleucel-T [89]. The natural immune tolerance to those self tumor 
antigens also could be overcome with different strategies, such as epitope 
modifications. For example, in transgenic mouse models which have the natural 
immune tolerance to the gp100209-217, the immunization of the natural epitope 
could not elicit the high avidity T cells. However, the strong immune response 
with high avidity T cell stimulation was achieved by the epitope modifications of 
the gp100209-217 [96]. Other advanced immunization platforms also could break 
the natural immune tolerance, such as strong adjuvant and immune modulators. 
Tumor derived immune suppression could not only suppress the 
stimulation of efficient immune responses, but also could reduce the activated 
immune cells in the tumor derived microenvironment.  The impaired immune 
response accelerates the evolution of tumor cells and their ability to escape from 
immune surveillance by altering the antigen presentation pathway. Different from 
the therapeutic vaccine, the prophylactic cancer vaccine targets the nascent 
transformed cells. These cells do not have the established immune suppression 
microenvironment as do tumors at later stages. First, the factors, such as TGF-β, 
that tumors utilize to suppress immune responses are the same factors for the 
efficient immune surveillance at the beginning. The function of TGF-β to promote 
or suppress the immune surveillance is determined by the context of the 
environment [80]. Second, the endogenous immune surveillance has a lag in the 
switch from innate immune response to more specific and stronger adaptive 
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immune response. This lag offers the time window for nascent transformed cells 
to further evolve and establish the immune suppression context [81, 82]. The pre-
activated adaptive immune response by the prophylactic immunization avoids the 
latency of the natural immune response switch and could more efficiently 
eradicate the nascent transformed cells [81, 113]. This leaves no chance for 
nascent transformed cells to further evolve and develop all kinds of mechanisms 
for survival.  
The prevention efficacy of prophylactic immunizations has been proven in 
numerous mouse tumor models with genetic or carcinogen-induced cancer risk, 
including the BALB-NeuT mice, one of the most aggressive mouse tumor models 
[113-118]. This transgenic mouse model has active rat Her2/neu oncogene 
expressed under the mouse mammary tumor virus promoter. All of the ten 
mammary glands develop breast tumors in 30 weeks [119, 120]. With the proper 
prophylactic immunization of Her2 that started from 6 weeks old, BALB-NeuT 
mice could keep palpable tumor free up to 2 years [113]. The gene transcriptome 
profiles of mammary glands from these tumor free mice at 15 weeks old and 26 
weeks old were clustered with the 6 weeks old non-treated BALB-NeuT mice 
[115]. This demonstrated the efficient prophylactic cancer vaccine could prevent 
the nascent transformed cells from further developing and evolving. In a natural 
setting, the tumor initiation events are spontaneous and even the endogenous 
immune surveillance can efficiently eradicate most of them.  
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1.7.3 Disadvantages of Autoimmune Disease Risk   
Most of current tumor antigens are tumor associated antigens (TAAs), 
which are abnormally over-expressed in tumor cells and down-regulated in 
normal adult cells [103, 108]. Basically, the immune responses elicited by these 
TAAs areself-antigen responses, which are the risk factors for autoimmune 
disease. Although these TAAs were well tolerated in both animal models and 
clinical trials [121]; eventually, the autoimmune disease risk of current 
therapeutic cancer vaccine needs to be addressed. However, with the fact of poor 
survival rate with the therapeutic cancer vaccine treatment, this is not the current 
priority. This is not the situation for the prophylactic cancer vaccine, whose 
recipients are healthy populations. This is the fundamental disadvantages for the 
prophylactic cancer vaccine based on these TAAs.  
Another problem for the prophylactic cancer vaccine based on TAAs is 
that most TAAs are tumor type specific. For example, Her2+ positive breast 
cancer only represents about 20% to 25% of the breast cancer. There is no way to 
accurately predict the cancer type of the potential patient. This limits the 
subsector of this cancer type specific prophylactic cancer vaccine could be 
vaccinated 
In summary, the prophylactic cancer vaccine is becoming an increasingly 
popular strategy for cancer prevention, and has started to attract more research 
attention. Current prophylactic cancer vaccine development mostly follows the 
strategy for the development of therapeutic cancer vaccine. Compared to the 
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therapeutic cancer vaccine in cancer control, the prophylactic cancer vaccine has 
both significant advantages and disadvantages. The prophylactic cancer vaccine 
could robustly elicit specific immune responses with the healthy immune system 
and could more efficiently eradicate the target cells, since they have not set up the 
established immune suppression. This advantage is based on the prophylactic 
immunization, not after tumor initiation as currently done.  
However, because the prophylactic cancer vaccine needs to cover a longer 
lifespan than the therapeutic vaccine, the prophylactic cancer vaccine has more 
risk for autoimmune disease with the current cancer vaccine candidates. 
Additionally, without knowing the specific risk of the cancer type in normal 
populations, the design of a prophylactic cancer vaccine is more complex and 
limited with current vaccine antigen candidates.  
All of these indicate that the prophylactic cancer vaccine is different from 
the therapeutic cancer vaccine. Therefore, it is necessary to develop a strategy that 
is suitable for the prophylactic cancer vaccine development.  
1.7.4 Discussion of strategy for prophylactic cancer vaccine development 
The targets of the prophylactic cancer vaccine are the potential 
transformed cells and the nascent transformed cells. Vaccines against cancer 
related viruses, such as HBV and HPV, could eradicate the virus infected cells 
that have the potential to transform. About 17.8% of cancers are proposed to be 
related to the pathogen infections [13]. However, there are only two types of 
human cancer related viruses that have been confirmed so far: HBV and HPV.  
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Their related cancers have been controlled by the anti-virus vaccines. Here, I will 
focus on the nascent transformed cells. This is the area we do not have any 
breakthrough to clinical application yet. Since the prophylactic cancer vaccine 
targets nascent transformed cells, it would also include the virus-induced 
transformed cells.  
The targets of the prophylactic cancer vaccine determine what the vaccine 
candidates should contain. There are two pivotal characteristics: 1) expression in 
nascent transformed cells and 2) wide coverage of different types of cancer.  
Identifying the early expression antigens in nascent transformed cells is the most 
critical step for the prophylactic cancer vaccine. With current advanced 
immunization technologies, the stimulation of a strong immune response is not 
the biggest hurdle for developing a prophylactic vaccine. The correct targets of 
nascent transformed cells fundamentally determine if the vaccine could efficiently 
eradicate the tumor cells in the first place, where the endogenous immune 
surveillance starts losing the whole war against cancers. 
The evolution of the tumor makes it a moving target. This causes most 
tumor antigen screening efforts to focus on the cancer deriving antigens which 
could be the constant references for the anti-tumor responses. However, those 
tumor antigens are not necessarily expressed in the nascent transformed cells. For 
example, the mutation of ras gene was detected in 58% of colon adenomas larger 
than 1 cm and 47% of carcinomas, while there were only 9% adenomas less than 
1 cm that carried the ras gene mutations [122]. This will make ras-mutant based 
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vaccine essentially a therapeutic vaccine for these patients, even if it was 
immunized prophylactically.   
Most cancers need a long time to develop from the nascent transformed 
cells to the established tumor cells. Even in the people with inherited gene 
mutations, it still takes decades for them to eventually develop cancers. For 
example, in Lynch Syndrome patients, who carry mutant genes of the DNA 
mismatch repair pathway, 80% of patient will not develop colon cancer until after 
44 years of age[123]. Additionally, as I pointed out previously, one of the 
advantages of the prophylactic immunization is efficiently preventing further 
evolution of the nascent transformed cells. Therefore, the nascent transformed 
cells are relatively quiescent targets for the prophylactic cancer vaccine. This 
suggests that all of the alternations of the nascent transformed cells are the 
potential vaccine candidates, as long as they can present properly to the immune 
system and are specific from the normal cells. This could include genetic 
mutations, alternative splicings and post-translational modifications, even if it is 
not integral to tumor development. 
Another essential criterion for the prophylactic cancer vaccine is the wide 
coverage of tumor types. Most cancers are unpredictable with current knowledge 
and techniques. Even the cancer from the same organ, such as mammary gland, 
could be divided into multiple subtypes based on the histological and 
transcriptome differences. Without knowing the specific cancer risk of most 
healthy people, an efficient prophylactic cancer vaccine needs to cover different 
 
31
cancer types. This suggests we need to screen the common alterations among the 
different nascent transformed cells. Most of cancer researches focus on 
characterizing the advanced cancers and has repeatedly shown that heterogeneity 
is a typical characteristic of advanced cancers, which was discovered at the 1950s 
[124-126]. It is now widely accepted that the heterogeneity of the tumor is mainly 
caused by tumor evolution [127]. This indicates that for each tumor, it is more 
homogeneous at early stages. However, there is little research on characterizing 
the alterations of different nascent transformed cells. We hypothesize that there 
are common alterations in different nascent transformed cells. First, genome 
instability affects all the levels of the cellular functions, and generates both 
“driver” alterations and “passenger” alterations [128]. As mentioned before, both 
specific alterations could be the candidates for the prophylactic cancer vaccine. 
This indicates it may be possible to find the common alterations for vaccine 
development. For example, we have discovered that FS transcripts are whole 
category of alterations that are frequently detected in different cancers [129]. 
Second, we also have discovered that cancer patients have common antibody 
profiles through the immunosignature analysis, and those profiles are 
distinguished from the healthy people [130]. We also can detect the common 
immunosignature changes of the early tumor stages in the mouse tumor models 
(unpublished data). The immune response reflects both historical and current 
exposure of the antigens. The common immunosignature of cancers indicates 
there are common immunological alterations in these different cancers, even at 
 
32
early stages. Those common immunological alterations can be the candidates for 
the prophylactic cancer vaccines. We should explore more the characterizing of 
alterations in nascent transformed cells in the future for the development of 
prophylactic cancer vaccine.     
In summary, the prophylactic cancer vaccine is an old concept but needs a 
new strategy for further development. I have discussed two essential 
characteristics of vaccine antigens for prophylactic cancer vaccine development 
by comparing it to therapeutic vaccines. Besides these two, the specificity of the 
antigens to tumor cells is also critical for the antigen screen to minimize the risk 
of inducing autoimmune disease. However, tumor antigen screens in nascent 
transformed cells have received little attention in current cancer research. With 
the development of high throughput research technologies, such as deep 
sequencing, more common and specific antigens in different nascent transformed 
cells will be discovered.  
1.7.5 Prophylactic cancer vaccine and metastasis cancer vaccine based on the 
Frame Shifted antigens 
Our overall goal is to develop a broad-spectrum prophylactic cancer 
vaccine to prevent a variety of different cancers. We are systematically applying 
bioinformatics, proteomics, and immunological methods to achieve this vision. I 
will discuss a novel strategy for the prophylactic cancer vaccine development, 
which is developed in our lab. One of our foci toward developing the prophylactic 
cancer vaccine is the identification of frame shifted (FS) neo-peptides in 
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nascent tumor cells as vaccine components. FS peptides are derived from 
transcripts expressed in alternate reading frames; these are activated by various 
gene mutations and abnormal splicing events in tumor cells. Based on the criteria 
I discussed above for the prophylactic cancer vaccine antigens, there are several 
advantages of the FS antigens. 
First, FS antigens can efficiently elicit a specific immune response 
with proper administration. A prophylactic cancer vaccine would be 
administered to a healthy population with a competent immune system. Unlike a 
therapeutic cancer vaccine, it doesn’t need to overcome any immunosuppression 
caused by an established tumor. Additionally, FS peptides come from mutant 
proteins and are encoded by the 2nd or 3rd reading frame of corresponding regions 
of genes. Consequently they should be seen as foreign antigens without natural 
tolerance of the immune system. These FS antigens can elicit high affinity 
antibodies and T cells more easily compared to current self tumor antigens. 
Second, FS antigens are an abundant source for the screen. The tumor 
is developed stepwise from nascent transformed cells. As summarized by Dr. 
Hanahan and Dr. Weinberg, nascent transformed cells need to achieve ten 
common hallmarks to become tumors, such as sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, activating invasion, metastasis 
and so on [105, 106].  Among all of the ten hallmarks, the genome instability is 
the molecular foundation for a nascent transformed cell developing all other 
hallmarks [106]. In addition to activating distinct driving factors for different 
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tumor development, genome instability also affects other factors which are not 
necessarily associated with tumor development, including genes, transcriptomes, 
and translated proteins. These aberrant features are sources for the generation of 
FS antigens. Because of this global affect genome and transcriptome instability, 
we believe the FS antigens are more commonly shared across all kinds of nascent 
transformed cells and tumors.  For example, SMC1A FS has been detected in 
almost all of the tumors we have screened so far. While most of the tumor 
associated self antigens on the other hand are only shared in distinct tumors.  
Third, the FS antigens are specific to tumors. Risk of autoimmune 
disease is a concern in both therapeutic and prophylactic cancer vaccine 
development. Especially for the prophylactic cancer vaccine, since it is applied in 
healthy people and needs to be activated for a much longer time than the 
therapeutic vaccine. The specificity of a tumor antigen has several levels: gene 
level, transcriptome level and protein level. The specificity of the FS antigens is 
significant in all of these three levels.  
First, the stability of the genome in normal cells decreases the chance for 
templates of FS transcripts and the production of FS transcripts by mis-functional 
transcription factors. Tumor cells have higher gene mutation rates compared to 
normal cells as well as a higher incidence of translocation [131-133]. High gene 
mutation rates cause high levels of FS transcripts, especially in those tumors with 
high levels of microsatellite instability (MIS). These microsatellite regions are 
sensitive to genome instability caused by defective DNA mismatch repair. We did 
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bioinformatics analysis of tumor sequence data shows that over 98% of mutations 
in microsatellite regions are FS mutations [129].  
The stability of the genome in normal cells also secures the normal 
function of gene duplication and transcription machinery at the fundamental level. 
Many transcription factors change during tumor initiation and development. 
These changes are caused either by direct mutations and abnormal expression of 
these factors or by the change of upstream signaling factors. For example, over 
40% of alternative splicing events are significantly changed in breast and ovarian 
cancer tissue compared with normal breast and ovarian tissues. And other studies 
estimated that 35% of the alternative splicing could produce a FS transcript [134, 
135].  
Second, the quality of the transcriptome in normal cells is tightly 
controlled by multiple mechanisms, especially by nonsense mediated decay 
(NMD) which targets most transcripts that contain premature termination codons 
(PTCs). The normal function of NMD could protect people carrying a PTC allele 
and prevent autosomal recessive disorders. For example, patients with a PTC 
containing β-globin allele usual are phenotypically normal, because NDM 
eliminated most PTC containing transcripts. However, some PTC containng β-
globin transcripts are insensitive to NDM. As a consequence, high level truncated 
β-globin is expressed and causes anemia [136]. Most FS transcripts contain PTCs, 
and they are favorite targets of NMD. About 90% of PTC containing transcripts in 
normal cells are efficiently eliminated by NMD[137] . This process would make it 
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unlikely a FS transcript would produce a FS peptide in normal cells. Although the 
activity of the NMD in tumor cells is still controversial, the up regulation of the 
FS transcripts by the genome instability still causes more FS transcripts escaping 
from the NMD [138].   
Third, besides these two control systems, normal cells have another fully 
functioning quality control system: endoplasmic reticulum associated degradation 
(ERAD) [139]. Truncated proteins with C-terminal FS peptides cannot be 
processed correctly and properly folded. Those truncated proteins produced from 
leaky FS transcripts in normal cells will be efficiently detected and destroyed by 
ERAD [140]. Therefore even if some FS transcripts escape from NMD, they will 
be destroyed before being presented on the normal cell surface. With all these 
security controls, normal cells will efficiently avoid attack from a specific 
immune response to FS antigens. 
 
 
 
37
 
Figure1. 1 Model of FS antigen presentation during tumor development 
 All of the characteristics discussed above make FS antigens good 
candidates for prophylactic cancer vaccine development. According to the 
research from my years of study, I developed a model of FS antigen exposure to 
the immune system during tumor development (Figure 1.1). It is a simplified 
model to emphasize the FS antigen exposure and development of endogenous 
immune response to those antigens. The FS transcript starts to accumulate right 
after transformation is initiated in normal cells by different factors such as viral 
infection, oncogene activation, and exposure to carcinogens. At this earliest stage, 
the nascent transformed cell still maintains normal functions of quality control 
systems to prevent the presenting of these FS antigens. As a tumor keeps 
developing, the gene mutations increase and normal cellular functions become 
deficient. The FS antigens start to leak from the quality control systems and can 
be presented on the tumor cell surface. Meanwhile, maybe earlier, apoptosis 
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and senescence are trigged in some tumor cells and different cytokines and 
chemokines are released, which attract immune cells and induce the endogenous 
innate and adaptive immune response. Presumably in most cases this early 
immune response is effective in eliminating these cells. However, if not, the 
tumor keeps evolving under immune surveillance and develops mechanisms to 
suppress anti-tumor immune response. Although more and more FS antigens are 
exposed to immune system during tumor development, the endogenous adaptive 
anti-tumor immune responses are more suppressed, including the FS immune 
responses. The tumor metastasis starts at the early stage of tumor development; 
those clones still share some common FS antigens with the primary tumor. By this 
time, immune suppression is getting stronger; the micro-metastasis tumors are 
developing faster. It usually takes 5 to 50 years for a nascent transformed cell to 
develop into a malignant tumor and develop metastatic tumors, especially in a 
developing solid tumor [141, 142]. Without any stimulation, the endogenous anti-
tumor immune response develops slowly and eventually gets suppressed.  
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Figure1. 2 Strategy of prophylactic cancer vaccine based on FS antigens  
According to this model, I developed a strategy for prophylactic vaccine 
development (Figure 1.2). With the active anti-tumor immune response, the 
immune system could efficiently detect and destroy the nascent transformed 
tumor cells without the established immune suppression induced by a developed 
tumor. There are two important characteristics for an efficient prophylactic cancer 
vaccine: First, the vaccine should include antigens that start to present at the early 
stage of tumor development. It will let the immune response catch the nascent 
transformed cells. The lessons from different vaccine trials indicate that 
completely controlling different tumor developments with a single antigen is 
difficult. Additionally, with the limitations of current studies, we cannot predict 
which antigens will present first. The goal is to include a pool of FS antigens in 
our prophylactic cancer vaccine based on the frequency analysis of genetics in a 
variety of tumors as well as the protection analysis of each antigen in different 
models.  
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Secondly, an efficient prophylactic vaccine should be administrated early 
in healthy individuals and elicit a proper immune response. For a prophylactic 
cancer vaccine, another important factor is to maintain a relatively strong immune 
response and an efficient memory immune response, especially to those antigens 
which present in late stages. These factors rely on the immunization regimen and 
an efficient adjuvant. In the mouse model, we developed a method to efficiently 
deliver both big (such as plasmids) and small (such as CpGs) nucleic acid 
fragments through a genetic immunization with a gene gun [143-146]. We are 
also developing methods to efficiently deliver other formats of adjuvants, such as 
siRNA and proteins. All of these developments facilitate the screening of vaccine 
candidates.  
 
Figure1. 3 Strategy of prophylactic cancer metastasis vaccine  
Based on the concept of a prophylactic cancer vaccine against the primary 
tumor, we also developed a sub-project to develop a prophylactic metastasis 
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cancer vaccine (Figure 1.3). Control of metastasis has an important clinical 
application in cancer treatment. 90% of the deaths caused by cancer are due to 
metastatic tumors [1, 3]. Most primary tumors on the other hand, especially solid 
tumors, are treatable. Evidence shows that tumor metastasis can start at an early 
stage of tumor development, even before any clinical symptoms of cancer [147-
149]. The early micro metastatic clones are not detectable with current technology 
and usually are resistant to current drugs. They usually take a long time to 
develop into a metastatic tumor. Because of the inherited genomic instability, 
these micro metastasis tumors still could share a similar gene expression profile 
the primary tumors [150-153]. Therefore, the prophylactic cancer vaccine 
containing those shared antigens should also be able to eradicate tumor 
metastasis. Our data demonstrates that the development of the primary tumor will 
also boost the specific anti-tumor immune response elicited by prophylactic 
vaccination. It enhances the immune system to destroy those micro metastasis 
tumors. Our strategy of the prophylactic cancer vaccine could prevent both 
primary tumor and metastatic tumor.      
1.8 Preventing tumor development by innate stimulation of the immune 
system 
The research of interaction between the immune system and tumor 
development shows that the innate immune system is also playing an important 
role in tumor development. The innate immune system can inhibit tumor 
development; meanwhile, the improper innate immune response also can 
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promote tumor development, such as chronic inflammation can lead to a tumor. 
Tumor cells can also recruit innate immune cells to escape immune surveillance, 
such as MDSCs and TAMs. These facts indicate that a properly active innate 
immune response could be the first defense to prevent tumor development. 
Studies of different innate immune system stimulators exhibit impressive effects 
on tumor prevention in various animal tumor models as well as in clinical trials 
and treatments of various cancers [153-156]. Most infectious diseases can elicit an 
efficient innate immune response. The remission of malignant diseases caused by 
infection was first observed in the 18th century. In the 1890s, Dr. William Coley 
found that a bacterial infection could induce cancer regression after sarcoma 
surgery and developed the first immunotherapy formula for cancer named “Coley 
Toxins”. Another innate stimulator, Mycobacterium bovis bacillus Calmette-
Gerin (BCG) was also found to have antitumor activity against a variety of 
cancers such as colon, lung, bladder, and skin [154, 156, 157]. The BCG is now a 
widely accepted clinical treatment in cancer immunotherapy, especially in the 
treatment of superficial urothelial carcinoma. Various effective components of 
BCG are identified for its antitumor activity such as polysaccharides, lipids, and 
other protein antigens that are irrelevant to tumors. The most important anti-tumor 
component that was identified was CpG ODN, which is now widely used in the 
treatment of both infectious diseases and cancers [158-160]. In addition to 
bacterial infection, other infections, such as virus infections, also exhibit anti-
tumor activity. The exact mechanisms of the anti-tumor activity of different 
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components by innate stimulation are variable. The most important mechanism is 
the active innate immune response through different Toll-like receptors (TLRs), 
which are extensively characterized pattern recognition receptor families for 
factors associated with bacteria, fungi or viruses. 
 
Figure1. 4 Strategy of innate stimulation to prevent tumor development 
Similar to cancer vaccine development, most current studies and trials of 
anti-tumor innate stimulation are focused on cancer treatment. We proposed here 
to develop a system of sustained stimulation of the innate system to prevent tumor 
development (Figure 1.4). The interaction between the immune system and tumor 
development starts at the beginning of the transformation process of a normal cell. 
The initiation of transformation of a normal cell, such as aberrant expression of 
oncogenes, could induce cellular senescence or apoptosis. The factors released by 
these cells first trigger the innate immune response and could have pro- and/or 
anti-tumor effects depending on the context of the environment.   For the model 
of FS antigen presentation that we proposed above, our strategy of a prophylactic 
cancer vaccine works at the stage when the adaptive immune response is 
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involved in the interaction. The strategy of innate stimulation could allow us to 
prevent tumor development at an earlier stage by directing the innate immune 
response to exhibit anti-tumor effects. Consequently, the active anti-tumor innate 
immune response could also enhance the adaptive immune response against tumor 
development.      
Although the current treatment of innate stimulation yields impressive 
effectiveness, the side effects of these treatments are still the major concern in the 
clinic. For instance, mild cystitis is common in about 90% of the patients who 
receive the BCG treatment. The severe side effects of the treatment can cause 
death, although this occurs in less than 5% of the patients [161]. These results 
indicate that it is necessary to reduce the toxicity of the treatment, especially for 
our strategy of prophylactic innate stimulation. The identification of specific 
effective components is a good direction of the effort since they are much easier 
to characterize and administer. Therefore, it will be easier to control the side 
effects, such as toxicity.        
Study of the B2L protein which was identified from parapoxvirus ovis in 
our Center shows that this protein can inhibit tumor growth in the transplant 
mouse tumor models without a detectable specific immune response to the B2L 
protein [162]. Results of my prophylactic cancer vaccine studies indicate CpG and 
GMCSF also have the potential to prevent tumor development. These kinds of 
innate stimulators are good components for cancer prevention. 
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1.9 Cancer Detection 
Early cancer diagnosis is another important aspect in cancer prevention. 
Most caners are curable in early stage with current therapies. For example, 5 year 
survival of early stage ovarian cancer is up to 95%, while it is only 25% to 30% in 
late stage patients [163]. The main areas of focus for early cancer diagnosis are 
detection through imaging and serological diagnostics. Although imaging 
technology has had tremendous advancements in the last decades, it is still not 
sensitive enough for early cancer detection or not applicable for routine screening 
for various cancers during physical examinations. Serological diagnosis is ideal 
for early cancer detection, since blood travels around all parts of the body and 
carries the information of each organ.  
Actually, all components found in tumors can be detected in the blood of 
cancer patient, such as cancer associated antigens, autoantibodies against cancer 
associated antigens and cancer associated nucleotides, such as RNA and DNA. 
These three different types of biomarkers are the main focus for early cancer 
diagnostic development in the serological analysis. The proteomics analysis of the 
tumor associated antigens attempts to directly detect these biomarkers in the 
blood. Those tumor associated antigens are usually released by the tumor. With 
the remarkable progress of proteomic analysis technology, such as mass 
spectrometry, the sensitivity of proteomics analysis has increased dramatically. 
However, the sensitivity of proteomic analysis is limited by the biomarker 
secretion rate of the tumor and the dilution factor of the volume of whole blood. 
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For example, in the prostate-specific antigen (PSA) test for prostate cancer 
diagnosis, Amelie et. al. estimated the minimum detectable prostate tumor size 
with current PSA analysis ranged from  27 mm3 to 3.45x105 mm3. [164]. Similar 
to the PSA detection, Hori et. al. estimated that with the current serum CA125 
assay for ovarian cancer detection, the detected tumor size will be 25.36mm and it 
will take about 10 years for the tumor to develop to that size [165]. Even with the 
ideal tumor specific proteomic biomarker, it still needs 8.8 years before the tumor 
can be detected at the size of 10.52mm [165].  This is not a sensitive enough test 
for early cancer diagnosis 
Unlike proteomic analysis, the signal of both autoantibodies and 
nucleotide biomarkers can be more sensitive by signal amplification through 
different pathways. For the autoantibody biomarker, the signal is endogenously 
amplified by the immune system. The active B cells can dramatically amplify the 
signal of antigen stimulation by secreting antibodies. The signal of the antibody 
could also be amplified in vitro by using enzyme-linked immunosorbent assay 
(ELISA), protein/peptide micro-arrays, or other antibody detection technologies. 
For the nucleotide biomarkers, the signal can be robustly amplified by in vitro 
methods, such as polymerase chain reaction (PCR). The sensitivity of these 
biomarker detections could be improved by the technology developments such as 
equipment upgrade, in vivo or in vitro signal amplification.  
However the specificity of the biomarker detections is not usually directly 
proportional with the sensitivity improvement. The specificity of those 
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biomarkers is limited by their own characteristics. Most of these types of 
biomarkers are not specific to tumors; they are either overexpressed in the tumor 
cells or induced by the overexpressed targets in the tumor cells. The 
determination of the over-expression of a biomarker is so variable in the 
population and could be effect by other diseases. For example, the current ovarian 
cancer serum biomarker CA125 can be induced by benign gynecologic causes, 
such as pelvic inflammatory disease, and nongyneologic disorders, such as 
peritoneal inflammatory disorders [166]. The CA125 serum level above the 
current ovarian cancer threshold of 35U/ml may be detected in 1% of the healthy 
population and 6% of the patient with benign disease [167]. For example, normal 
cells also express PSA, a current biomarker for prostate cancer. The false positive 
of the prostate cancer diagnosis based on PSA detection is approximately 80%. 
The nucleotide biomarkers are similar to proteomic biomarkers. For example, 
most micro RNA biomarkers have comparably higher levels in cancer patient 
blood compared to normal people. The specificity limitation of the microRNA 
biomarkers is the sensitive quantification of the in vitro signal amplification 
without a reliable internal reference. One of the specificity limitations of the 
autoantibody is that some of those are shared biomarkers with other diseases. For 
example, autoantibody against c-myc is also detected in autoimmune disease, 
such as systemic lupus erythematosus [168].     
These limitations of current serological biomarkers indicate that it is 
necessary to discover more specific biomarkers with robust detection methods.  
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CHAPTER 2  
PROPHYLACTIC CANCER VACCINE DEVELOPMENT 
2.1 Introduction 
Cancer prevention through the prophylactic cancer vaccine is a historical 
goal of the cancer research area and it has been revised recently with the 
development of an approved therapeutic cancer vaccine. However, most recent 
strategies for prophylactic cancer vaccine development are still limited by the 
vaccine antigens that have been tried for the therapeutic vaccines. We 
summarized previously studies and developed our own strategy of the cancer 
prophylactic cancer vaccine development, which is based on the FS antigens.     
The inherited characteristics of genomic instability in tumor cells make FS 
antigens a good source of candidates for screening for prophylactic cancer 
vaccine development. The FS transcript can be generated by various processes 
that are fundamentally affected by genomic instability, such as abnormal 
alternative splicing, trans-splicing, translocation and microsatellite instability 
(MSI).  
Particularly, MSI can be caused by genetic FS mutations in genes 
containing coding microsatellites and are well documented in colorectal, gastric 
and endometrial cancers with DNA mismatch repair deficiency. For example, by 
analyzing 11 MSI-high colon cancer cell lines, David et. al showed high FS 
mutation frequency of genes containing coding microsatellites, including 13 
previously reported genes and 5 new candidates [169]. 
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Abnormal splicing is another source of FS transcripts. The tumor 
associated and specific abnormal splicing events are also well studied, while most 
of them focus on the functional analysis of these splicing events for tumor 
development. By bioinformatics analysis of the Expressed Sequence Taq (EST) 
database, we detected 43 tumor specific and 53 tumor associated FS transcripts 
that encode longer than 8 amino acids FS peptides in various tumor EST libraries 
[129].  
In addition to those two well studied sources, we also discovered a de 
novo source of FS transcripts: the chimeric FS transcripts which contain two 
different genes with a shifted reading frame of downstream gene. These 
transcripts can be caused by translocation at the genomic level or trans-splicing at 
transcriptional level. After years of study, we generated a list of the chimeric FS 
candidates by bioinformatics analysis and cDNA sequence confirmation, 
including 48 chimeric FS transcripts that were validated in 50 human breast tumor 
cell lines and 68 primary human breast tumors. All of these FS antigens are 
suitable candidates for vaccine development. In silico analysis reveals that the 
whole list of FS candidates contains enough epitopes to cover most HLA 
haplotypes in the human population. Although different types of tumors possess 
different FS transcript profiles, the whole list of FS candidates is enough to cover 
the tumor types that we have investigated so far. 
We tested our concept of a prophylactic cancer vaccine in two types of 
mouse tumor models: a transplant mouse tumor model and a transgenic mouse 
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tumor model. In the transplant mouse tumor model, we set up the mouse breast 
tumor model 4T1/Balb/c and the mouse melanoma tumor model 
B16F10/C57BL6. These models allowed us to quickly evaluate FS candidates. 
We also set up two strains of transgenic mouse models which were BALB-NeuT 
and FVB/N-NeuT. These are two models that are widely used mouse breast tumor 
models which more closely resemble human breast tumor development. The 
BALB-NeuT mouse strain contains rat mutant Her2 and specifically expresses the 
constant active Her2 in the mammary glands by the MMTV promoter [119]. All 
of the 10 mammary glands of the mice will develop a breast tumor in 25 weeks 
[117]. The FVB/N-NeuT mouse strain contains Rat wild type Her2 gene with the 
same promoter as BALB-NeuT [170]. This strain takes 20 to 40 weeks to develop 
2.5 breast tumors on average. We used these two transgenic mouse tumor models 
to evaluate our vaccine candidates in a prophylactic setting.  
Here, I will discuss our proof of concept experiments for the development 
of the prophylactic cancer vaccine based on the FS antigens. I mainly use one FS 
antigen from our list, SMC1A FS, which is shared by both human and mouse 
tumor cells. 
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2.2 Results 
2.2.1Detection of SMC1A FS  
2.2.1.1 Detection of SMC1A FS transcript 
 
Figure2. 1 SMC1A WT and FS A. SMC1A WT and FS splicing transcript; B. 
FS peptide in human, mouse and dog; C. different SMC1A peptides used in 
following experiments. WT: wild type; FS: frame shift; PTC: premature 
termination codon  
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Table 2. 1 Alignment of mouse and human SMC1A exon 4. A. DNA sequence 
alignment of mouse and human SMC1A exon 4. There is 90% identity. B. 
Alignment of peptide sequence of third reading frame (FS) of SMC1A exon 4. 
Red bars present the stop codons. There is 74% identity of the entire sequence and 
76% identity of the FS peptides. C. Alignment of peptide sequence of first reading 
frame (WT) of SMC1A exon 4. There is 100% identity.   
 
 
The wild type SMC1A has multiple important functions in stabilizing 
sister chromatids during DNA replication, DNA repair in the ATM pathway and 
controlling gene expression. The SMC1A FS transcript was first detected by 
bioinformatics analysis by Bu and Johnston. The SMC1A FS transcript was 
present in 3 different human tumor EST libraries: mammary gland, skin and eye 
tumors. The SMC1A FS transcript is generated by directly splicing exon1 to 
exon4 of the SMC1A gene. The FS transcript is 302 base pairs shorter than the 
WT by missing exon2 and exon3 (Figure2.1). The abnormal splice changes the 
reading frame of exon4 and generates a PTC. The FS transcript encodes a 
truncated 54 amino acids protein including 37 amino acids of the wild 
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type sequence and 17 amino acids of the FS peptide tail at C-terminus. The 
predicted molecular weight of the truncated protein is 6.08 KD. The SMC1A is a 
highly conserved gene. Alignment of both DNA sequence and peptide sequence 
of the WT exon4 between mouse and human SMC1A showed the 90% and 100% 
identity respectively. It is interesting that the third reading frame of the exon 4 of 
mouse and human SMC1A also showed 74% identity (Table 1.1). The molecular 
weight of the FS truncated proteins in mouse is 5.94KD. To validate the 
bioinformatics analysis in tumor cDNAs, I designed a pair of flanking primers 
located on exon1 and exon4. The pair of primers can amplify both WT and FS 
transcripts in the same RT-PCR reaction with a 302bp difference from missing 
exon2 and exon3 in the FS transcript. We detected SMC1A FS in all human 
tumor cDNAs by endpoint RT-PCR with the flanking primers. These results came 
from a variety of cDNAs including 8 commercially primary breast tumor cDNAs 
(Figure 2.2 A) and 33 breast tumor cell lines (Figure AP 2.1). We also detected a 
relative lower level of the SMC1A FS transcript in 2 commercially human normal 
mammary gland cDNAs (Figure 2.2 A) and a non-tumorigenic epithelial cell line 
MCF-10A and normal pancreatic epithelial cell line HPDE6 (Figure AP 2.1). To 
quantify the different FS transcript levels in tumor and normal tissues, we applied 
quantitative RT-PCR with a Taqman probe which specifically hybridized to the 
SMC1A FS transcript (the experiment was performed by Dr. Buendia, Jose Cano, 
CIM). This data was normalized by beta-actin RNA. Results demonstrated that 
the FS transcript level is frequently higher 2 to 72 fold in human primary breast 
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tumors compared to normal mammary gland tissues (Figure 2.2 B). To validate 
the bioinformatics prediction of the SMC1A FS transcript in mouse and dog, we 
also screened the SMC1A FS in mouse and dog primary tumors and normal 
tissues cDNAs (Figure 2.3 A, Figure 2.4), as well as different mouse tumor cell 
lines (Figure 2.3 B). Similar to the screen in human cDNAs, we detected the FS 
transcript in all tumor cDNAs, as well as in some normal tissues. The different 
RT-PCR results of B16F10 cell in Figure2.3 A and B were caused by the different 
PCR settings. In summary, the RT-PCR analysis of different tumors demonstrated 
the SMC1A FS transcript presents commonly in different tumors and the q-PCR 
analysis suggested that the SMC1A FS may be overexpressed in tumors.      
 
Figure2. 2  RT-PCR and Q-PCR analysis of SMC1A transcript in human 
primary brease tumors and normal mammary glands. A. RT-PCR analysis of 
8 human primary breast tumor cDNA and 2 normal mammary gland cDNA; B. Q-
PCR analysis of relative expression of SMC1A FS transcript in those cDNA 
samples. Expression level is normalized by beta actin. The experiment was 
performed by Dr. Buendia, Jose Cano, CIM. 
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Figure2. 3  RT-PCR analysis of SMC1A FS transcript in mouse normal 
tissues and tumors. A. SMC1A FS transcript in C57BL6 mouse normal tissues 
and melanoma tumor cell line B16F10; B. SMC1A FS transcript in mouse tumor 
cell lines and mouse spontaneous tumor 
 
 
Figure2. 4  RT-PCR analysis of SMC1A FS transcript in dog primary tumors 
and normal tissues. A SMC1A FS in dog tumor. 1. melanoma; 2. osteosarcoma; 
3.lymphosarcoma;4.hemangiosarcoma; 5. mammary; 6. mast cell tumor; 7. 
transitional cell carcinoma; 8. thyroid adenocarcinoma; B. SMC1A FS transcript 
in dog normal tissues. 1. cerebellum; 2. spleen; 3. mammary; 4. ovary; 5. 
pancreas; 6. thyroid; 7. small Intestine; 8. stomach; 9. tonsil; 10. heart; 11. liver 
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Figure2. 5 RT-PCR analysis of SMC1A FS transcript in normal mammary 
gland and breast tumors of FVB/N-NeuT . 1. normal adjacent mammary gland; 
2. neoplasm of mammary gland; 3 and 4. established breast tumors 
   
As described above, one important characteristic of the FS antigens for use 
in a prophylactic cancer vaccine is their expressions during early stages of tumor 
development. I analyzed the FS transcript of SMC1A in different stages of tumor 
in the FVB/N-NeuT mouse breast tumor model. cDNAs from a normal adjacent 
mammary gland, an early neoplasm and two fully developed breast tumors were 
analyzed (Figure2.5). As predicted, the expression of tumor derived transgene rat-
her2 is increased along with tumor development. Interestingly, the SMC1 FS 
transcript level is also increased with tumor development. This indicates that the 
SMC1 FS transcript is trigged at an early stage of tumor development.    
2.2.1.2 Analysis of SMC1A gene in Panc1 cell line 
It is important to determine if there is a genetic mutation causing the FS 
transcript, because this will determine the level of the specificity of the SMC1A 
FS for the vaccine development. I did the investigations on the human Panc1 cell 
lines. Since the SMC1A FS transcript is a perfect splicing of the exon1 and exon4, 
I first checked if there is any genetic mutation at the splicing sites. I designed 
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primers to amplify a SMC1A gene fragment around the splicing sites of exon 2 
and 3 in Panc1 tumor cell line. It starts from about 100 base pairs of 3’ end of 
intron1 to 100 base pairs of 5’ end of intron3 (Figure 2.6). Sequence results 
confirmed that there is no gene mutation in these areas. To investigate if there is 
exon2 and 3 deletions in the Panc1 cell line, I set up a long fragment PCR 
reaction to amplify the gene fragment from exon1 to exon4. However, there was 
no amplified band. This indicates that there is no big gene deletion including 
exon2 and exon3. This indicates the SMC1A FS transcript may be caused by the 
alternative splicing in Panc1 cells. The detail characterization need to be done to 
confirm that alternative splicing is the common causing of the SMC1A FS 
transcript in different tumors.  
 
Figure2. 6  Analysis of SMC1A gene in Panc 1 tumor cell line. Sequence 
confirmed that there was no mutation around exon2 and exon3. There was no 
deletion from intron1 to intron3 
2.2.1.3 Detection of the immune response to SMC1A FS peptide in tumor 
bearing mice    
As described above, there are different levels to control the specificity of 
the FS antigens as the vaccine candidates. Some FS antigens may be caused by 
genetic mutations, such as translocations; some may be caused by 
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alternative splicing, such as SMC1A FS in our studies. The relevant specificity 
with regard to the vaccine development is whether this FS antigen is specifically 
exposed to the immune system by tumor cells. The way to determine this 
specificity is detecting endogenous immune response to the FS antigens. This 
analysis could not only demonstrate the specificity of the FS antigen, but also 
potential immunogenicity of the FS antigen, which is also important for the 
vaccine development. I analyzed both antibody reactivity and T cell responses to 
SMC1A FS peptide in the FVB/N NeuT mouse model. All FVB/N NeuT mice in 
the analysis were breeding females with end point tumor development according 
to our animal protocol. I detected antibody reactive to mouse SMC1A FS in sera 
from 5 of the tumor bearing females compared to 4 age matched no-tumor bearing 
breeding males which carried the same transgene (Figure 2.7). I also detected 
splenocytes specific to the SMC1A FS peptide in 3 of 4 tumor bearing females 
through an IFN-gamma ELISPOT assay (Figure 2.8). More importantly, there 
was no T cell activation of the FS portion (17aa) or the WT portion (37aa) alone. 
Only the combination of FS peptide and 10aa upstream of WT portion stimulated 
strong IFN-γ release splenocytes. I did not detect the IFN-γ releasing splenocytes 
in non-tumor bearing FVB/N male mice, nor in normal BALB/C and C57BL6 
mice. This demonstrated that although some normal tissues also express the 
SMC1A FS, only the tumor cells expose the antigen to the immune system and 
induce the immune response.  
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The detection of the endogenous immune response to the SMC1A FS 
peptide only in tumor bearing mice demonstrated that the SMC1A FS antigen is 
specific to tumor cells at the immune response level. This also indicates there is 
an efficient T cell epitope in the junction of the WT and FS tail of the SMC1A FS 
truncated protein.  
 
Figure2. 7  ELISA analysis of IgG activity to mouse SMC1A FS 27aa. 1. 26 
weeks old tumor bearing FVB/N-NeuT females (n=5); 2. Age matched tumor free 
FVB/N-NeuT males (n=4). one-tail t-test p<0.05 
 
 
Figure2. 8  ELISPOT analysis of IFN-gamma release splenocytes. Splenocytes 
from four tumor bearing FVB/N-NeuT mice were restimulated with different 
peptides. The IFN-gamma releassed splenocyte were detected and counted with 
stand protocol 
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2.2.2 Protection of immunization of SMC1A FS in mouse tumor models   
2.2.2.1 Epitope prediction 
SMC1A FS is a very simple antigen. Mouse SMC1A FS peptide tail is a 
total of 17 amino acids long. I used Rankpep to predict the H2d, H2b and H2q 
binding epitopes. Those MHC I haplotypes belong to BALB/c, C57BL6 and 
FVB/N respectively, which were three mouse strains used for our mouse tumor 
models. Unlike most self protein antigens containing many epitopes, there is a 
handful epitopes of the SMC1A FS peptide, even by adding 10aa of WT peptide. 
Additionally, there is no epitope which has a predicted binding score higher than 
the binding threshold. The limited number of eptitopes and limited binding 
capacity make it a challenge to elicit efficient and appropriate immune responses 
against tumor. Besides the possible epitope prediction based on the binding 
capacity to different haplotypes, there are only two predicted epitopes based on 
proteasome cleavage prediction and both of them are located at the junction of 
WT and FS peptide. These results correspond to the detected T cell immune 
response in tumor bearing mice.  
The SMC1A FS epitope predication in human population presents a 
similar situation. With the IEDB analysis, there are only 4 epitopes that could be 
recognized by four rare HLA types. One of them is located at the junction of WT 
and FS peptide. However, based on the proteasome cleavage prediction, there are 
four epitopes, 2 of them are located at the junction of WT and FS peptide, and 
another two are located at FS tail.    
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2.2.2.2 Optimization of Immunization 
I mainly used genetic immunization with gene gun in most of the in vivo 
protection analysis. Later on, I also boosted the immune response with peptides or 
recombinant proteins. It is widely accepted that with the appropriate regimen and 
adjuvant, genetic immunization can efficiently elicit Th1 immune response [143, 
145]. The combination of genetic immunization and protein boost is also the most 
efficient immunization regimen. Additionally, genetic immunization with the 
gene gun is an efficient method to screen our FS antigen candidates in the future.  
The efficiency of an immunization regimen varies among different strains 
of mice with different genetic backgrounds relative to their immune system. I 
needed to adjust the immunization regimen in different models. Predicting the 
level of protection based on the immune response alone is also difficult. 
Therefore, I usually directly evaluated the protection of different regimens in 
mouse tumor models to optimize the immune regimen. This is a more direct 
method to optimize the efficiency of the immunization regimen.  
Setting up the correct control is also important for optimization. In the 
study, there was a negative control for tumor inhibition to evaluate the protection 
of FS antigen and a positive control of immune response to evaluate the efficiency 
of immunization. I tried different controls over the course of the study. Human 
alpha-1 antitrypsin (AAT) is the first control antigen I tried. This is a high 
immunogenicity antigen and is irrelevant for tumor inhibition. The high 
immunogenicity of AAT makes it easy to elicit a strong immune response. 
 
62
Consequently, it is hard to evaluate the efficient of different immunization 
regimens. I also tried another control antigen, CPV172. This is a protein from 
cowpox virus studied in our lab [171]. CPV172 can efficiently induce a T cell 
immune response. I used this antigen to optimize the regimen for eliciting a T cell 
immune response to SMC1 FS. Later I also used empty vectors and no-antigen 
fused recombinant protein for negative controls.  
The adjuvant was another important factor for both protein and genetic 
immunizations. The choice of adjuvant is expanded with the development of 
genetic immunization with the gene gun [143-145]. The conventional micro gold 
delivery method can only deliver 1ug DNA molecules, such as plasmids. I tried 
two adjuvants for genetic immunization: a plasmid expressing mouse 
Granulocyte-macrophage colony-stimulating factor (GM-CFS) and two plasmids 
expressing heat-labile enterotoxins (LT). GM-CSF is a hematopoietic cytokine. It 
is widely use as an adjuvant in cancer vaccine trials in both humans and mice. 
Local administration of GM-CSF enhances the recruitment of dendritic cells and 
also induces their maturation [172]. This cytokine also has a function to activate 
macrophages, granulocytes and NKT cells. LT is another strong adjuvant that can 
elicit a Th1 immune response with the genetic immunization [173]. After we 
developed charged gold and nano gold delivery methods [146], we could 
efficiently deliver small nucleotides for genetic immunization, such as CpG 
oligodeoxynucleotides (CpG ODNs). CpG is another widely used adjuvant in 
both infectious disease and cancer vaccines. This adjuvant enhances the immune 
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response by triggering Toll-like receptor 9 in antigen presenting cells and 
inducing the releasing of Th1 cytokines. Both CpG 2395 and CpG 2216 were 
tested.  CpG2216 belongs to CpG class A, which can active NK cells and induce 
IFN-alpha production in plasmacytoid dendritic cell precursors; CpG2395 belongs 
to CpG class C and it can active B cells and NK cells, as well as induce IFN-alpha 
production of human peripheral blood mononuclear cells. Both CpGs are directly 
compared in mouse tumor model. I also tried a novel adjuvant for genetic 
immunization: B2L, the virus protein identified in parapoxvirus ovis[162]. 
Besides its anti-tumor activity mentioned earlier, the adjuvant function of B2L 
mainly relies on the attraction of antigen presenting cells (mainly DC). B2L can 
significantly increase the immune response when it is co-immunized with 
antigens [162].  
2.2.2.2.1 Dosage optimization 
There are many factors that need to be optimized in order to elicit an 
appropriate immune response. The dosage of an antigen is one of the most 
important factors in the immunization. Especially in the primary immunization, 
different dosages of antigen will activate different proportions of high affinity T 
cells and low affinity T cells. Consequently, the dosage will affect the efficiency 
of an anti-tumor immune response. Instead of setting up a complex immune 
response analysis, such as titration ELISPOT, to evaluate the proportion T cells 
with varying affinity that have been activated by different dosages of primary 
immunization; I designed a quick immunization regimen with one 
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primary genetic immunization following tumor challenge. This strategy can 
directly reveal the best primary immunization dosage that necessary to elicit an 
efficient anti-tumor immune response by FS genetic immunization. In the dosage 
optimization experiments, I used the combination of two FS antigens with known 
protection: 1-78 and 6-21. 1-78 and 6-21 are FS antigens found in different human 
and mouse tumor cells, and they provide protection in different mouse tumor 
models. Besides the non-treated group and the AAT negative control group, there 
were four groups immunized with 1.5ug, 0.1ug, 20ng and 5ng of combined FS 
antigens. After 5 days of one genetic immunization with different dosages, all of 
the mice were challenged with 106 B16F10 tumor cells subcutaneously. 
Interestingly, the tumor growth curve revealed that the group immunized with 
20ng of FS antigens received the best protection. All of the other groups did not 
show protection by primary immunization (Figure 2.9). High amount of antigen 
apparently are not protective.  Therefore the 20ng of primary genetic 
immunization was chosen as the optimized dosage for the following experiments. 
I also compared the genetic immunization alone and genetic immunization with 
protein boost (Figure 2.10). It revealed that the protein boost did not improve the 
protection with a pool of FS antigens of 1-78 and 6-21.    
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Figure2. 9  Dosage optimization of FS antigen. A. Immunization regimen. B. 
tumor growth curve of different groups as labeled. 5 mice per group; antigen 
group were immunized with different dosage of pooled 6-21 and 1-78 as 
indicated; GMCSF as adjuvant for genetic immunization; error bar are standard 
error.  
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Figure2. 10  Comparing different immunization regimens. A. immunization 
regimen. B. tumor growth curve of different groups. 5 mice per group; AAT 
group as negative control; vaccine group were genetic immunized pool of 20ng 
each of 1-78 and 6-21; protein boost were a pool of 5ug each recombinant 
proteins of GST fused 1-78 FS peptide and GST fused 6-21 FS peptide; GMCSF 
as genetic adjuvant and IFA as protein adjuvant; error bar are standard error.  
2.2.2.2.2Antigen optimization 
Both endogenous immune responses and epitope prediction showed that 
the potential protective epitope was located at the junction of the WT and FS 
peptide. To confirm the prediction and decide which form of FS antigen to further 
study, I compared the protection of SMC1A FS peptide (17aa) and SMC1A 
WT+FS peptide (10aa WT with 17aa FS) in the B16F10/C57BL6 mouse tumor 
model. With the prophylactic immunization setting, the tumor growth curve of the 
SMC1A FS immunization group is no different from the negative control group, 
while the SMC1A WT+FS group exhibited the inhibition of tumor growth (Figure 
2.11). These results confirmed the prediction that the immunogenic epitope was 
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located at the fusion of the WT and FS peptides. I decided to use SMC1A WT+FS 
as a vaccine candidate for further investigation. In following description, I will 
use SMC1A FS to represent the immunization of the 27amino acid SMC1A 
WT+FS peptide for convenience.   
 
Figure2. 11  Optimization of SMC1A FS antigen. A. Immunization regimen. B. 
tumor growth curve of different groups as labeled. 5 mice per group; AAT were 
immunized with AAT as negative control; 1+6 were immunized with pool of 1-78 
and 6-21; SMC FS were immunized with SMC1A FS 17mer peptide; SMC 
WT+FS were immunized with SMC1A FS peptide puls with 10 aa upstream WT 
peptide; GMCSF as genetic adjuvant; error bar are standard error   
2.2.2.2.3 Adjuvant and regimen optimization 
The most optimizations were developed in the B16F10/C57BL6 mouse 
model. With the genetic immunization of conventional micro gold particles, I 
compared adjuvant affects of LT and GM-CSF with the optimized dosage of 
SMC1A in the same setting (Figure 2.12). The different adjuvants did not affect 
tumor growth in the AAT control group. The LT adjuvant caused the loss of 
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protection in the 1-78 and 6-21 pooled group and it even promoted tumor growth 
in the SMC1A group. There was a higher IgG antibody reactivity to SMC1A FS 
in mice immunized with LT adjuvant (Figure 2.13). No antibody reactivity to 1-
78 and 6-21 FS peptides was detected in both groups immunized with 1-78 and 6-
21 FS peptides. There was no detectable IFN-gamma releasing splenocytes to any 
FS peptide in all groups in the ELISPOT assay. This indicated that antibody 
activity is not the important protective immune response in this model. I need to 
test adjuvants that can elicit more balanced immune responses.  
 
Figure2. 12  Optimization of genetic adjuvant. A. Immunization regimen. B. 
tumor growth curve of different groups as labeled. 5 mice per group; 20ng of each 
FS antigen or AAT per mouse; 1ug LT or GMCSF as adjuvant; AAT were 
immunized with AAT as negative control; 1+6 were immunized with pool of 1-78 
and 6-21; SMC1 were immunized with SMC1A FS 27mer peptide; error bars are 
standard error   
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Figure2. 13  ELISA analysis of IgG activity against SMC1 FS 17mer peptide 
in mice immunized SMC1 FS with different adjuvants. 5 mice per group; 
duplicates of individual mouse endpoint serum with different group at 1:270 
dilution; error bar are standard error of each group 
 
 
Figure2. 14  Experimental plan for immunization optimization. A. Group 
setting. B. immunization regimen 
 
 
70
 
Figure2. 15  Individual tumor volume at 13 days after tumor inoculation. *: 
p<0.05  
With the genetic immunization with charged microgold particles, I tested 
different combination of GMCSF and CpG as adjuvants followed by tumor 
challenge (Figure 2.14). To analyze the immune response, I ended the experiment 
before the tumor fully developed. By comparing the tumor growth in different 
groups to the immunization with GMCSF alone, only two groups exhibited the 
improvement of protection against tumor: the group4 with the primary and boost 
immunizations with combination of GMCSF and 0.5ug CpG2216 and the group6 
that was just primary immunized with combination of GMCSF and 5ug CpG2216 
(Figure 2.15). To investigate the immune response of the improved protection, I 
analyzed IgG isotype activity by ELISA and IFN-gamma releasing splenocytes by 
ELISPOT. The group that was primary and boost immunized with the 
combination of GMCSF and 0.5ug CpG2216 exhibited the balance of IgG 
subtype activity against SMC1A FS peptide by ELISA and T cell activity by 
ELISPOT, while the group that was just primary immunized with combination of 
GMCSF and 5ug CpG2216 exhibited no antibody activity but the high T cell 
activity (Figure2.16 and 2.17).  
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In summary, based on the efficacy of tumor inhibition, the immunization 
regimens of the group4 and group6 exhibited the most protection. It also 
suggested that both antibody and T cell immune response are important for the 
protection. For example, the group1 had strong antibody activity and low T cell 
activity, while the group5 had no antibody activity and high T cell activity. 
Neither of these groups showed as protection as the group4, which had more a 
balanced immune responses of antibody activity and T cell activity. It was 
interesting that the group6 showed the best protection while only exhibiting the 
strong T cell activity by one low dosage genetic immunization. In the infectious 
diseases vaccine development, the low dosage and long period resting time could 
elicit high avidity T cell response ([173] and communication with Dr. Stephen 
Johnston). This may be the same mechanism in the group6. Although there was 
no antibody response, the high avidity T cell response still could efficiently 
inhibit the tumor development. However, there was no immune response detected 
to the 6-21 and 1-78. And both group2 and group3 exhibited relative balanced 
immune responses, while there were no significant improvements of the 
protection. This indicates that the immune response analysis that I applied may be 
not sensitive enough to detect all of the anti-tumor activities. I need to improve 
the analysis in the future.    
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Figure2. 16  ELISA analysis of IgG subtype activity against SMC1A FS 
peptide of pooled endpoint serum of each group. Serum dilution 1:100; in 
duplicate 
 
 
Figure2. 17  ELISPOT analysis of IFN-gamma released by splenocytes. 
Splenocytes from each mouse were incubated with different antigens in triplicate 
for 48 hours at 20ug/ml concentration and followed standard protocol for spots 
development; each column represents average spots of each group with different 
antigens; error bars represent standard error (SEM)  
 
Later, I also compared the different immunization regimens of 
combination of SMC1A FS and CPV172 with different adjuvant compositions 
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with the protein boost (Figure 2.18). All groups demonstrated the robust IgG1 
activity to SMC1A FS, while only the group with the adjuvant of CpG2216 and 
LTAB had the IgG2c (equivalent of IgG2a in C57BL6) activity (Figure 2.19). 
More detailed subtype analysis of the two groups with CpG plus GMCSF and 
CpG plus LTAB demonstrated that the latter adjuvant combination elicited a 
balanced IgG subtype activity with genetic immunization alone and an even more 
balanced activity with a protein boost (Figure 2.20). This indicated that the CD4 T 
help cells were successfully activated by the immunization regimen. There is no 
detectable SMC1A FS specific IFN-gamma releasing splenocytes in any of the 
groups.    
 
Figure2. 18  Detail of experimental plan for adjuvant optimization. 5 mice per 
group; GI: genetic immunization; PI: protein immunization; all mice were 
euthanized at week 14 for immune response analysis  
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Figure2. 19  ELISA analysis of IgG subtype activity against SMC1A FS 
27mer. Serum dilution 1:1000; each column represents average OD of each group 
with different IgG subtype as labeled; error bars are standard error 
 
 
Figure2. 20  Detail subtype IgG analysis against SMC1A FS 27mer of two 
groups: A. subtype analysis of group use CpG and GMCSF as adjuvant; B. 
subtype analysis of group use CpG and LTAB as adjuvant. Each column 
represents average OD of each group with different IgG subtype as labeled; error 
bars are standard error  
 
I also tried a regimen to knock down the Treg cells with 
cyclophosphamide treatment before the immunizations to enhance the cellular 
immune response. This approach failed to enhance the immune response or 
provide protection. The treatment needs to be optimized and more carefully 
administrated.  
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Figure2. 21 Summarize of IFN-gamma release splenocyte ELISPOT analysis 
of SMC1A FS and CPV172 immunization with different regimens 
 
Summarizing all of the optimizations in C57BL6 mice, the results showed 
that the proper immunization regimens could robustly elicit specific IgG activity 
to SMC1A FS with a balanced IgG subtype, which indicates that the CD4 T cells 
were activated. On the contrary, there was no detectable cellular immune response 
measured by IFN-gamma ELISPOT of the splenocytes in all settings with 
immunization alone, while the cellular immune response to a positive control 
CPV172 was increased alone with an immunization intensity dependent increase 
as predicted (Figure2.21). However, the cellular memory immune response was 
successfully elicited by the primary genetic immunization with a low dosage of 
SMC1A FS and boosted more than 20 folds higher by the B16F10 tumor cell 
challenge (Figure 2.21).  
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In summary, the optimization suggested the following principles for FS 
antigens immunization: 
1. There are possible protective epitopes located at the junction of the WT 
and FS peptide tails. Those also are specific tumor epitopes and it is helpful to 
include them into the FS immunization. 
2. The humoral immune response could be robustly elicited by different 
immunization regimens.  
3. Low primary immunization dosage is critical for eliciting the cellular 
immune response to the FS antigens.  The antibody isotype switch indicates the 
stimulation of the CD4+ T cell. The memory CD8+ T cell immune response also 
could be elicited. However, there is no evidence of eliciting the active CD8+ T 
cell by the immunization.  
4. CpG2216 is the essential adjuvant for stimulating the efficient anti-
tumor immune response. Both GMCSF and LTAB need to be combined with 
Cp2216 to maximize the adjuvant to enhance the anti-tumor immune response.  
5. Protein based boosts did not show a positive effect to improve the anti-
tumor immune response, and it did not have negative effect either.   
Because C57BL6 is a TH1 immune response biased mouse, the detailed 
immunization regimens may still need to be further adjusted based in a more 
wild-type background and humans.   
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2.2.2.3 Evaluation of primary tumor prevention   
During the optimization of the immunization, I have already demonstrated 
the protection provided by SMC1A FS, as well as other FS candidates. This work 
was primarily performed with the B16F10/C57BL6 mouse tumor model. To 
prove our concept of a broad prophylactic cancer vaccine, I also tested the 
protection in various mouse tumor models by immunization of SMC1A FS and 
other FS candidates. The initial optimization indicated that the general principles 
of the FS antigen immunization could be successful. The efficient immunization 
regimen is also dependent on the different genetic background of the immune 
system in different mouse models. The adjusting of the immunization was 
performed to evaluate the effect of tumor prevention in different mouse tumor 
models.     
2.2.2.3.1 Protection in transplanted mouse tumor models 
Both B16F10/C57BL6 and 4T1/BALB/c transplant mouse tumor models 
are the first models that were introduced in our studies. These models are useful 
to quickly evaluate our FS candidates.   
2.2.2.3.1.1 Protection in B16F10/C57BL6 model 
With the optimized immunization regimen (Figure 2.14), I evaluated 
individual FS candidates in this model (Figure 2.22). As predicted, all of the three 
FS candidates provided the protection by inhibiting the tumor development 
compared to CVP172 negative control group (Figure 2.23).  Without the protein 
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boost, there was no detectable IgG activity as demonstrated in the previous 
optimization experiments (Figure 2.24).   
 
Figure2. 22  Detail experimental plan for protection evaluation of FS 
antigens in B16F10/C57BL6 mouse melanoma tumor model 
 
 
 
Figure2. 23  Tumor size measurement. A. Tumor growth curve. B. Individual 
tumor size of each mouse at 14 days after tumor inoculation. * p<0.05   
2.2.2.3.1.2 Protection in 4T1/BALB/c model 
4T1/BALB/c is another model in my study. I tested the protection with 
different immunization regimens along with the development of the 
 
79
optimization. Only the 1-78 and SMC1A FS transcripts were detected in the 4T1 
cells. In some experiments, I included the 6-21 for control. Before the dosage 
optimization, there was barely detectable protection of 1-78 in this model. The 
lower dosage immunizations significantly increased the protection (Figure 2.24 
and Figure 2.25 A). Both SMC1 and 1-78 and 6-21 pooled groups exhibited the 
inhibition of tumor growth compared to the AAT negative control group. The 
specific IgG activity against SMC1A FS peptide was detected in the SMC1 group 
(Figure 2.25B); while there was no detectable IgG activity against 1-78 and 6-21 
peptides in the 1-78 and 6-21 pooled group.  
 
Figure2. 24  Detail experimental plan for protection evaluation of FS 
antigens in 4T1/BALB/c mouse breast tumor model 
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Figure2. 25  Protection analysis of 4T1/BALB/c mouse breast tumor model. 
A. Tumor growth curve. B. ELISA analysis of IgG activity against SMC1A FS 
27mer 
 
I also tested the regimen of one genetic immunization alone with GMCSF 
and CpG2216 in the 4T1/BALB/c model (Figure 2.26). This experiment was 
designed for evaluating the prevention of the tumor in BALB-NeuT breast tumor 
model. Those transgenic mice failed to develop spontaneous breast tumors after 
they were 30 weeks old for unknown reasons. As an alternative, I used these mice 
as a transplanted tumor model by challenging these mice with 4T1 cells to 
evaluate the long term prevention of our prophylactic cancer vaccine. As 
designed, all mice were immunized with different antigens at 4 to 5 weeks old and 
were challenged with 5x103 4T1 cells at 26 to 38 weeks old. One primary 
immunization can efficiently inhibit tumor development after more than 3 months 
as seen on the tumor growth curve (Figure 2.27). There was no detectable IFN-
gamma released splenocytes to any of the FS peptides and there was low IgG 
activity to SMC1A FS 27mer in the SMC1A FS immunized group.  
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Figure2. 26  Detail experimental plan for protection evaluation of FS 
antigens in 4T1/BALB/c mouse breast tumor model 
 
Figure2. 27  Tumor growth curve of each group. Error bars are standard 
error 
In summary, I demonstrated the prophylactic protection of SMC1A FS 
antigen in two different mouse transplant tumor models, as well as other FS 
antigens. The mouse transplant tumor models are useful for quick functional 
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vaccine candidate screening. However, since the tumor development in these 
models is so aggressive, they are not suitable to test the concept of the 
prophylactic cancer vaccine. Therefore, we tested the prophylactic cancer vaccine 
in transgenic mouse tumor models.      
2.2.2.3.2 Protection in transgenic mouse tumor models 
The transgenic mouse tumor models are widely used in different types of 
cancer research. The mice in these tumor models spontaneously develop different 
types of tumors due to different gene modifications. These mouse tumor models 
more closely mimic the natural tumor development compared with the traditional 
tumor cell transplant mouse tumor models. The transgenic models offer an 
alternative to the transplanted mouse models to test the prophylactic cancer 
vaccines. However they are still limited relative to tumor development in humans 
in that many cells over a short period are converted to pre-tumor cells.    
2.2.2.3.2.1 Protection in the FVB/N NeuT model 
All mice were genetically immunized with different antigen components 
and GMCSF and CpG at 4 to 5 weeks old. The tumor development was monitored 
weekly (Figure 2.28). I did not detect 6-21 FS transcript in the FVB/N NeuT 
tumors as was the case for 4T1 cell line. Both CPV172 and 6-21 immunized 
groups were negative control groups. To evaluate the protection, I analyzed the 
tumor free rate and tumor multiplicity curve along with the tumor development in 
different groups (Figure 2.29 and Figure 2.30). Over all, both 1-78 and SMC1 FS 
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antigens exhibited inhibition of breast tumor development in the FVB/N-NeuT 
mouse model compared to the no-treatment group. However, with all individual 
antigen immunization, there was no difference in the tumor inhibition among 
these four groups. The negative control groups CPV172 also exhibited the 
significant tumor inhibition compared to the no-treatment group. This may be 
caused by the adjuvant of CpG and GM-CSF treatment, which can enhance the 
innate immune response. I will describe this effect in another chapter. Therefore, 
the adjuvant effect masked the protection of the SMC1A FS and 1-78 compared 
to the other two negative control groups. It is interesting that the pool of them 
with other negative antigens (CPV172 and 6-21) significantly improved the tumor 
inhibition compared to the 6-21 group. This implies that the pool of the SMC1A 
FS and 1-78 may have the additive protection. This need to be further 
investigated.     
 
Figure2. 28  Detail experimental plan for protection evaluation of FS 
antigens in FVB/N-NeuT mouse breast tumor model.  
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Figure2. 29  Tumor free curve of different group in FVB/N-NeuT model. No-
treated group vs. SMC1 group, 4 antigens group and CPV172 group p<0.05  
 
 
Figure2. 30  Tumor multiplicity curve of different groups of FVB/N-NeuT 
model.  
2.2.2.3.2.2 Protection in BALB NeuT model 
The BALB-NeuT mouse carries the active form of rat Her2, which starts 
to be over-expressed in mammary gland at 4 weeks old. The BALB-NeuT mouse 
starts to develop the first palpable tumor around 11 weeks old. Because of 
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the different genetic background of the immune system in BALB/c mice and 
different tumor development period, I tested different immunization regimens in 
the BALB-NeuT mouse tumor model to achieve the best protection (Figure 2.31). 
This revealed that the regimen of a genetic primary immunization followed by 
two genetic boosts and one protein based boost was the best immunization 
regimen for inhibition of tumor development in this model (Figure1.43). The 
combination of LTAB and CpG was the adjuvant for the genetic immunization 
and CpG plus Alum was the adjuvant for the protein based immunization.  
 
Figure2. 31  Detail experimental plan for immunization regimen optimization 
of SMC1A FS in BALB-NeuT mouse breast tumor model 
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Figure2. 32  Tumor multiplicity curve of different groups with different 
immunization regimens.  
 
I also tried different adjuvant combinations with CpG and B2L for the 
genetic immunization (Figure2.33). B2L was found to inhibit of tumor growth in 
the transplant mouse tumor model B16F10/C57BL6. Because of the anti-tumor 
activity of the B2L, the negative control group also had the partial protection 
(Figure 2.34).  
 
Figure2. 33  Detail experimental plan for immunization regimen optimization 
of SMC1A FS in BALB-NeuT mouse breast tumor model with CpG plus B2L 
as adjuvant 
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Figure2. 34  Tumor multiplicity curve of SMC1A group and CPV172 group 
with CpG plus B2L as adjuvant 
 
With the optimized immunization regimen (Figure 2.35), the prophylactic 
immunization of SMC1A FS exhibited not only significant inhibition of first 
tumor initiation (Figure 2.36 A), but also the significant inhibition of  tumor 
progression of developing 10 independent breast tumors (Figure 2.36 B). The 
tumor multiplicity curve also exhibited the significant protection by the 
prophylactic immunization of the SMC1A FS (Figure 2.37).  
 
 
88
 
Figure2. 35  Detail experimental plan for protection evaluation of SMC1A FS 
in BALB-NeuT mouse breast tumor model 
 
 
 
 
Figure2. 36  Tumor development in different immunization groups. A. Tumor 
free curve. P value of SMC1A vs. no-treated group and negative group<0.05. B. 
Tumor progression curve. Measure percentage of mice doesn’t fully develop 
tumors. P value of SMC1A vs. no-treated group and negative group<0.0001; the 
SMC1A FS data were collected from two independent experiments with 11 mice 
and 7 mice respectively.  
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Figure2. 37  Tumor multiplicity curve of SMC1A group, negative group and 
no-treated group in BALB-NeuT model 
 
There was no detectable IFN-gamma released splenocytes in these mice 
with different SMC1 FS antigens stimulation, including peptides, peptide 
conjugated to KLH (Figure 2.38). All mice had high IgG activity to SMC1A FS. 
IgG1 activity was the dominant activity and there were partial subtype switch to 
IgG2a and IgG2b (Figure 2.39). There was no detectable immune response to the 
wild type SMC1A peptide encoded by exon1 of the SMC1A gene including the 
IgG activity and the IFN-gamma released splenocytes. I further analyzed the 
relation between the IgG active and the tumor development in those protected 
mice (Figure 2.40). It indicated there was a significant positive correlation 
between the tumor progress time and the IgG and IgG1 activity to SMC1A FS 
peptide in first set of 11 mice.  
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Figure2. 38  ELISPOT analysis of IFN-gamma release splenocyte in SMC1A 
immunized mice. X axis are individual mouse; stimulators: smc-37: WT(exon 1); 
smc-27: 10aa WT+17aaFS; Smc pool 9mer: 9mers in smc1-27. smc1-54mer: 
exon 1+FS. Ran: random peptide in genetic plasmid; CPV: pool peptides as 
negative control.  
 
 
Figure2. 39  ELISA analysis of subtype IgG activity to SMC1A FS 27mer in 
SMC1A FS immunized mice (11mice). Each bar represents average OD of 
serum from 11 mice with duplicate at 1:5000 dilution; error bars are standard 
error.   
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Figure2. 40  Correlation analysis of tumor progression time and IgG activity. 
OD of total IgG and IgG1 activity against SMC1A FS peptide were measured by 
ELISA of serum after last genetic immunization of 11 mice in first experiment. 
Tumor progression time was defined as time period of mouse getting first 
palpable tumor to 10 tumors. A. Correlation of total IgG activity to tumor 
progression time. B. Correlation of IgG1 activity to tumor progression time. Both 
p value <0.05 by linear regression analysis  
2.2.2.3.3 Additive protection by combine other FS antigens 
The FS antigens are usually short polypeptides containing limited epitopes 
compare to most currently identified self antigens. The expected additive 
protection from adding more FS antigens is one of the important anticipated 
characteristics of the prophylactic cancer vaccine. We expected pooling FS 
antigens to increase the efficiency of tumor prevention and provide more 
coverage of protection against different type of tumors. Single FS antigens as well 
as the combination of a few have already provided the protection in two mouse 
tumor models. Here I summarize some experiments I performed by directly 
comparing the protection of pooled and individual FS antigens.  
First additive protection was analyzed by 1-78 and 6-21 immunization 
(Figure 2.41). With low FS antigen dosage and GMCSF as the adjuvant, both 
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individually immunized 1-78 and 6-21 groups had protection compared to the 
AAT control. Combining 1-78 and 6-21 improved the protection compared to the 
single FS immunization (Figure2.42).  
 
Figure2. 41  Detail experimental plan for additive protection of FS antigens 
in B16F10/C57BL6 mouse melanoma tumor model 
 
 
Figure2. 42  Tumor growth curve of different groups 
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The pool of 1-78 and 6-21 exhibited additive protection with the 
conventional genetic immunization. We expected to have stronger additive 
protection by adding SMC1A FS to the pool and the use of the new genetic 
immunization system and stronger combination adjuvant: CpG plus GMCSF. In 
the experiment, using combination of CpG and GMCSF as the adjuvant and one 
primary immunization (Figure 2.43), all individual FS antigens immunizations 
provided the inhibition of tumor development, as well as the pooled FS antigens 
immunization. However there was no improvement of the protection by pooling 
three FS antigens compared to individual ones (Figure 2.44).  
 
Figure2. 43  Detail experimental plan for additive protection of FS antigens 
in B16F10/C57BL6 mouse melanoma tumor model 
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Figure2. 44  Tumor growth curve of different groups 
Comparing the tumor growth curve of the pooled FS antigens group to an 
earlier experiment with the same adjuvant and similar antigens setting, the 
protection was reduced in the later experiment (Figure 2.45). The different 
protection efficiency between the two experiments may be caused by different 
preparation of the micro gold particles for the genetic immunization (Figure 2.46). 
In the earlier experiment, each gold particle were coated with pooled antigens, 
consequently, each active DC could present all these antigens; while in the later 
experiment, each gold particle only contained a single FS antigen, consequently, 
each active DC could only present one antigen. We need to further investigate if 
the different preparation methods cause the different efficiency of immune 
response and consequently cause the different efficacy of the protection. Earlier 
experiments in infectious disease models had shown that preparing gene gun 
bullets that carried plasmids encoding a mixture of antigens on each microparticle 
performed better than attaching plasmids encoding only one antigen per 
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microparticle. (Kathryn and Bert ASFV manuscript in preparation, and Dr. 
Stephen Johnston, personal communications).     
 
Figure2. 45  Comparison of tumor growth curves from different experiment 
with the same immunization regimen. 1+6+s group was immunized 
combination of 1-78fs, 6-21fs and SMC1A FS; 1+6+s+CPV group was 
immunized with the same combination of FS antigens plus CPV172. They all 
used the same immunization regimen as described in Fig 1.54. Error bars are 
standard error 
 
 
Figure2. 46  Comparison of the bullets preparation of two individual 
experiments. In 1+6+s+CPV group immunization, the gold particles carried 
pooled antigens; while in 1+6+s group immunization, the gold particles carried 
individual antigen.    
 
The additive protection was also observed in genetically modified mouse 
tumor model. Combination of the effective FS antigens SMC1 and 1-78 and 
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negative antigens 6-21 and CPV172 had significant improvement of protection in 
the FVB/N-NeuT model (Figure 2.30).   
2.2.2.4 Evaluation of metastasis prevention 
The immune response analysis of SMC1A FS immunization demonstrated 
that the tumor development can boost the specific immune response by increasing 
the T cell activity (Figure 2.21). The protection analysis in transgenic mouse 
models also revealed that the established specific immune response to FS antigen 
not only could prevent the first tumor initiation, but also could more efficiently 
prevent the second tumor and later independent tumor initiations (Figure 2.37). 
All of these results indicated that the tumor development could boost the memory 
immune response which was elicited by the prophylactic immunization. With the 
proper prophylactic immunization, the tumor cell could enhance the immune 
response to the antigens in the prophylactic vaccine. This implies that a 
prophylactic cancer vaccine could not only inhibit the primary tumor, but could 
also prevent or inhibit tumor metastasis.  
 
Figure2. 47  Detail experimental plan for anti-metastasis evaluation of 
SMC1A FS antigen in 4T1/BALB/c mouse breast tumor model 
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Figure2. 48  Protection evaluation against primary tumor development. A. 
Tumor growth curve of different groups. P value of SMC1A FS vs. negative or 
no-treated group <0.05; B. Endpoint tumor weight of individual mouse. SMC1A 
FS antigen in 4T1/BALB/c mouse breast tumor model. P value of SMC1A FS vs. 
negative or no-treated group <0.05 
 
For the preliminary experiment, I evaluated lung metastasis prevention in 
the 4T1/BALB/c model by the prophylactic immunization of SMC1A FS (Figure 
2.47). Besides the SMC1A FS immunization group, there were two control 
groups: non-treated group and negative control group with the empty plasmids 
immunization. The experiment was designed to try to reflect the real tumor 
treatment based on immune therapy (Figure 2.47). 4T1 tumor cells were 
inoculated after the prophylactic immunization. Three weekly immunization 
boosts were applied after palpable tumor detection to strengthen the immune 
response. The count of 6-thioguanine resistant 4T1 cell colonies from the whole 
lung cells in in vitro culture dishes was used to evaluate the efficacy of metastasis 
prevention. The SMC1A FS immunization successfully inhibited the primary 
tumor development comparing to the negative or the no-treatment group (Figure 
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2.48). Though there may have been a trend for reduced metastasis colonies in the 
SMC1A FS vaccinated group, the differences were not significant (Figure 2.49). 
Over all, the primary tumor size was positively correlated with the lung metastasis 
colon number (Figure 2.50). This corresponded with the literature reports.  
 
Figure2. 49  4T1 lung metastasis assay. A. pictures of the 4T1 lung metastasis 
clones. Whole lung from each mouse was harvested and digested into single cells 
after authorization of the mouse. All cells were resuspended in culture media with 
6-thioguanine and incubated for 14 days. The 4T1 clones were fixed and stained 
with methanol blue. B. Count clone number of each lung. p value of SMC1A FS 
vs. negative or no-treated group>0.05 
 
 
Figure2. 50  Correlation analysis of over all tumor size and lung metastasis 
colon number. Linear regression analysis p<0.005 
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Although we did not significantly inhibited the 4T1 metastasis in this 
experiment; the trend of the inhibition by SMC1A FS immunization is still 
encouraging. The optimization of the immunization regimen and including more 
FS antigens should help efficiently inhibit the 4T1 metastasis. Also this 
experiment did not directly test the concept of the prophylactic metastatic cancer 
vaccine as we vaccinated after tumor developed. So we could not separate 
therapeutic effects. The multiple immunizations could also have an immune 
inhibiting effect.  
2.2.3 Prevention of tumor development by innate stimulations of the immune 
response 
The prevention of tumor development by innate stimulation of the immune 
response is well documented in both various animal models and clinical trials. I 
also observed tumor prevention by influenza infection in the BALB-NeuT model. 
The experiment was designed for immunosignature analysis of chronic disease 
(cancer) and acute infection (influenza). All mice were infected with a non-lethal 
dose of influenza strain A/PR/8/34 at 6 weeks old or 10 weeks old. They all 
successfully recovered in 2 weeks after the infection. Although compared to the 
no-treatment group and the group infected at 10 weeks old, there may have been 
trend of tumor inhibition in the group infected at 6 weeks old, the difference was 
not significant (Figure 2.51). The influenza infection could strongly induce the 
innate immune response through Toll-like receptor (TLR), the retinoic acid 
inducible gene I (RIG-I) and NOD-like receptors (NLR) [174]. The active 
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innate immune response release proinflammatory cytokines and type I interferons 
to against virus infection. It also sensitizes innate immune surveillance to inhibit 
the tumor development. Because of the continuous expression of the strong 
oncogene in this mouse model, the sensitized innate immune surveillance by 
influenza infection may not sufficient to inhibit the tumor development.  
 
Figure2. 51  Influenza infection of BALB-NeuT mice. Two group of mice were 
infected with non-lethal dosage of influenza strain A/PR/8/34 at 6 weeks old 
(n=12) or 10 weeks old (n=9). A. Tumor progression curve; B. tumor multiplicity 
curve. No significant different among three groups. 
 
Based on the previous experiments, I tested two different innate 
stimulators in the BALB-NeuT model: CpG2216 plus GMCSF and B2L. The 
CpG2216 plus GMCSF were delivered by the gene gun with the synthetic ODNs 
and the plasmid expressing GMCSF. All mice were given five treatments in 3 
week intervals from5 to 6 weeks old (Figure 2.52 A). However, this could only 
partially inhibit the tumor progression without significant difference compared to 
non-treated group (Figure 2.52 B and C). 
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Figure2. 52  CpG plus GMCSF treatment of BALB-NeuT breast tumor 
model. A. treatment schedule, all mice treated with 5ug CpG2216 plus 1ug 
GMCSF each time through gene gun. B. Tumor progression curve. No significant 
different from no-treatment group. C. Tumor multiplicity curve. No significant 
from no-treatment group.   
 
In B2L treatment experiment, the treatment of empty plasmid served as 
the negative control of B2L treatment. The schedule of the treatment was the 
same as the CpG plus GMCSF treatment (Figure 2.53 A). The B2L treatment did 
not significantly inhibit the first tumor initiation. However the B2L treatment did 
significantly inhibit the tumor progression (Figure 2.54 B and C). Further 
investigations need to be performed in analysis of protection mechanism as well 
as the treatment optimization.  
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Figure2. 53  B2L treatment of BALB-NeuT mouse breast tumor model. A. 
Treatment schedule. all mice were treated 2ug B2L (n=18), empty plasmid (n=16) 
or no-treated (n=14) each treatment was with the gene gun. B. Tumor progression 
curve. P value of B2L vs. empty plasmid group and no-treatment group <0.001. 
C. Tumor multiplicity curve.   
2.3 Materials and Methods  
2.3.1 Mice 
Four to five weeks old wild type BALB/C and C57BL6 mice were ordered 
from Chariles River Laboratories International, Inc. BALB-NeuT and FVB/N-
NeuT mice were bred at ASU. Thanks to Dr. Joseph Lustgarten at Mayo Clinic 
Arizona for the breeding pairs. All mouse related studies were under the animal 
use protocol 1000R and revised to 1197R. Animal use protocols were approved 
by Arizona State University Animal Care and Use Committee.  
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2.3.2 Cell lines.  
All the cell lines were purchased from ATCC and cultured under the 
ATCC recommended media and conditions. HPDE 6 was kindly send by Dr. 
Douglas Lake.  
2.3.3 Tumor samples and cDNAs samples 
All dog cDNAs were supplied by Dr. Doug Thamm, Colorado State 
University. Pancreas Cancer patient matched tumors and normal adjacent tissues 
were offered by Dr. Douglas Lake. Human primary breast tumor cDNAs and 
normal mammary gland cDNAs were purchased from BioChain Institute, Inc.   
2.3.4 RT-PCR 
Total RNA was extracted with TRIzol and the RNA purification kit (Life 
Technologies, Carlsbad, CA) following the manufacturer protocols. Total RNA 
concentration was measure by Nano-drop 1000 (NanoDrop Products, 
Wilmington, DE). cDNA was synthesized from 1ug total RNA with the 
SuperScriptTM III First-Stand Synthesis SuperMix (Life Technologies, Carlsbad, 
CA) following the manufacturer protocols. All the primers were designed using 
Primer3 or GeneRunner and synthesized by Life Technologies, Carlsbad, CA or 
Sigma. End point PCR was performed with GotaqTM PCR kit (Promega 
Corporation, Madison, WI) and Mastercycler ep gradient S (Eppendorf, Hamburg, 
Germany).  
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2.3.5 Quantitative PCR 
The quantitative PCR with TaqmanTM probe was followed with the 
manufacturer protocol.  
SMC1A FS probe: CAATGGCTCTGGGTGCTGTGGAATC 
SMC1A FW: 5’- GGGTCGACAGATTATCGGACC 
SMC1A RV: 5’- GTCATACTCCTGCGCCAGCT 
2.3.6 ELISA 
The following is the standard protocol I used for all of the ELISA assays 
in this thesis. ELISA plates were coated with 50 uL of 10 ug/mL of peptide or 
protein in carbonate coating buffer and incubated at 4° C overnight.  The coated 
plates were washed 3X with PBST and blocked with 200 uL of 3% BSA in PBST 
at 37° C for 30 minutes.  The blocked plate was washed 3X with PBST and 50 uL 
of primary α-serum or purified antibody diluted in 3% BSA in PBST was applied.  
The plate was then incubated at 37° C for 1 hr.  After the incubation, the plate was 
washed 3X with PBST.  The antibody was detected with 50 uL HRP-goat α-rabbit 
IgG diluted 1:2000 in 3% BSA in PBST.  After the plate was incubated at 37° C 
for 1 hr, the plate was washed 3X and developed with 50 uL TMB for 10 minutes 
at room temperature.  The development was stopped by adding 50 uL of 0.5 N 
HCL, and the plate was read with a SpectraMax 190 Molecular Devices 
instrument at OD 450 nm. 
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2.3.7 IFN-γ ELISPOT  
ELISPOT assays were performed with mouse IFN-γ ELIPOT sets (BD 
Biosciences, San Jose, CA) following the manufacturer protocols. The plate was 
coated IFN-γ capture antibody according the protocol at 4°C over night and 
washed two times with complete RPMI medium before blocked with complete 
RPMI medium at 37°C for 2 hours. 106 mouse splenocyts were then plated in 
each well and co-cultured with 20ug peptide or protein and a final volume 200ul 
RPMI complete medium for 48 hours. Each peptide or protein was assayed in 
triplicate. After cell activation, the plate was incubated with biotin labeled IFN-γ 
detection antibody, HRP labeled strepavidin and final developed with EC 
substrate following the protocols at room temperature for 15 minutes. The plate 
development was stopped by washing wells with DI water and air-drying at least 
for 2 hours.  
2.3.8 Genetic Immunization 
Mouse genetic immunization was performed with the Helios® Gene 
Gun System (Life Science Research, Hercules, CA) by published protocols [143-
146].  
Conventional bullets preparation 
The gold is weighted based on the calculation (0.5mg of gold is needed 
per bullet), and washed with 1x water, 1x 95% ethanol and 2x water. Gold is 
resuspended in calculated DNA solution and add equal amount CaCl2.  10% total 
volume of 1M spermadine is added drop by drop and vortex on ice for 30 
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minutes. The gold is spun down and washed in three times with 100% ethanol. 
The gold is resuspended with 0.05x PVP solution and transfered into the tubing. 
The mixture is allows to sti for 15minutes, then discarded and the tube dred with 
Helium for 20min.  The tubes are cut and stored in 15ml tubes with dryrite in the 
bottom. 
Charged gold preparation 
2 grams gold are washed with15ml H2SO4 and 5ml 30% H2O2. After the 
solution cools to room temperature, wash the gold with 8 times 40ml water and 2 
times 20ml 100% ethanol. Resuspend the gold with another 20ml ethanol and add 
0.5g 11-mercaptoundecanoic acid. Shake the mix at 1400 rpm for 2 hours at room 
temperature. After vortex, wash the gold 2 times with 40ml water. Resuspend the 
gold in 20ml 0.1M MES, add 300mg NHS and 200mg EDC directly into the mix 
and keep shaking at 1400rpm for 30 minutes. Remove the supernatant after the 
incubation, add 20ml PEI1750 (2 grams in 20ml water and pH9) and keep shaking 
another 2 hours. Finally, wash the gold 2 times with 40ml water and lyophilize 
overnight. The dried gold should keep at 4 °C. 
Bullets with charged gold 
Make 167mg/ml charged gold in 0.1M MES [2(N-
Morpholino)ethanesulfonic acid] solution (pH6). Add the calculated amount of 
charged gold (6ul per bullet) to the DNA solution and vortex 10 minutes. Then 
spin down the gold-DNA complex and wash with 1ml ethanol. Resuspend the 
washed complex with butanol (55ul per sample), and let sit still for 15 minutes. 
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Discard the butanol and dry with helium for 20 minutes. Then cut thetubes and 
store in 15ml tube with dryrite. 
Bullets with nanogold particles 
Nanogold particles preparation: add 25mg HAuCl4 to 40ml water and mix 
well. Then add 400ul 213mM fresh cysteamine and stir with a spinbar for 10 
minutes. Add 10ul 10mM sodium borohydrate and keep stir for 30 minutes. The 
final solution should be deep wine red. 
Bullets preparation: add calculated DNA into 1ml nanogold solution, 
vortex for 10 minutes. Then add calculated charged gold (167mg/ml charged gold 
in 0.1M MES, and 6ul per bullet) into the mixed solution, Mix occasionally at RT 
for 10min. Spin down the gold complex, wash with 1ml ethanol. Resuspend the 
washed complex with butanol (55ul per sample), and let sit for 15 minutes. 
Discard the butanol and dry with helium for 20 minutes. Then cut the tubes and 
store in 15ml tube with dryrite. 
2.3.9 4T1 lung metastasis assay 
The 4T1 lung metastasis assay was followed the protocol proposed by 
Pulaski [238]. Briefly, the lung was taken from euthanized mice, minced into 
small pieces and digested in final volume 5 ml collagenase type IV/elastase 
cocktail for 75 minutes at 4°C. Filter the digested samples through 70um nylon 
cell strainer and wash with 10ml 1xHBSS 3 times. The cell pellet was 
resuspended with 10ml IMDM supplemented with 10% FBS, 1×antibiotic-
antimycotic (Life Technologies), and 60 μM 6-thioguanine and plated into a 
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10cm cell culture dish. Place dishes in a 37°C tissue culture incubator, 5% CO2 
for 10-14 days. After the incubation, the cells were fixed with 5ml methanol and 
stained with 5ml 0.03% methylene blue. The colonies were counted after the plate 
dried. 
2.4 Discussion 
Although different types of tumors possess different FS transcript profiles, 
the whole list of FS candidates is enough to cover the tumor types that we have 
investigated so far. For example, the SMC1A FS transcript was detected in almost 
all of the different human tumor cDNA samples we investigated, including breast 
(n=34), pancreas (n=4), and lung cancer (n=1) cell lines and primary breast (n=7) 
and pancreatic tumors (n=4). We also detected homologous SMC1A FS 
transcripts in all mouse and dog tumor samples, including melanoma cell lines 
(n=2), one breast tumor cell line, primary tumors of three spontaneous mouse 
breast tumor models and 22 cDNAs from 8 different primary dog tumors, such as 
melanoma, osteosarcoma, lymphosarcoma, breast tumor etc. I also detected other 
FS transcripts in most of these cDNAs, such as 6-21 and 1-78. Detection of 
SMC1A FS transcript in the early stages of the FVB/N-NeuT breast tumor 
indicated that some of these FS transcripts may be involved in tumor development 
and could be exposed to the immune system at the early stages of tumor 
development. Those FS antigens are the most valuable candidates for a 
prophylactic cancer vaccine development which tries to prevent tumor at early 
stage. The high frequency of FS transcripts that were confirmed by 
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screening of a broad tumor sample setting and the high coverage of HLA types by 
in silica analysis suggest that a general prophylactic cancer vaccine is feasible 
(Lee and Johnston, in preparation). Further investigation in more tumor samples is 
necessary to have a more accurate estimation of FS frequency in different human 
cancers.  
With the limitation of the proteomics analysis, I did not confirm the 
translation of SMC1A FS transcript in tumor cells. The western blot, IHC and IF 
analysis implied that the SMC1A FS protein may be expressed and SUMOylated 
in both tumor cells and normal tissues (see detail at Chapter 4). In any case, the 
absence of the detectable FS protein is a common situation in this research area. 
For instance, only 2 of 18 FS mutations found in the MSI-high colon tumor cell 
lines were detected at the protein level by western blot and confirmed by siRNA 
knock down [169]. This indicates that the impaired product quality control 
systems in tumor cell, such as NMD and ERAD, can still efficiently decrease the 
translation of some FS antigens and keep them below the limitations of the 
current direct detection technologies. The absence of direct evidence of 
translation FS antigens does not indicate that they are not suitable targets for 
vaccine development. The NMD is the translation dependent process. The 
degradation of NMD targeted transcripts must be trigged by the primary 
translation [175]. Therefore, the NMD targeted FS transcripts may possibly be 
translated even without the detection of the transcripts. Consequently, these 
transcripts can still be presented and detected by the immune system, which is 
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more sensitive and competent detection system than any other current technology 
[176]. Researchers have shown that a few target peptide/MHC complexes are 
sufficient to trigger specific CTL mediated killing [177-180]. This indicates that 
all of these FS antigens still could be good vaccine candidates by eliciting specific 
and efficient immune response. There are several reports supporting this idea. For 
example, the FS mutation of TGFBR2 occurs in 80-90% of the colorectal cancers 
(CRCs) with MSI. This mutant gene encodes a truncated protein bearing a 49 
amino acids FS peptide if there is a nucleotide deletion in the cMS region. The FS 
transcript of TGFBR2 is sensitive to NMD in the MSI colon cancer cell lines. No 
FS truncated protein of TGEBR2 was directly detected [147]. On the other hand, 
researchers successfully detected the immune responses that are specific to the 
TGENR2 FS peptides in CRCs, including specific IgG activity in 10% of the 
CRCs and specific IFN-gamma released T cell in about 50% of the CRCs in two 
independent studies [181, 182].  
This may be the same situation for the SMC1A FS truncated protein. I 
successfully detected the specific immune response of both antibody and T cell to 
the SMC1A FS peptide in tumor bearing FVB/N-NeuT mice. That is direct 
evidence of translation of the SMC1A FS antigen in tumor cells. These results 
also indicated the immunogenicity of SMC1A FS antigen and that it is an 
effective candidate for vaccine development.  
The limitation of current technologies, especially the technologies in 
proteomics analysis make them inefficient methods for cancer vaccine candidate 
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screens. I used the mouse tumor model system to efficiently screen the 
prophylactic cancer vaccine candidates by directly evaluating the tumor 
prevention caused by FS antigens in the tumor models with the optimized 
immunization regimen. This approach can evaluate all factors for a vaccine 
candidate in one sensitive system, such as expression, immunogenicity and 
protection. With this system, we first demonstrated the concept of the 
prophylactic cancer vaccine with FS antigens based on the analysis of the SMC1A 
FS antigen and/or other FS antigens. The additive protection with variable FS 
antigens compositions in different tumor models further supports our concept. 
Although the SMC1A FS antigen is only 27 amino acids long, and contains only a 
handful of predicted epitopes with low binding scores to all MHC I and MHC II 
haplotypes in both BALB/c and C57BL6, the immunization of SMC1A FS 
antigen in the prophylactic setting successfully produced significant inhibition of 
primary tumor growth of mouse melanoma (B16F10/C57BL6), mouse breast 
tumor (4T1/BALB/c), as well as two transgenic spontaneous mouse breast tumor 
models (FVB/N-NeuT and BALB-NeuT), which may closely mimic in some 
respects the natural development of human breast cancer. The immune response 
analysis revealed that although SMC1A FS is a poor immunogenicity antigen by 
in silico analysis, both specific memory humoral and cellular responses are 
successfully elicited and correlated with tumor inhibition in different mouse 
models. In C57BL6 mice, the genetic immunization of SMC1A FS antigen 
elicited memory cellular immune response which was efficiently stimulated after 
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B16F10 tumor cell inoculation with more than 20 fold higher activity and 
significantly inhibited primary tumor growth. The antibody activity is variable 
depend on different immunization regimens. In BALB/c mice, the primary 4T1 
tumor was significantly inhibited even when the tumor cell were inoculated more 
than 25 weeks after a single low dosage genetic immunization of a pool of 3 FS 
antigens and a negative control antigen. The same immunization regimen in 4 
week old FVB/N-NeuT mice with a single SMC1A FS antigen or a pooled 
antigens inhibited spontaneous breast tumor development. This indicated that 
there was an effective memory immune response that was elicited in both mouse 
models. The end point mice with no detectable immune response may not have 
had a strong response due to systemic immune suppression by fully developed 
tumors. The tumor inhibition in the negative control group in FVB/N-NeuT 
indicated the antitumor activity of the adjuvant included in the immunization. 
Further immunization optimization is necessary to clarify the correlation of 
immune responses and individual FS protection. The SMC1A FS has shown 
significant protection in the BALB-NeuT mouse tumor model with an optimized 
immune regimen. The tumor inhibition is correlated with specific IgG activity to 
the SMC1A FS peptide.  
The analysis of protection in transgenic mouse models demonstrates that 
the prophylactic cancer vaccine can more efficiently inhibit multiple tumor 
development after the first tumor has been established. This indicates that the 
tumor itself can boost immune surveillance at the prophylactic immunization. The 
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immune response analysis in the B16F10/C57BL6 mouse model supports this 
hypothesis. The specific cellular immune response was boosted 20 fold higher by 
tumor cell inoculation. This led us to develop the concept of prophylactic cancer 
vaccine against tumor metastasis. The metastasis of 4T1 tumor cells usually starts 
around 7 days after the primary tumor inoculation. This leaves a short time 
window for the immune system to have been boosted by the primary tumor. This 
may be the reason that there was no significant metastasis reduction by the 
SMC1A FS immunization alone. These results may also have been caused by an 
insufficient immune response elicited by the current immunization regimen and 
antigen composition. These factors should be tested in further experiments with 
another proper metastasis model with a longer metastasis window, which more 
closely resembles natural tumor metastasis development.  
Our results and other studies demonstrated the expansion of the pre-
activated tumor specific adaptive immune response could be augmented by the 
primary tumor itself [183]. This tumor activation of vaccine immune response 
could not only inhibit the primary tumor development, but also have potential to 
inhibit or prevent tumor metastasis, which I tested in my study. Additionally, this 
tumor derived immune response activation led me to development a new concept 
for cancer early detection: “amplified diagnosis”. The concept is straightforward: 
healthy people receive prophylactic immunization with a set of tumor specific 
antigens to establish an efficient memory immune response. The memory immune 
response will be activated by exposure of the immune system to some of these 
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antigens being presented by the tumors. This response would presumably be 
stronger and earlier than the endogenous immune response without pre-
vaccination. By monitoring the specific immune response, such as antibody 
activities against the immunized antigens, we can detect early tumor onset. As I 
discussed in the 1st chapter, people are exploring early cancer diagnosis with the 
tumor derived autoantibody detection. However, the endogenous adaptive anti-
tumor response is always markedly delayed. For example, about 45% of colon 
cancer patients have p53 mutations, and about 50% of colon cancer patients have 
P53 over-expression [184, 185]. Johannnes et. al. reported that with the 
overlapping P53 peptides array, they could detect anti-P53 autoantibody about 1.4 
years (median lead time, range 0.12-3.8 years) prior to clinical diagnosis of colon 
cancer [186]. It usually takes about 40 to 50 years for a colon tumor developing a 
clinically detectable size. We believe that with “amplified diagnosis”, we should 
detect these tumor specific immune response much earlier. Actually, the concept 
of the amplify diagnosis could be use for early detection of any disease with 
specific immune response. We should further test this concept, especially in 
cancer early diagnosis. 
The autoimmunity caused by the off target effects of a cancer vaccine is 
always a major concern, especially in prophylactic cancer vaccine development. 
Actually, with the proper administrations, almost all clinical cancer vaccine trials 
with cancer associated self antigens have been remarkably safe. The slight 
autoimmunity symptoms in some trials were tolerable and are related to a better 
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treatment outcome. There is no evidence of severe autoimmune activity related to 
a specific immune response to those self antigens in all therapeutic clinical trials 
and even in animal trials with a prophylactic immunization setting.  
As described previously, compared to self antigens, the cancer specific 
and associated FS antigens are a better source for a prophylactic cancer vaccine 
development in both effectiveness and safety. The fully functioning quality 
control systems and other mechanisms in normal cells prevent FS antigens from 
been produced and displayed to the immune system, and this avoids the off target 
effects. Although there are no thorough studies about the safety of prophylactic 
cancer vaccines based on FS antigens in clinical trials yet, the results from related 
clinical studies indicate the safety of the prophylactic immunization of FS 
antigens. For instance, both the humoral and cellular immune response to specific 
FS antigens were detected in lynch syndrome patients with the MSI CRC and the 
healthy non-tumor bearing individuals [181]. The lynch syndrome is caused by 
inherited mutations in DNA mismatch repair genes, which can subsequently 
induce the MSI and increase the risk of colon cancer and other related cancers. 
There is no report about serve autoimmune diseases in those healthy lynch 
syndrome patients. On the contrary, compared to the sporadic CRC, the better 
outcome of MSI CRC with lynch syndrome is correlated with a higher frequency 
of tumor infiltrating lymphocytes. This indicates that the immune responses 
against FS antigens will not cause server autoimmune diseases. On the contrary, 
they could contribute to tumor inhibition.  
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As I discussed in the prophylactic cancer development, there are three 
levels of control systems to ensure that the FS antigens are specific to tumor cell: 
genetic control, transcription control and translation control. The most specific FS 
antigens are generated by the genetic mutations in tumor cells. Apparently, the 
SMC1A FS antigen is not the most specific FS antigen. SMC1A FS transcript was 
detected in some normal cDNAs from variable organs, such as cDNA from 
normal mouse splenocytes displaying similar levels of the FS transcripts as 
B16F10 tumor cells. This may be caused by the alternative NMD in those 
immune cells as indicated by other studies [137, 187]. And the western blot, IHC 
and IF analysis also implied that the SMC1A FS protein may be expressed and 
SUMOylated in both tumor cells and normal tissues (see detail at Chapter 4).  
However, the results from my studies implied that the SMC1A FS antigen 
is still safe for prophylactic immunization. With a detectable SMC1A FS 
transcript level in a variety of normal cells, even in normal immune cells, there is 
no detectable specific immune response to the SMC1A FS antigen in normal 
mice. This clearly indicates that normal cells have full control to avoid the 
SMC1A FS antigen been displayed to and recognized by the immune system. 
There may be two mechanisms for the specific control. First, most normal tissues 
have low level or no detectable level of the SMC1A FS transcript, so the 
expression of the SMC1A FS protein has been tightly controlled by the NMD and 
ERAD in these cells. Second, except the normal heart tissue, only the 
SUMOylated form of the SMC1A FS was detectable in the normal tissues (see 
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details in Chapter 4). The SUMOylation tightly controlled the subcellular 
localization of the SMC1A FS protein and prevented it from being presented. 
Another directive evidence of the safe of the SMC1A FS antigen is that there are 
no severe autoimmune reactions observed in the mice with various intense 
immunizations of SMC1A FS and other FS antigens in my studies. Further 
complementary analysis is necessary to clarify the safety of FS antigens.   
The investigation of tumor inhibition with innate stimulation demonstrated 
that the tumor can be inhibited by utilizing only innate stimulation. I tested the 
concept of a prophylactic innate stimulation in the BALB-NeuT mouse tumor 
model. In the preliminary data, the prophylactic administration of B2L could 
significantly prevent spontaneous breast tumor development in the mouse model. 
GMCSF and CpG had similar effects. Further investigation is necessary to 
optimize the administration and characterize the mechanisms of the tumor 
inhibition.  
In summary, I believe my studies, as well as others in the Center, support 
the idea and suggest strategies for pursuing tumor prevention through a 
prophylactic cancer vaccine and prophylactic innate stimulation. Further 
investigation will focus on optimization of the administration, identification of 
more components and integration of different strategies.  
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CHAPTER 3  
CANCER DETECTION 
3.1 Introduction 
Cancer detection is one of the major components for the global cancer 
control. The development of the cancer detection technology has significantly 
contributed decreasing mortality decreasing in several major cancer types. The 
serological detection of cancer has unique advantages in sensitivity, specificity 
and simplicity.      
Based on our investigations of tumor FS antigens, I discover two new 
potential serological cancer biomarkers: the antibodies against FS peptides and 
the FS transcripts. They not only share the advantages of current autoantibody and 
nucleotide biomarkers, such as signal amplification, but also have advantages of 
the specificity by their unique characteristics. I also developed a unique detection 
strategy for each of them which make them more sensitive and robust. Here I will 
discuss the principle studies of these two cancer biomarkers for early cancer 
detection.  
3.2 FS antibody as cancer biomarker 
3.2.1 Introduction 
As discussed previously, the NMD and ERAD and other quality control 
systems of normal cells reduces the incidence of the elicitation of antibodies 
against FS peptides by normal cells. This unique characteristic of the FS 
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peptides increases the specificity of the FS-antibodies as cancer biomarkers. As 
discussed, the FS peptides are mutant peptides, and should be novel to the 
immune system. This makes FS peptides more sensitive at eliciting the specific 
antibody reaction in vivo, unlike the autoantibody response to the self-antigens 
that are tolerated by the immune system.  
Besides the sensitivity and specificity, there is another important 
characteristic that needs to be addressed before using the antibodies as 
biomarkers: the antibodies that are elicited in vivo are highly diverse in two 
aspects. First, the in vivo elicited antibodies to a specific antigen are always 
polyclonal antibodies. There are multiple B cell clones that could be activated 
even by a single epitpoe. Second, the antibodies in the whole population are more 
divers because of various genetic backgrounds of the immune system in the 
population, such as various HLA types. This high diversity allows the antibodies 
to recognize all of the possible epitopes of a specific antigen, including the linear 
epitopes and conformational epitopes. A method designed to robustly detect these 
antibodies in the population should consider the diversity of the antibody. 
However, most current autoantibody biomarkers target big antigens, such as P53 
which is 393 amino acids long and naturally folds into a 3D structure. The current 
strategies of autoantibody detection are either using the recombinant proteins or 
overlapping peptides. Those recombinant proteins are folded and can not fully 
represent all linear eptitopes, while the overlapped peptides can not represent the 
conformational epitopes. Therefore, the current strategies for antibody detection 
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will lose part of the antibody signal either way and consequently cause a decrease 
in sensitivity.   
Although most FS mutations usually generate short and simple FS 
peptides, they still contain multiple epitopes. Therefore the antibodies in the 
population that could recognize the FS peptides are still quite diverse. The 
efficient epitope representation of the FS peptide is still necessary. However, 
because of the uncontrolled orientation of the peptides on the surface and the 
space limitation, the natural peptides tend to not perform as well on a surface as in 
solution. To avoid these limitations, I developed a unique strategy to more 
efficiently exposure the epitopes of the FS peptides by using a set of mimotopes. 
There are three advantages: First, with a set of mimotope, the possible epitopes of 
the FS peptide can be fully represented. Second, these mimotopes are screened 
using the random peptide arrays and selected to function on the surface. 
Therefore, all of the epitopes can be fully represented and accessible to all of the 
FS-antibodies. Third, sometimes mimotope can elicit a better immune response 
than the original peptide [96]. This indicates that the mimotope could have higher 
affinity to antibodies than the original peptide depending on HLA backgrounds. 
The same strategy can also be used for the autoantibody detection. To prove the 
concept, I used SMC1A FS peptide as the target for the preliminary experiment.  
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3.2.2 Results 
3.2.2.1 Screen the mimotope of the SMC1A FS peptide            
 
Figure 3. 1 Strategy for mimotope screen. Serum samples with different anti-
SMC1A FS peptide activity were applied on the 10K array. The random peptides 
(circled) that had low reactivity to SMC1A FS peptide absorbed sample and high 
reactivity to non-absorbed sample and control peptide absorbed sample were the 
mimotope candidates.   
 
We used CIM 10K random peptide array for the SMC1A FS peptide 
mimotope screen. The anti-human SMC1A FS peptide serum samples with 
different anti-SMC1A FS peptide activity were applied on the array. The random 
peptides that had decreasing reactivity corresponded to the anti-serum samples 
with decreased antibody activity were the mimotope candidates (Figure 3.1). The 
rabbit anti-serum that recognized human SMC1A FS peptide (the FS peptide 
alone with 17 aa) was prepared by the Global Peptide Service LLC. The anti-
serum was elicited by immunizing the New Zealand white rabbit of the KLH 
conjugated human SMC1A FS peptide. This anti serum contained antibody 
activity against both SMC1A FS peptide and the KLH protein. The samples with 
decreased anti-SMC1A FS activity were prepared by a step wise specific 
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absorption with the plates coated by SMC1A FS peptide. The 11 step absorption 
and 20 step absorption anti-serum were prepared. Their specific anti-SMC1A FS 
peptide activities were confirmed by ELISA analysis as well as the anti-serum 
samples that were absorbed by a negative control peptide: 
AVLLMCQLYQPWMCKEYYRLL (Figure 3.2). The non-absorbed sample, 11 
step specific absorbed sample, 20 step specific absorbed sample and 20 step 
negative absorbed samples were applied on the 10K random peptide array. 50 
peptides were selected as the mimotope based on the t-test analysis of the results 
of different arrays (Figure 3.3).  
 
Figure 3. 2 ELISA verification of absorbed anti-serum samples. The antibody 
against human SMC1A FS peptide in the rabbit anti-serum were specifically 
absorbed away by the plates coated with SMC1A FS peptide. The anti-serum was 
also treated with a negative control peptide: AVLLMCQLYQPWMCKEYYRLL 
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Figure 3. 3 Heat map of intensities exhibited by peptides specific for anti-
SMC1A FS antibodies.  Four different types of sera were applied to the random 
peptide microarray: 1. Non-absorbed serum, 2. 11 steps SMC1A FS peptide 
absorbed, 3. 20 steps SMC1A FS peptide absorbed, 4. 20 steps negative control 
peptide absorbed. The experiment and analysis were performed by Kurt 
Whittemore, PhD student at CIM 
 
Figure 3. 4  ELISA analysis of the specificity of the mimotope candidates. A. 
ELISA analysis of the reactivity of the mimotopes with the rabbit anti-hSMC1A 
FS anti-serum. B. ELISA analysis of the reactivity of the mimotopes with the 
mouse anti-KLH anti-serum 
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3.2.2.2 Validation of the mimotopes 
We developed a scoring system to evaluate the specificity of these 
candidates. Each peptide was scored by the following formula: (max_signal - 20 
steps specific_absorbed_signal)/max_signal + (20 step negative_absorbed 
signal) / max _signal. The high scoring peptide yield a low signal with 20 steps 
specific absorbed serum, and a high signal with the 20 steps negative absorbed 
serum. We chose 4 peptides with the highest score to synthesize and further 
validate. These peptides were named IS-1 to IS-4 (the array experiment and 
analysis were performed by Kurt Whittemore, PhD student at CIM). The ELISA 
analysis of these 4 mimotopes against the rabbit anti-serum demonstrated that 
these 4 mimotopes could be recognized by the rabbit anti-serum (Fig 3.4 A). To 
exclude the possibility of the mimotope reactivity to the KLH antibody, I also 
applied mouse anti-KLH polyclonal anti-serum to these mimotopes. There was no 
reactivity of these mimotopes to the anti-KLH antibody (Figure 3.4 B). This 
demonstrated that these 4 mimotopes were specific to the human SMC1A FS 
peptide. To further validate the specificity of the 4 mimotopes, I synthesized these 
mimotopes on the Tentagel beads and affinity absorbed the specific antibodies to 
each peptide from the total IgG of the rabbit anti-serum. Each affinity absorbed 
antibody could specifically recognize the SMC1A FS peptide by the ELISA 
analysis (Figure3.5). In the cross reaction analysis, the antibody purified by IS4 
mimotope did not have cross reaction to the other 3 mimotopes, while all the 
other three peptides have cross reaction to each other (Figure3.6). This indicates 
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the IS4 mimotope represented a different epitope of the human SMC1A FS 
peptide compared to the other three mimotopes.  
 
Figure 3. 5 ELISA analysis of antibody that were affinity purified by 
different peptide against hSMC1A-27mer and KLH protein. ATK is the 
negative control peptide with the sequence: ATKAAIPGPNTVPRAP  
 
 
Figure 3. 6 Cross reaction of antibodies that were affinity purified by 
different peptides 
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3.2.2.3 Screen cancer patient serum with the mimotopes 
To test the concept that mimotopes can be used for FS antibody detection, 
we printed these 4 mimotopes and the human SMC1A FS peptide on the array and 
screened the clinical cancer patient serum samples including breast cancer, lung 
cancer and pancreas cancer, as well as pancreatitis patient and health people (The 
array experiments performed by Peptide Array Core at CIM). To calculate the 
positive rate of each cancer type of each peptide, I used a cut-off value by 
calculating the average intensity plus two fold standard deviation of all healthy 
people samples. The results were summarized in table 3.1. When we use the 
original SMC1A FS 17mer peptide, the positive activity rate is almost zero in all 
cancer patient samples. While using the 4 selected mimotope peptides as a panel, 
the positive rate increased to 53.8%, 56.5% and 12.5% in breast cancer patient, 
pancreas cancer patient and lung cancer patient, respectively. The “false positive” 
rate in healthy people is 10% by using the four peptides as a panel. Interesting, the 
pancreatitis patients also has high positive rate of 40% by using the 4 peptides 
panel (Table 3.1).  
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Table 3. 1 Screen cancer patient’s sera. The mimotopes and the human SMC1A 
FS 27mer peptides were printed on the slides with other peptides that were 
irrelevant to this topic. The serum of different patients and healthy people were 
run on the slides. The raw signal intensities of four mimotopes and SMC1A FS 
27merwere analyzed. The positive cut-off value is the average intensity plus two 
fold standard deviation of all healthy people samples. 
 
To further investigation the possible reason of the performance of the 
mimotopes, I analyzed the possible MHC-II epitopes of the human SMC1A FS 
peptide and the four mimotopes. I choose the five highest frequency MHC-II 
alleles in North America from the NCBI bdMHC: DQB1*03:01, DQA1*03:01, 
DQB1*03:02, DQA1*05:01, DPB1*04:02. I then predicted the binding epitopes 
of each peptide with the IEDB MHC-II binding predictions. The table 3.2 lists the 
top 5 peptides with the highest binding affinity to the 5 selected MHC-II alleles. 
A lower percentile rank indicates higher affinity of the peptide. The binding 
affinity showed that the human SMC1A FS peptide has lower affinity MHC-II 
epitopes compared to IS1, IS3 and IS4 in the 5 selected MHC-II alleles. This 
corresponds to the result of the cancer patient sera screen with the peptide array 
(Table 3.1). The affinity of the predicted epitopes of IS2 was lower 
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than human SMC1A FS peptide; however the IS2 performed better than the 
SMC1A FS peptide in the cancer patient screen. This indicates there are other 
factors that also could affect the peptide performance, such as the orientation of 
the peptide on the surface.   
I also analyzed the MHC-I epitope of the SMC1A FS peptide and the 
mimotopes to check whether the mimotopes also have better MHC-I epitopes than 
the SMC1A FS and have potential to be the vaccine candidates. HLA-A*02:01 is 
the most frequent MHC-I allele in the US. The HLA-A*02:01 epitope prediction 
showed that all of four mimotopes have better epitopes than SMC1A FS peptide. 
Further analysis is necessary to verify the predicted MHC-I and MHC-II epitopes 
of mimotopes are the mimo-epitopes to the SMC1A FS peptide.  
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Table 3. 2 MHC II epitope prediction of human SMC1A FS peptide and 
mimotopes. Epitope prediction was performed with IEDB MHC-II binding 
predictions and analyzed in 5 highest frequency MHC II allele in North America: 
DQB1*03:01, DQA1*03:01, DQB1*03:02, DQA1*05:01, DPB1*04:02. The 
lower percentile rank indicates the higher predicted affinity. 
Human SMC1A 27mer: TAIIGPNGSGCCGIYCHEEPQREDSSI
Allele Sequence Percentile Rank
HLA‐DQA1*05:01/DQB1*03:01 TAIIGPNGSGCCGIY 30.47
HLA‐DQA1*05:01/DQB1*03:01 AIIGPNGSGCCGIYC 31.75
HLA‐DQA1*05:01/DQB1*03:01 IIGPNGSGCCGIYCH 35.6
HLA‐DQA1*05:01/DQB1*02:01 SGCCGIYCHEEPQRE 39.48
HLA‐DQA1*05:01/DQB1*02:01 GCCGIYCHEEPQRED 39.56
IS1: TISKYVMVEPMRQHEEWGSC
Allele Sequence Percentile Rank
HLA‐DPA1*03:01/DPB1*04:02 TISKYVMVEPMRQHE 10.38
HLA‐DQA1*03:01/DQB1*03:02 TISKYVMVEPMRQHE 14.53
HLA‐DQA1*03:01/DQB1*03:02 SKYVMVEPMRQHEEW 17.51
HLA‐DQA1*03:01/DQB1*03:02 ISKYVMVEPMRQHEE 17.61
HLA‐DPA1*03:01/DPB1*04:02 ISKYVMVEPMRQHEE 18.91
IS2:AVSHQEMNEGEQGPMREGSC
Allele Sequence Percentile Rank
HLA‐DQA1*05:01/DQB1*03:01 EMNEGEQGPMREGSC 58.44
HLA‐DQA1*05:01/DQB1*03:01 QEMNEGEQGPMREGS 58.78
HLA‐DQA1*05:01/DQB1*02:01 AVSHQEMNEGEQGPM 59
HLA‐DQA1*05:01/DQB1*03:01 HQEMNEGEQGPMREG 59.42
HLA‐DQA1*05:01/DQB1*03:01 SHQEMNEGEQGPMRE 59.94
IS3:RVGEMPMREYDISGGSGGSC
Allele Sequence Percentile Rank
HLA‐DQA1*05:01/DQB1*03:01 PMREYDISGGSGGSC 10.93
HLA‐DQA1*05:01/DQB1*03:01 MPMREYDISGGSGGS 19.32
HLA‐DQA1*05:01/DQB1*03:01 EMPMREYDISGGSGG 45.84
HLA‐DQA1*05:01/DQB1*02:01 RVGEMPMREYDISGG 57.65
HLA‐DQA1*05:01/DQB1*02:01 VGEMPMREYDISGGS 61.93
IS4: TAFYRTLTKHEVDPGIAGSC
Allele Sequence Percentile Rank
HLA‐DQA1*05:01/DQB1*03:01 TLTKHEVDPGIAGSC 16.64
HLA‐DPA1*03:01/DPB1*04:02 TAFYRTLTKHEVDPG 33.76
HLA‐DQA1*03:01/DQB1*03:02 RTLTKHEVDPGIAGS 34.86
HLA‐DQA1*03:01/DQB1*03:02 TLTKHEVDPGIAGSC 36.59
HLA‐DQA1*05:01/DQB1*03:01 RTLTKHEVDPGIAGS 37.1  
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Table 3. 3 HLA-A*02:01 epitope prediction of human SMC1A FS peptide 
and mimotopes. Epitope prediction was performed with IEDB MHC-I binding 
predictions with artificial neural network. Lower IC50 value indicates better 
binder. 
 
3.2.3 Discussion 
Through this preliminary experiment, I demonstrated that the specific 
antibody activity to the SMC1A FS peptide has potential to be a biomarker for the 
diagnosis of breast cancer and pancreas cancer. By using 4 mimotope peptide 
panel of the SMC1A FS peptide, I detected the antibody activity to the SMC1A 
FS peptide from 50% to 60% of the breast cancer patients and pancreas cancer 
patients. Only 10% normal healthy people showed the positive antibody activity 
to the SMC1A FS peptide. This positive rate of the antibody against SMC1A FS 
peptide is about two fold higher than currently reported rate of single 
autoantibody detection in cancer patients, which is only 20% to 30% [188]. Since 
the SMC1A FS transcript was detected in all the different types of tumor samples 
that we have screened so far, the antibody against the SMC1A FS peptide may be 
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a general cancer biomarker. It is interesting that the specific antibody against the 
SMC1A FS peptide was also detected in pancreatitis patients with 40% positive 
rate by using the panel of the 4 mimotope peptides. Pancreatitis is highly 
associated with pancreas cancer. This indicates antibody against the SMC1A FS 
peptide might be used for early pancreatic cancer diagnosis. To confirm the 
antibody against the SMC1A FS as an early cancer biomarker, further 
investigation is needed to be performed on more samples with detailed clinical 
information.  
The preliminary data also demonstrated the unique advantage of the 
specific antibody detection strategy by using the mimotope peptides. Different 
cancer patients have different antibody activity to the 4 selected mimotopes. This 
indicates the diversity of the antibodies against the SMC1A FS peptide in the 
population. Each patient has a unique antibody profile to the SMC1A FS peptide. 
The sensitivity of the antibody detection with the human SMC1A FS peptide itself 
was very low. The positive rates of the antibody directly against the human 
SMC1A FS peptide in different cancers were almost 0. While the positive rate of 
antibody detection of the panel of the 4 selected mimotope peptides were from 
12.5% to 56.5%. Each individual mimotope was more reactive to the patient 
serum than the original SMC1A FS peptide. This may, however, be due to 
technical problems with binding the SMC1A FS peptide to the surface. The 
MHC-II binding affinity prediction showed that the MHC-II epitopes of 
mimotopes IS1, IS2 and IS4 had higher affinity than the predicted MHC-II 
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epitope of SMC1A FS peptide in the 5 selected MHC-II alleles. This indicated 
that these mimotopes could have higher affinity to the antibodies generated by the 
human SMC1A FS peptide with the 5 selected MHC-II alleles. This may be one 
of the reasons that these mimotopes were more sensitive in detecting the antibody 
against the SMC1A FS peptide. Another possibility is that the mimotope, such as 
IS3, has higher sensitivity because the FS peptide orientation on the surface is not 
controlled and could not present the epitope correctly, while the mimotopes are 
selected to function on the surface. Therefore, some mimotopes with lower 
predicted affinity still could perform better than the FS peptide. In summary, this 
result demonstrates that the mimotope not only can efficiently present all possible 
epitopes, but also can present higher affinity epitopes. Using the mimotopes for 
the specific antigen is an advanced strategy for increasing the sensitivity of 
antibody detection. This strategy is general and could also improve the detection 
of the autoantibody that is against self-antigens, which usually contain multiple 
epitopes. The low activity of SMC1A FS antibodies in lung cancer patients may 
reflect the low immunogenicity of lung tumors, which has been reported by 
various studies on lung cancer. This also may be caused by the different epitopes 
present on lung tumor cells. The sensitivity of the detection in lung cancer 
patients could be improved by including more mimic peptides, which could 
present different epitopes of the SMC1A FS peptide. 
The successful detection of the antibody activity against SMC1A FS 
peptide in cancer patients also suggests the importance of the antibody activity to 
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cancer related FS peptides, and therefore their potential as biomarkers for cancer 
diagnosis. As I described above, the FS transcripts were frequently detected in 
different cancers. Further investigation of antibodies against other cancer related 
FS peptides will identify more effective biomarkers for early cancer diagnosis. 
With the panel of antibodies against different FS peptides, it should improve the 
sensitivity and specificity for early cancer diagnosis.   
Detection of the antibody activity against SMC1A FS peptide in cancer 
patients also provides the evidence of the expression of the SMC1A FS peptide in 
these tumor cells. This suggests the SMC1A FS peptide could be a valuable 
cancer vaccine candidate. The investigation of the FS-antibody in cancer patients 
not only could develop this as a unique cancer biomarker, but also could evaluate 
the potential of the related FS peptides as cancer vaccine candidates. In addition, 
as discused above, the mimotopes may serve as better antigens than the FS 
peptide itself.      
The successful detection of the antibody against the SMC1A FS peptide 
with a set of mimotopes also directly indicates the biological significance of the 
immunosignature technology for disease diagnosis. The technology of 
immunosignature was developed by our lab to diagnose different diseases by 
profiling antibody activity with random peptides arrays. We clearly demonstrated 
that the immunosignature could differentiate cancers patients from the healthy 
people without knowledge of the specific disease related targets of the antibodies. 
I applied the same platform to screen the mimotopes of the SMC1A FS peptide. 4 
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mimotope peptides of the list were confirmed that had high antibody activity in 
cancers patients. The detected antibody activities were specific to MC1A FS 
peptide. Therefore, it demonstrates that the antibodies against the SMC1A FS 
peptide contribute to the antibody profiling of cancer patients compared to healthy 
individuals by immunosignature analysis.  
3.3 Circulating FS transcript as cancer biomarker 
3.3.1 Introduction 
Circulating nucleic acids (cNAs) were first detected by Mandel and Metais 
[189]. The cNAs were not attractive to scientists for diagnosis until the detection 
of mutated RAS gene in the blood of cancer patients in 1994 [190]. Since then, 
the various cNAs (such as DNA, mRNA and more recently micro RNA) were 
detected in patients and healthy populations. These cNAs are released by tumor 
and normal cells and often diseased cells, and protected from nucleases by 
proteins or micro vesicles [191-193]. Disease related cNAs became popular as a 
biomarker for diagnostics, especially for early cancer diagnosis. A long list of 
cNAs have been reported as cancer biomarkers, however there is no single 
biomarker that is widely used in the clinic. The main problem of the cNAs 
biomarker development is quantification. Most cancer related circulating mRNA 
and micro RNA needs to be quantified for the diagnosis, while the reality is there 
is no reliable reference for the circulating cNAs quantification. More, the cNA 
quantification is highly sensitive to the sample process and there is no standard 
assay for cNAs quantification. All of these make the current cNAs 
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biomarkers that were reported in the literature not widely used for clinical 
applications. However, many companies are pushing this diagnostic strategy. 
Digital PCR has created new potential in this area.  
As I described above, we identified a list of the FS transcripts from the 
bioinformatics analysis and validated by RT-PCR of the tumor cDNAs. One type 
of FS transcripts is caused by insertion or deletion of a  nucleic acid fragment. 
Those FS transcripts were frequently generated in different cancers, such as the 
SMC1A FS transcript. Both WT and FS transcripts of the SMC1A could be 
amplified by a set of flanking primer from tumor cDNA and separated by the gel 
electrophoresis. The Q-PCR analysis of the SMC1A FS transcript in human 
primary breast tumor and normal mammary glands demonstrated that the SMC1A 
FS transcript was highly expressed in breast tumor cells. Here I investigated a 
hypothesis that this highly expressed SMC1A FS transcript could be detected in 
the blood, and it could be a unique cancer biomarker. I discovered that the 
SMC1A FS transcript also existed in the blood of tumor bearing mice. I also 
developed a unique method to correlate the level of both SMC1A FS and WT 
transcripts with the tumor development by the regular RT-PCR and gel 
electrophoresis.  
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3.3.2 Result 
3.3.2.1 Discover the SMC1A WT and FS transcript in tumor bearing mice 
and healthy mice 
The experimental design for SMC1A WT and FS transcript detection was 
straight forward. The total circulating RNA was purified from the mouse plasma 
by Trizol-ethanol precipitation. This protocol will extract both free and protein 
bound RNA. The total circulating RNA was reverse transcribed into cDNA and 
then used for regular PCR analysis with the flanking primers that can amplify 
both WT and FS transcript of the SMC1A (Figure 3.7).  
 
Figure 3. 7 Process of the analysis of the circulating SMC1A FS and WT 
transcript. Mouse blood was collected by cardiac puncture and centrifuged for 
plasma collection. Total circulating RNA was extracted from the plasma by 
Trizol-ethanol precipitation followed by RT-PCR with flanking primers for 
amplification of both SMC1A FS and WT transcripts. The PCR products were 
analyzed by gel electrophoresis and gel scan to quantify the amplified SMC1A FS 
and WT transcripts. 
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Figure 3. 8 Gel electrophoresis of the RT-PCR products of the circulating 
RNA from the blood. 4 end-point 4T1 tumor bearing mice and 1 healthy mouse 
were included in the assay 
 
Tumor bearing mice were established by inoculating 5x103 4T1 tumor 
cells into the mouse mammary glands. The mice were euthanized and the plasmas 
were collected when tumor volume increased to 2 cm3 according to the approved 
protocol. 4 tumor bearing mice and 1 healthy mouse were included in the first 
trial. The PCR products were analyzed by regular gel electrophoresis. Both WT 
and FS transcript of the SMC1A were detected in the plasma from tumor bearing 
mice and only the WT transcript of the SMC1A was detected in the healthy 
mouse (Figure 3.8). It is interesting that the FS transcript of the SMC1A was 
predominant relative to the WT transcript in three of four PCR products from 
plasma of tumor bearing mice. This discovery led me to further investigate the 
possibility of using this pattern of the SMC1A FS and WT transcript as a cancer 
biomarker. Importantly, the ratio of the WT and FS RNAs could produce an 
internal control.  
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3.3.2.2 Correlation between tumor size and ratio of the WT and FS 
transcript by regular RT-PCR of the circulating RNA 
 
Figure 3. 9 Analysis of the circulating SMC1A FS and WT transcripts with 
4T1-BALB/c mouse breast tumor model. 5x103 4T1 cell were inoculated into 
mouse mammary gland. The circulating RNA was extracted from mice at 2 days, 
7 days and 15 days after tumor inoculation as indicated at the top of the fig. All of 
the total RNA samples were processed the same time for RT-PCR and gel 
electrophoresis analysis. The gel was scanned and PCR products of the WT and 
FS transcripts were labeled and quantified. 
 
To investigate the correlation between tumor status and the detection of 
WT and FS transcript by regular RT-PCR, I set up a time sensitive experiment. 
The plasma samples were collected at different time points after 4T1 cell 
inoculation. To exclude the possibility that circulating FS transcripts were directly 
released during the process of inoculating the tumor cells, plasma samples were 
collected 2 days after 4T1 tumor cell inoculation. 7 days after tumor inoculation 
was another time point to investigate the early detection since most mice did not 
develop palpable tumor by that time. At 15 days after tumor inoculation most 
mice develop palpable 4T1 tumors with variable tumor size. The cDNA from the 
total circulating RNA was prepared at the time of the plasma collections and the 
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PCR analysis performed at the same time (Figure 3.9). There was no detectably 
circulation of FS transcripts of SMC1A in the plasma samples collected 2 days 
after tumor inoculation. The FS transcripts started to be detected with plasma 
collected 7 days after tumor inoculation and the intensity of the PCR product of 
the FS transcript trended to increase when the tumor further developed, while the 
WT transcript PCR products trended to decrease. To quantify the change of the 
PCR amplified WT and FS transcript and investigate the correlation between this 
change and the tumor development, I calculated the ratio of the PCR amplified FS 
verse WT transcripts by scanning the electrophoresis gel and quantifying the 
intensity of both bands (Figure 3.10 A). The ratio increased with the time of 
tumor development. I also discovered that the tumor size was positively correlated 
with the ratio of the PCR amplified FS transcripts verse the WT transcripts 
(Figure 3.10 B).  
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Figure 3. 10 Correlation between tumor development and the PCR products 
ratio of the FS and WT transcripts. A. the ratio of the quantified PCR products 
of the FS and WT transcripts of each plasma samples. B. palpable 4T1 tumor size 
of each mouse by the time of the blood collection. 
 
3.3.3 Discussion 
With the experiments that were described above, I demonstrated that the 
ratio of the PCR amplified SMC1A FS transcript verse the WT transcript could be 
used as a biomarker for early cancer diagnosis as well as tumor development. I 
showed that both the circulating SMC1A WT and FS transcripts could be detected 
from the tumor bearing mice, while only the WT transcript could be detected in 
healthy mice. There is no detectable circulating FS transcript in plasma collected 
2 days after tumor cell inoculation. This indicated that the detected FS transcripts 
in later stages were not directly released by the inoculated tumor cells. They 
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should be specifically released by developing tumors. The circulating FS 
transcript could be detected as early as 7 days after tumor cell inoculation at 
which time there is no palpable tumor. I also demonstrated that the ratio of the 
PCR amplified FS transcript verse the WT transcript was positively correlated 
with tumor development. The absence of detectable FS transcript in two tumor 
bearing mice may be caused by the procedure process, such as contamination of 
the RNA from blood cell by erythrocytolysis. This also may simply be caused by 
the small number of tumor cells in these two mice. Further investigation of 
protocol optimization is necessary.  
Comparing other currently studied cNAs biomarkers, this biomarker 
represents advantages by simplifying the analysis and keeping the sensitivity.  
Unlike other cNAs analysis, this unique biomarker analysis does not need the 
quantitative PCR analysis, which is limited by the reference and also sensitive to 
the sample process. In this unique biomarker analysis, the circulating WT 
transcript acts as the internal reference for the increase of the circulating FS 
transcript and this reference factor is included in the calculation of the ratio of the 
PCR products. The analysis of this biomarker could be accomplished by the 
regular RT-PCR and gel electrophoresis, which is more simple and robust.  
There are some unique characteristics of this biomarker that improve the 
sensitivity and specificity of this biomarker analysis. First, the signal of this 
biomarker is amplified in vivo by natural characteristics. Studies showed that the 
smaller fragments of the cNAs were more frequent and stable in the blood. This 
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suggested that the target fragment of the SMC1A FS transcript tends to be more 
enriched in the blood than the target fragment of the WT transcript, which is 
302bp longer. Therefore, the target FS fragments that are released by the tumor 
cells should be more efficiently accumulated in the blood than the target WT 
fragment. Consequently, this increases the sensitivity of the detection. This is in 
contrast to most approaches to monitoring cancer cNAs in the blood which focus 
on mutations. Because of the difficulties in PCR monitoring of mutations, this 
approach usually requires using digital PCR. Secondly, the sensitivity of this 
biomarker in vitro is improved by the unique setting of the assay. The PCR 
amplifications of the FS and WT fragments in the same reaction compete for the 
same primer set. The shorter FS fragment is more efficient to be amplified than 
the longer WT fragment. Therefore, the signal of this biomarker is further 
amplified. This may explain why there is less WT fragment as more FS is present 
in Figure 3.9.    
The proof of concept study of this biomarker by analysis of the circulating 
SMC1A WT and FS transcripts suggests wide applications of this biomarker and 
others like it. First, this indicates that all of the cancer related splicing variants 
could be candidates for this biomarker analysis. A list of the tissue specific and 
cancer specific splicing variants have been identified [194] (Lee and Johnston, in 
preparation). We could develop the general and specific cancer biomarkers by 
analyzing the splicing profile of these biomarkers. Second, this class of 
biomarkers could not only be used for early cancer diagnosis, but also could be 
 
143
used for the cancer treatment monitoring, such as tumor metastasis and 
recurrence. The studies of the circulating cNAs showed that the level of the 
cancer related cNAs significantly decreased after the treatment, such as surgery 
[195]. The sensitivity of this biomarker to the cancer related transcripts suggests 
its important value for the treatment, evaluation and monitoring.  
In summary, this proof of concept study suggests that this biomarker 
analysis has an important value for the early cancer diagnosis and treatment 
monitoring. Further investigation should focus on the optimization of the 
biomarker analysis, such as circulating RNA isolation and PCR analysis. We also 
should evaluate this biomarker in more animal tumor model and clinical samples 
and screen more candidate targets. 
3.4 Materials and Methods 
3.4.1 Rabbit SMC1fs Serum 
Rabbit anti-SMC1A FS peptide serum was produced for me by Global 
Peptide Service LLC.  The New Zealand white rabbit was immunized with KLH 
conjugated human SMC1A FS peptide with a sequence of 
CCGIYCHEEPQREDSSI. 
3.4.2 Antibody absorption 
Specific antibodies were absorbed from the rabbit anti-SMC1A FS serum 
by applying the serum to the hSMC1Afs 17mer peptide coated plate.  The amino 
acid sequence of this hSMC1Afs- 17mer peptide was 
 
144
CCGIYCHEEPQREDSSI.  In some experiments, the hSMC1Afs-27mer peptide 
was used which contains 10 amino acids of wild type sequence upstream of the 
hSMC1Afs-17mer for better epitope representation.  The amino acid sequence of 
the hSMC1Afs-27mer is TAIIGPNGSGCCGIYCHEEPQREDSSI .  The rabbit 
serum was diluted 1:250 with 3% BSA in PBST and incubated with the hSMCfs 
peptide coated plate at 37°C for 1 hour.  The unbound antibody in the supernatant 
was then removed and applied to another peptide coated well to remove more 
antibody specific for the peptide.  This process was repeated up to 20 times, and 
this serum was then later applied to the peptide microarray with a dilution of 
1:500.  This same method was used to produce negative control, antibody 
absorbed serum using the negative control AVLLM peptide with a sequence of 
AVLLMCQLYQPWMCKEYYRLL. 
3.4.3 Random peptide array printing 
10,000 peptides made up of a randomly generated sequence were 
chemically synthesized.  These peptides contain 17 random amino acids and 3 
amino acids on the C terminus with the sequence of GSC.  The C terminal 
cysteine binds to a sulfo-SMCC coated aminosilane glass slide.  The solutions of 
different random peptides were spotted onto the glass slide using a Nanoprint 60 
instrument. 
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3.4.4 Customized peptide array 
Peptides were synthesized by Sigma and printed with another 144 peptides 
by AMI.   
3.4.5 Application of serum to random peptide array 
Rabbit serum was applied to the random peptide microarray using a Tecan 
HS 4800 Pro microarray hybridization station.  Slides were first washed for 30s 
with TBST, and then blocked with a blocking buffer consisting of BSA, 
mercaptohexanol, Tween 20, and PBS for 1 hr at 23 C.  Duplicate samples of 
serum were diluted 1:500 in an incubation buffer consisting of BSA, Tween 20, 
and PBS and incubated with the slide for 1 hr at 37 C.  The slide was then 
washed, and 5 nM of goat anti-rabbit AlexaFluor 647 dye was applied for 1 hr at 
37 C.  The slide was then washed and dried for 5 minutes. 
3.4.6 Scanning and analysis of array 
The slides were scanned with an Agilent Technologies DNA Microarray 
Scanner with Surescan High-Resolution Technology instrument and analyzed 
with GenePix Pro 6.0 software to determine the fluorescence intensity of each 
spot.  GeneSpring GX 7.3, Microsoft Excel, simple custom Java code, and 
GraphPad Prism 4 were then used to perform further analysis of this data. 
3.4.7 Antibody purification 
Specific antibodies were purified from serum by flowing serum through a 
column filled with TentaGel beads with synthesized peptides on their 
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surface such as the SMC1Afs peptide, selected random peptides, or an irrelevant 
ATKAA peptide as a negative control with a sequence of 
ATKAAIPGPNTVPRAP.  The total IgG of the rabbit anti-hSMC1A FS serum 
was purified using Pierce Protein A/G Agarose beads with the protocol of the 
manufacturer.  1 ml of the TentaGel beads were mixed with 3ml of the purified 
total IgG, and this solution was incubated for 1 hour at room temperature. The 
column was then washed with 10ml PBST. The specific IgG was eluted with 4 
fractions of 1ml IgG Elution Buffer from Pierce and each fraction was neutralized 
with 100 uL 1M Tris.  All of the eluted fractions were measured at an absorbance 
of 280nm.  The two fractions with the highest absorbance were combined and 
used for further analysis at a 1 to 40 dilution in 3% BSA in PBST.     
3.4.8 Human serum samples 
Center for Innovations in Medicine, Biodesign Imstitute, Arizona State 
University holds IRB 0912004625.  
3.4.9 Circulating RNA extraction and RT-PCR 
The circulating RNA extraction was modified from the manufacter’s 
protocol for TRIzol. Mix 250ul mouse plasma with 1ml TRIzol and vortex for 30 
seconds and let sit at room temperature for 5 minutes. Add 20ul chloroform and 
shake for 30 seconds. Sit at room temperature for 2 minutes. Then centrifuge the 
mix 12,000xg for 15 minutes and transfer the aqueous phase to another tube. Mix 
the aqueous phase with 500ul isopropyl alcohol and incubate at -20°C for 15 
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minutes. Then centrifuge 12,000xg for 30 minutes at 4°C. Remove the 
supernatant and wash the pellet with cold 75% ethanol. Centrifuge 8000xg for 10 
minutes. Then remove the supernatant and air-dry the pellet. Then dissolve the 
pellet in 30ul RNase free water.  
The RNA concentration was too low to measure with the Nano-drop. 
Therefore I directly use 8ul for cDNA synthesizing with SuperScriptTM First-
Stand Synthesis SuperMix (Life Technologies, Carlsbad, CA). The end-point 
PCR was performed with GotaqTM PCR kit (Promega Corporation, Madison, WI) 
and Mastercycler ep gradient S (Eppendorf, Hamburg, Germany).  
3.4.10 Gel electrophoresis and quantifing the intensity of the PCR products  
The PCR product was analyzed by gel electrophoresis with 2% argrose 
containing EB. The gel was scanned on the Typhoon. The intensity of each band 
was quantified by Image Quant 5.2. The ratio of the FS fraction verse the WT 
fraction was calculated by the intensity.  
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CHAPTER 4  
SMC1A AND TUMORIGENICITY 
4.1 Introduction 
The cancer related genes, such as tumor suppressor genes and oncogenes, 
are the traditional topic of cancer research. Dozens of cancer related genes have 
been characterized [196]. These cancer related genes are involved in each step of 
tumor development, from tumor initiation to metastasis. Cancer related genes that 
are triggered by genetic and epigenetic alterations are well studied. More recently, 
the accumulated evidence shows that the mis-regulated alternative splicing also 
plays an important role during tumor development by affecting genes that are 
involved in almost every aspect of tumor progression; such as metabolism, cell 
cycle control, apoptosis, invasion and metastasis [194, 197]. Alternative splicing 
increases the diversity of the genome. It is tightly regulated in normal cells by 
specifically expressing different isoforms with different functions in different 
stages of the development of different tissues [198]. The tumor cells take 
advantage of this regulation system of alternative splicing and triggers the 
splicing isoforms that is not normally expressed in normal adult cells. A major 
type of mis-regulated splicing in cancer cells is the expression of isoforms that 
encode proteins with appositive functions that were encoded by isoforms 
expressed in normal cells [199]. The expression of these mis-regulated splicing 
isoforms increases the advantage for tumor progression. For example, Bcl-x has 
two isoforms with different sizes that are generated by alternative splicing at 
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two splice sites at the 5’ end of the exon2 [200]. The longer isoform of Bcl-x has 
anti-apoptosis function, while the short isoform could induce the apoptosis of the 
cancer cells. The bias of the splicing to the long isoform of Bcl-x is observed in a 
variety of types of cancers [201-204]. Some other mis-regulated splicing isoforms 
have unknown functions but reduce the normal functional isoforms by consuming 
the pre-mRNA. For example, the caspase-2 gene with full length splicing isoform 
(caspas-2L) is involved in a variety of cellular processes and acts as a tumor 
suppressor gene [205, 206]. The mis-regulated splicing isoform of the caspase-2 
(caspase-2S) contains an additional exon (exon9). The splicing of exon9 causes a 
frameshift and generates a PTC in the caspase-2S, which makes it a target of the 
NMD. The reduction of the expression of the caspase-2 was observed in different 
tumors and this may be caused by mis-regulated splicing of the caspase-2S and 
degradation by NMD [207, 208].     
During my research on neo prophylactic cancer vaccine candidate 
discovery, we identified the SMC1A FS alternative splicing by directly splicing 
exon 1 to exon 4 of the SMC1A pre-mRNA which generates a FS transcript with 
a PTC in exon4 (Figure 1.5).  This SMC1A FS transcript was highly expressed in 
primary human breast tumors (Figure 1.6). The SMC1A FS transcript was also 
detected in a variety of types of human tumors, mouse tumors and dog tumors 
with highly conserved sequences, as I described above (Figure 1.7-1.9).  
The WT SMC1A has important functions in different cellular activities. 
SMC1A was first identified in Saccharomyces cerevisiae by studying a mutant 
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strain with unstable maintenance of minichromosomes [209]. It is an important 
component of a cohesion complex which is formed by a heterodyne of SMC1A 
and SMC3 and two non-SMC proteins: Scc1 and Scc3. The primary function of 
cohesin is in holding sister chromatids together by forming rings that locate along 
the chromosome during DNA replication in S phase until anaphase. It stabilizes 
the chromosome. The homozygous deletion of Smc1A in S.cerevisiae is lethal 
and heterozygous deletion causes haploinsufficiency [210, 211].  
Recently, cohesin was found to be involved in the regulation of gene 
expression. In Drosophila, the cohesin homologue is the Nipped-B protein. The 
Nipped B binding sites in the transcribed regions in the Drosophila genome 
overlap with RNA polymerase II. The binding of both cohesin and Nipped-B is 
associated with the expression of genes located in these regions [212, 213]. In 
mammals, cohesin is co-localized with zinc finger transcription factor CTCF 
along the mammalian genome. CTCF functions as an enhancer-blocking 
transcriptional insulator. Studies indicate its function depends on interaction with 
cohesion [214-216].  
SMC1A is also involved in DNA repair mechanisms. The early indication 
of SMC1A being involved in DNA repair was finding that the SMC1A/SMC3, 
DNA polymerase E and DNA ligase III are involved in the RC-1 complex, which 
can recombine homologous DNA and repair both gaps and deletions in those 
DNA in vitro [217]. Studies in yeast show impaired DNA double stranded break 
repair through the homologous recombination pathway in SMC1A mutated cells 
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[218]. It also shows recruitment of SMC1A around DNA double stranded break 
sites even in the G2 phase of cell cycle division [219]. In mammalian cells, 
SMC1A is phosphorylated by ataxia telangiectasia mutated (ATM) after ionizing 
irradiation. Mutation of the phosphorylation site of SMC1A will decrease cell 
survival only after DNA damage. This suggests a role of SMC1A in DNA repair 
that is independent of its essential role in cohensin [220].  
Since SMC1A has such important functions in different aspects of cellular 
processes, people suspected that the alteration of SMC1A is related to inherited 
diseases. The genetic mutations of SMC1A are well characterized with being 
involved in the genetic disease Cornelia de Lange Syndrome (CdLS). CdLS is a 
developmental disorder of multiple systems. The typical syndromes of this 
heterogeneous disease are consistent facial dysmorphia, upper extremity 
malformations, hirsutism cardiac defects and so on. Multiples gene mutations are 
identified that cause this disease, such as NIPBL, PDS5B, SMC3 and SMC1A 
[221-224]. The mutation of the SMC1A is responsible for 3% of CdLS cases. The 
mutation of the SMC1A is also detected in human colorectal cancers [225]. The 
mutation of SMC1A hypothetically causes a defect of the cohesin, consequently 
inducing chromosomal instability, which is a hallmark of colorectal cancers. The 
alteration of the SMC1A is also correlated with acute myeloid leukemia (AML). 
Low or absent SMC1A protein expression is detected in 64% AML specimens 
and the low SMC1A protein expression is significantly correlated with shorter 
event free and overall survival of the AML patients [226]. There is no significant 
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correlation between the mRNA level and the protein level of SMC1A in those 
AML patients. This indicates there are epigenetic alternations of the SMC1A in 
AML patients. It is also reported that knocking down SMC1A expression by 
antisense oligonucleotide treatment of the primary human fibroblast cell line 
could induce both aneuploidy and chromosome aberrations. However, there was 
no tumorigenicity induced by measuring the anchorage independent growth [227]. 
So far, there is no direct evidence demonstrating that either decreasing the WT 
SMC1A expression, or increasing the SMC1A FS expression, or both could 
increase the tumorigenicity of the normal cells.  
Our findings with SMC1A correlate with previous literature reports, and 
has lead to the hypothesis that SMC1A is involved in the general tumor 
development through its mis-splicing. This mis-regulated splicing either 
decreases the expression of the WT transcript by consuming the pre-mRNA 
of SMC1A, has the function to increase the tumorigenicity of the normal 
cells, or both effects.  
To test this hypothesis, I investigated the expression of both WT and FS 
isoforms of SMC1A in tumor and normal tissues. I also directly tested the 
tumorigenicity induction by knocking down the expression of the WT isoform in 
non-tumorigenic cell lines.   
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4.2 Result 
4.2.1 Detection of the alternative splicing of SMC1A in tumor 
 
Figure 4. 1 Detection of alternative splicing of the SMC1A. A. Whole mature 
SMC1A mRNA were divided into 9 overlap fragments. 9 sets of primer were 
designed for amplifying each fragment. B. RT-PCR of B16F10 cDNA with the 9 
sets primers. Starts indicate the PCR products with predicted WT size. 
 
SMC1A FS is detected in a of variety tumors. To test if there are other 
alternative splicings of the SMC1A in tumors, I analyzed all alternative splicing 
of the SMC1A in B16F10 cells (mouse melanoma cell line) by RT-PCR with 9 
sets of the primers across the whole SMC1A exons (Figure 4.1 A). The whole 
CDS of SMC1A was divided into 9 overlapping fragments and each fragment was 
amplified by RT-PCR with a set of primers and analyzed by gel electrophoresis 
(Figure 4.1 B). However, because of the different primer sets and PCR 
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conditions, the SMC1A FS transcript could not be efficiently amplified in this 
experiment. The result demonstrated that there are several alternative splicing 
transcripts of SMC1A in B16F10 tumor cells with a variety of expression levels. 
The PCR products with shorter lengths of the fragments 3, 4 and 9 were cloned 
and analyzed by clonal sequence. A total of 30 clones were sequenced with clear 
traces. 7 clones were WT sequences, 6 clones were FS deletions, and 17 clones 
were in frame deletions. A total of 18 different deletions were detected. All of the 
deletions, except one, were not perfect exon skipped splicing. They were spliced 
from the middle of the exon to another middle of an exon (Figure 4.2). These 
results indicated that the splicing of the SMC1A was mis-regulated in the tumor 
cells. The splicing of the WT isoform may be affected by these mis-regulated 
alternative splicing mechanisms.  
 
Figure 4. 2 Sequence analysis of the alternative splicing of the SMC1A. The 
alternative splicing from the 3 fragment RT-PCR were cloned and sequenced. 
Total 17 alternative splicing were detected by sequencing 30 clones. The red bars 
indicate the approximate splicing sites of each alternative splicing. The width of 
the bar indicates the splicing number, wider bar indicate more splicing. 
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4.2.2 The SMC1A WT is down regulated and the FS is up regulated in 
pancreatic tumors 
 
Figure 4. 3 q-PCR analysis of the WT and FS isoforms expression in 
pancreas tumors and the normal adjacent tissues. The expression of the WT 
and FS isoform were measured in patient matched pancreas tumor and normal 
adjacent tissues. The expression ratios of each isoform in tumor verse normal 
tissue were calculated with the actin as the reference. The ratio below 1 indicates 
the isoform expression level in tumor is less than normal and vice versa. 
 
The mis-regulated alternative splicing could not only increase the 
expression of the oncogenic isoforms, but also could decrease the expression of 
the tumor suppression isoforms. The SMC1A FS splicing is frequently increased 
in human breast tumors. To test the hypothesis that the increasing SMC1A FS 
splicing decreases the WT splicing by consuming the pre-mRNA of the SMC1A, 
I investigated the expression of both WT and FS isoforms in the patient matched 
pancreas tumor and normal adjacent tissue samples. To accurately compare both 
relative isoforms, the WT isoform was measured by a primer pair that could 
amplify a fragment within exon2 and exon3. Both exon2 and exon3 were skipped 
in the FS isoform. The FS isoform was measured by a primer pair with the 5’ 
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end primer located at the junction of the exon1 and exon4. This primer pair could 
specifically amplify the FS isoform. A total of 5 pairs of the patient matched 
samples were analyzed by q-PCR. The expression ratio of the WT isoform in the 
tumor sample verse the matched normal adjacent tissue was calculated, as well as 
the expression ratio of the FS isoform (Figure 4.3). The results demonstrated that 
the WT isoform was frequently down regulated in pancreatic tumors, while the FS 
isoform was frequently up-regulated in pancreatic tumors.  
However, two pairs of patient matched samples have both WT and FS 
isoforms up-regulated or down-regulated in pancreatic tumors compared to the 
normal adjacent tissues. This may be because the FS isoform is the substrate of 
the NMD and is not stable after being spliced. Or there may be other alternative 
splicing that affects the measurements. Therefore, I could not measure the actual 
consumption rate of the pre-mRNA by the FS isoform in this assay. 
4.2.3 Transient knock down of the expression of the WT SMC1A could not 
induce the tumorigenicity of the HPED6 cell. 
Down-regulated expression of SMC1A was frequently observed in human 
pancreatic tumors. To test if the down regulation of the SMC1A could induce 
tumorigenicity, I first tried using siRNA to transiently “knock-down” SMC1A 
expression in HPDE6 cells. HPDE6 cell were established from primary normal 
pancreatic duct epithelial cells by transducing HPV16-E6E7 gene. The HPDE6 
cell exhibits near normal genotype and phenotype of the pancreatic duct epithelial 
cells. The proliferation of the HPDE6 cells is anchorage dependent, and they 
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are non-tumorigenic in SCID mice. Two siRNA of human SMC1A were designed 
and I tested their efficiency at “knocking-down” the gene through RT-PCR 
techniques after 48 hour transduction. The GAPDH siRNA was included as the 
positive control for the procedure, and the non-target siRNA was included as the 
negative control for the tumorigenicity induction. The RT-PCR results 
demonstrated that all of the three siRNA could specifically knock down the 
targets in 48 hours, and the non-target siRNA had the same expression of the 
tested genes as the non-treated cells (Figure 4.4). All of these cells were treated 
with siRNA for 72 hours and then were expanded. The tumorigenicity of these 
cells was measured by the anchorage independent growth (AIG) assay. I just did 
one plate for each siRNA treatment and no-treatment cells. The AIG assay 
demonstrated that there was only a few colonies more in SMC1A siRNA treated 
cells compared to the negative control cells. Overall the number of anchorage 
independent growth colonies was low. This result and other reports suggested that 
the transient knock down of SMC1A could not efficiently induce the 
tumorigenicity.  
4.2.4 Stably knock down the expression of the WT SMC1A could induce the 
tumorigenicity of BALB-3T3 cell.  
The transient knock down of SMC1A for 72 hours may not be enough 
time for cells to take on characteristics of tumorigenicity. I then tried to stably 
“knock-down” SMC1A in BALB-3T3 mouse embryonic cells by shRNA through 
the lentivirus expression system. BALB-3T3 mouse embryonic cell have no 
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tumorigenicity in SCID mouse. Switching the target cell lines from the human to 
mouse system helped with the future in vivo analysis. Two efficient shRNA 
targets were selected and cloned into the lentivirus expression vector. These two 
shRNAs were located at exon21 and exon23 of the mouse SMC1A mRNA and 
named smc38 and smc75, respectively. Two BALB-3T3 cell clones with stable 
expression of smc38 and smc75 were isolated and established, as well as, the 
BALB-3T3 cell clone with stable expression of a non-target shRNA as the 
negative control. The efficiency of the SMC1A mRNA “knock-down” in these 
three cell lines was analyzed using RT-PCR with the primer set that could amplify 
a fragment in exon23 and exon24, as well as the non-treated BALB-3T3 cells 
(Figure 4.4). This demonstrated that about 50% of the WT SMC1A mRNA was 
“knocked-down” in both smc38 and smc75 clones. It was reported that 100% 
deficiency of SMC1A in yeast was lethal, so that the 50% knock down should be 
the most efficient knock-down achieved. Heterozygous deletion of SMC1A in 
yeast is sufficient to induce chromosome instability [211]. The tumorigenicity of 
these two cell lines was analyzed by the anchorage independent growth assay, as 
well as the negative control cell line. I also analyzed the tumorigenicity of the 
polyclonal smc38 BALB-3T3 cells (Figure 4.5). 5x103 cells were plated in the 
agarose medium and cultures were kept for 3 weeks. The cell clones greater than 
50um were counted. Both polyclonal and single clones of smc38 BALB-3T3 cells 
had more anchorage independent growth compared to the negative control cells. 
This clearly demonstrates that the knock-down expression of SMC1A could 
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induce tumorigenicity of normal cells. I also tried to characterize the in vivo 
tumorigenicity of the smc38 BALB-3T3 by subcutaneously inoculating the cells 
into normal BALB/c mice. The smc38 BALB 3T3 cell failed to develop into a 
tumor in normal BALB/c mice. This may be caused by the immune rejection 
induced by the expression of the lentivirus protein in the cells. Further 
investigation should use the immune deficient mice for the in vivo tumorigenicity 
evaluation.
 
Figure 4. 4 RT-PCR analysis of the SMC1A knock down in HPDE6 with 
siRNA. The HPDE6 cells were treated with the different siRNA as indicated for 
48 hours and followed by the RT-PCR analysis for the mRNA level of the 
different genes. 1. No-target siRNA treatment was the negative control for the 
tumorigenicity; 2. GAPDH siRNA treatment was the positive control for the 
experiment procedure; 3 and 4. smc05 and smc08 siRNA treatment respectively; 
5. no-treated cells   
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Figure 4. 5 Anchorage independent growth assay. 1x104 of each treated 
HPDE6 cells were plate in the argarose medium and incubated for 16 days. 
Colony size >50um were counted. 
4.2.5 Detection of the SMC1A FS truncated protein    
The SMC1A FS isoform was frequently detected in the different tumors. 
To test the hypothesis that FS isoforms of SMC1A have the ability to promote 
tumor development, I first designed the experiment to detect the expression of the 
truncated protein encoded by the FS isoform in tumors. We generated high titer 
anti-human SMC1A FS peptide rabbit serum by immunizing rabbits with the 17 
amino acid human SMC1A FS peptide conjugated to KLH. Both the ELISA and 
western blot showed that the anti-serum has cross reactivity to the mouse SMC1A 
FS peptide (Figure 4.6). As mentioned above, the predicted molecular weight of 
the human truncated SMC1A FS protein is 6.08KD and 5.98KD in humans and 
mice, respectively. Both of them contain the same initial 37 amino acids on the N-
terminus of the WT SMC1A protein, and there is a 2 amino acid difference in the 
C-terminus FS peptide tails.  I performed a western blot (WB) of four human 
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breast tumor cell lysates and a mouse melanoma tumor cell lysate with the affinity 
purified rabbit anti human SMC1 FS antibody. All 5 tumor cell lysates showed a 
specific detected band around 16KD (Figure 4.7).  
 
Figure 4. 6 RT-PCR analysis of the expression SMC1A stable knock down in 
BALB-3T3 cell. The fragment in the exon23 and exon24 were used to evaluate 
the efficiency of the SMC1A knock down by shRNA through the lentivirus 
expression system. The negative cell line expressed the no-target shRNA, both 
SMC38 and SMC75 cell lines expressed shRNA that target different sequence of 
the WT SMC1A.    
 
 
 
Figure 4. 7 Anchorage independent growth assay. 5k of each transfected 
BALB-3T3 cells was plated in the argarose medium and incubated for 3 weeks. 
Colony size >50um were counted. Data presented were from three repeated 
experiments with duplication of each cell line in each experiment. Each bar was 
the average from 6 plates and error bar is the standard error. ***: p<0.0001; **: 
p<0.005 
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Figure 4. 8 Analysis of cross reaction of rabbit anti-human SMC1A FS 
peptide anti-serum to mouse SMC1A FS peptide. A. Western blot analysis of 
the cross reaction of the rabbit anti-human SMC1 FS peptide anti-serum to the 
GST fused mouse SMC1A FS peptide protein. Left: the SDS-page with simple 
staining of the protein fractions. Arrows indicate the detected fractions. Right: the 
WT analysis with the rabbit anti-human SMC1A FS anti-serum. Arrows indicate 
the detected fractions that specifically recognized by the anti-serum. 1. 1ug BSA 
coupled human SMC1A FS 17aa; 2. 1ug BSA; 3. 2ug GST-fused mouse SMC1A 
FS 27aa.   B. ELISA analysis of rabbit anti-human SMC1A FS anti-serum, plate 
was coated with 50ul of each peptide at 10ug/ml. 1. human SMC1A FS 17aa; 2. 
human SMC1A FS 27aa; 3. mouse SMC1A FS 17aa; 4. mouse SMC1A FS 27aa; 
5. human 1-78 FS peptide 21aa, as negative control.   
 
Figure 4. 9 WB of human and mouse tumor cell lysate with affinity purified 
rabbit anti-human SMC1A FS antibody. Load 100ug lysate of each tumor cell 
line. 1. CRL2351; 2. CRL2335; 3. CRL7253; 4. CRL2326; 5. B16F10. Arrow 
indicates the 16KD fraction that was specifically recognized by the rabbit anti-
human SMC1A FS peptide anti-serum. 
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Figure 4. 10 WB of human breast tumor cell CRL2351 lysate with the 
commercial rabbit anti-human wild type SMC1A N-terminal antibody. 
100ug lysate of each sample was loaded for WB. 1. the commercial anti-human 
SMC1A 1-288aa antibody, top arrow indicates the WT SMC1A; bottom arrow 
indicates the 16KD fraction; 2. rabbit anti-human beta-actin antibody, arrow 
indicates the beat-actin expression in the lysate for the positive control; 3. HRP 
labled goat anti-rabbit IgG 2nd antibody for the control of the secondary antibody 
background. 
To confirm that the specifically detected 16KD fraction contained the 
truncated SMC1A FS protein, I also performed a WB of human breast tumor cell 
lysate with a commercial polyclonal antibody that can recognize WT human 
SMC1A N-terminal 1 to 288 amino acids. This commercial antibody should 
recognize both the whole WT SMC1A protein and the truncated FS protein, 
which contains the first 37 amino acids of the WT SMC1A protein. This antibody 
can also recognize the mouse wild type and truncated SMC1A proteins since both 
human and mouse share the same protein sequence that is encoded by exon1. The 
result showed that the commercial antibody also could specifically detect the 
16KD band in the lysate of human breast tumor cell line CRL2351, as well as the 
full length of SMC1A protein (Figure 4.8). The specifically detected band by both 
antibodies was 10KD bigger than the predicted protein size. It was possible that 
the truncated protein is modified.  
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To further investigate this 16KD fraction, I used the B16F10 tumor cell 
lysate. Protein glycosylation is one of the most common post-translation 
modifications. To test if the 16KD fraction is glycosylized, I treated the total 
B16F10 cell lysate with enzymatic deglycosylation with the deglycosylation kit 
and chemical deglycosylation with trifluoromethanesulfonic acid (TFMS). Both 
treatments did not change the mobility of the 16KD fraction in WB analysis 
(Figure4.9). This indicated that glycosylation did not affect the mobility of the 
detected band.  
 
Figure 4. 11 WB of deglycosylation of B16F10 tumor cell lysate with the 
rabbit anti-human SMC1A FS peptide antiserum. A. WB of enzymatic 
deglycosylation cell lysate. 1. 10ul untreated lysate; 2. 10ul of 4 hours enzymatic 
treated lysate; 3. 10ul of 8 hours enzymatic treated lystae. B. WB of 
trifluoromethanesulfonic acid (TFMS) chemical deglycosylation cell lysate. 1. 
20ul untreated cell lysate; 2. 20ul TFMS treated cell lystae. Arrows indicate the 
16KD fractions. 
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Figure 4. 12 WB of total B16F10 denatured lysate (20ul). Rabbit anti-
SUMO2/3 antibody (lane 1); rabbit anti-human wild type SMC1A N-terminal (1-
288aa) antibody (lane 2); rabbit anti-human SMC1A FS antibody (lane 3). Arrows 
indicate the 16KD fractions. 
 
Before further analysis of the 16KD fraction, I searched the other possible 
post modifications that could add about 10 KD mass to the target proteins. It was 
turned out that the SUMOylation is the most likely post-translational modification 
which can add about a 12KD mass to the target proteins. The WB analysis 
demonstrated that anti-sumo2/3 antibody, anti-human SMC1A N-terminal 
antibody and anti-human SMC1A FS antibody can recognize the same 16KD 
fraction of the B16F10 lysate (Figure 4.12). This indicated the 16 KD fraction of 
from the tumor lysates contain the truncated SMC1A FS protein which could be 
SUMOylated by sumo2 or sumo3.  
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Figure 4. 13 WB of B16F10 denatured lysate and normal C57BL6 tissues 
lysates (200ug each) with rabbit anti-human SMC1A FS antibody. 1. B16F10 
lysate; 2. heart lysate; 3. intestine lysate; 4. lung layeste; 5. spleen lysate. Arrow 
indicates the 16KD fractions. Star indicate the possible un-modified SMC1A FS 
truncated protein in heart lysate 
 
It was demonstrated that the SMC1A FS transcript was low in the normal 
tissues, and was barely detected by RT-PCR in some normal tissues from mouse, 
such as lung, intestine and heart. To investigate the different expression of the 
truncated protein between tumor and normal tissues, I performed the WB analysis 
of some normal mouse tissue lysates with anti-human SMC1A FS antibody 
(Figure 4.13). Surprisingly, the WB result exhibited that all of the normal tissues 
contain the same 16KD fraction as the B16F10 tumor cells. The intensities of the 
detected 16KD fractions were similar among B16F10 lysate, intestine lysate and 
lung lysate. Both the intenstine lysate and spleen lysate exhibited the same WB 
pattern as the B16F10 lysate. The normal heart lysate also exhibited the specific 
detection of the 4KD band, which is approximately the size of the SMC1A FS 
isoform. 
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To directly confirm if the 16KD fraction contain the truncated SMC1A FS 
protein, I tried different methods. The immunoprecipitation of tumor cell lysate 
with the FS antibody failed to pull down the 16KD fraction. Additionally, in-gel 
trypsin digestion of the 16KD fraction followed by mass spectrum analysis failed 
to detect the truncated protein as well.  
4.2.6 The truncated protein encoded by the SMC1A FS transcript is located 
in the nucleolus 
To further investigate the expression of the truncated protein in both tumor 
and normal tissues, we collaborated with Dr. Atul K. Tandon at NeoBiomarkers 
Inc. and performed the immunohistochemistry (IHC) analysis of primary tumor 
and normal tissue sections with the rabbit anti-SMC1A FS serum (Figure 4.14). 
The nucleolus of both tumor and normal tissues were stained by the anti-serum, as 
well as the cytoplasm of some tissue structures. Both of the squamous cell 
carcinoma of the skin and the esophagus exhibited the clear membrane staining by 
the specific rabbit anti-serum.   
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Figure 4. 14 Immunoehistiochemistry analysis of formalin-fixed human 
normal tissues and primary tissues with rabbit anti-human MSC1A FS anti-
serum. 1. normal breast; 2. normal skin; 3. normal rectum; 4. normal bladder; 5. 
normal esophagus; 6. breast carcinoma; 7. squamouse cell carcinoma of skin; 8. 
rectum adenocarcinoma; 9. transitional cell carcinoma; 10. squamouse cell 
carcinoma of esophagus. blue: hemotoxylin staining nuclear; red/brown: antibody 
staining. The experiments were performed by Dr. Atul K. Tandon at 
NeoBiomarkers Inc 
 
The WT SMC1A usually forms cohesin and localizes in the cell nucleolus. 
Although the truncated protein was detected in both tumor and normal cells, it is 
possible that the expression of the truncated protein increases in tumor cells and 
promotes the tumor development by affecting the function of the WT protein in 
the cell nucleolus. It has been reported that the WT SMC1A protein will 
accumulate at the sites of the double stranded DNA break (DSB) of the DNA. To 
test if the truncated protein accumulated at DSB sites, we 
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collaborated with Dr. Yaron Galanty (The Wellcome Trust/Cancer Research UK 
Gurdon Institute) and performed the laser micro-irradiation of the U2OS cells 
(human osteosarcoma cell ) and followed the immunofluorescence (IF) assay 
(Figure 4.15 A). IF results of the non-treated U2OS cells demonstrated that the 
truncated protein was located in the nucleolus of the cells. This was consistent 
with the IHC results. IF assay of the mitotic cell exhibited that the truncated 
protein was excluded from the chromosomes at anaphase (Figure 4.15 B). 
However, the truncated proteins were not accumulated at the sites of the DSBs 
(Figure 4.15A).  
 
Figure 4. 15 IF assay of the cellular location of the truncated protein of the 
SMC1A FS isoform in U2OS cell, human osteosarcoma cell line. A. laser 
micro-irradiation of the cells before the IF staining. B. IF staining of the mitotic 
cells (indicated by the arrows). Blue: indicates nucleolus with DAPI staining; 
Red: indicates DSB sites by laser irradiation with anti-γ-H2AX antibody; Green: 
indicates the SMC1A FS truncated protein with the affinity purified rabbit anti-
serum against human SMC1A FS peptide (17aa). (Assay were performed by Dr. 
Yaron Galanty, The Wellcome Trust/Cancer Research UK Gurdon Institute) 
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4.2.7 Evolutionary evidence of the truncated SMC1A FS protein may have 
function in normal cells 
The detection of Sumolyation of the SMC1A FS truncated protein and the 
nucleolus localization of this truncated protein in normal cells indicated that the 
SMC1A FS protein may have nucleolus function in normal cells. SMC1A is a 
highly conserved gene in eukaryotes. It is interesting that the SMC1A FS peptides 
are also highly conserved between human and mouse (Table 1.1). I explored an 
evolutionary analysis of the SMC1A FS protein to see if there was any evidence 
to support the suggestion.  
Table 4. 1 Conservation analysis of the SMC1A DNA sequence. The identities 
of different DNA fragments of 5 eukaryote species to Homo sapiens were 
analyzed with NCBI Blast. Higher identity presents higher conservation. P values 
of the paired t test of identities of DNA fragment encoding the SMC1A FS 
peptide (exon4-fs) verse entire CDS and the downstream of the exon4-fs of the 
exon (exon4-rest) were less than 0.05.   
 
The conservation of a gene is derived from the evolutionary selection. A 
gene with a critical cellular function is usually highly conserved across different 
species [228]. It is also true for an important domain within a gene. For example, 
the N-terminal Walker A domain is highly conserved in the SMC super family 
genes [229]. Therefore, the highly conserved DNA fragment of a gene may 
encode an important domain. I analyzed the conservation of the DNA fragments 
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encoding the SMC1A FS peptide (exon4-fs) and the two connected fragments: the 
exon 3 which is upstream of the exon-fs and the downstream of the exon4-fs of 
the exon 4 (exon4-rest), as well as the conservation of the entire coding DNA 
sequence (CDS) of the SMC1A (Table 4.1 A).  There is no significant difference 
comparing the DNA identities among the entire CDS, exon3 and exon4-rest 
across the 5 eukaryote species. This indicates that both upstream and downstream 
DNA fragments of the exon4-fs are under similar evolutionary selection as the 
entire CDS. It is interesting that the exon4-fs has significantly higher identities 
than the entire CDS and the exon4-rest. Although the average of identities of the 
exon4-fs across the 5 species is higher than the exon3, there is no significant 
difference of the conservation between the exon3 and exon4-fs. The exon3 
encodes the first coiled-coil region after the highly conserved N-terminal Walker 
A domain. This may increase the conservation of the exon3 and select for less 
difference of the conservation between exon3 and exon4-fs. The DNA 
conservation analysis compared to the other sequences, however, indicates that 
the exon4-fs may encode a functional domain. I further analyzed the conservation 
of the peptides encoded by these three DNA fragments (Table 4.2). The peptides 
encoded by the primary reading frames of the exon3, exon4-fs and exon-rest are 
100% identical in 4 of the 5 selected eukaryote species. The entire exon4 encodes 
part of the coiled-coil region and there is no special annotated domain in this 
region of the WT protein. This indicates that the higher identity of the exon4-fs 
may not be evolutionally derived by the primary reading frame. However, the 3rd 
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reading frame of the exon4-fs has significantly higher identity than the other two 
fragments (Table 4.2). This is the reading frame that encodes the SMC1A FS 
peptide. It is interesting that there is no significant difference in the conservation 
of the primary and 2nd reading frames between the exon3 and exon4-fs. This 
suggests that the higher conservation of the exon4-fs may be derived by the 
evolutionary selection of the peptide encoded by the 3rd reading frame. The 
peptide alignment of the FS peptides from 5 eukaryote species shows that there is 
a highly conserved peptide fragment: CHEEPQ. In summary, these evolutionary 
conservation analyses indicate that the SMC1A FS truncated protein may have the 
cellular function in normal cells. It is necessary to bioinfomatically analyze the 
conservation of the FS fragment in more species and possible functional motifs of 
the FS peptide for the further investigation of the biological function of the 
SMC1A FS truncated protein.  
 
 
 
 
 
 
 
 
 
 
 
173
Table 4. 2 Conservation analysis of peptides encoded by different reading 
frames the SMC1A DNA fragments. A. The identities of different peptides of 5 
eukaryote species to the correspond peptide of Homo sapiens were analyzed with 
NCBI Blast. Higher identity presents higher conservation. P values of the paired t 
test of identities of the third reading frame of the exon4-fs verse the exon3 and 
exon4-rest were less than 0.05. B. The comparision of the SMC1A FS peptide 
sequence of different species.   
 
4.3 Materials and Methods 
4.3.1 Quantitative PCR 
Real-time PCR were performed with REALMASTERMIX kit (Eppendorf, 
Germany), follow the manufacturer’s protocols. PCR condition: 95oC 2 min; 
(95oC 15 sec; 60 oC 15 sec, 68 oC 20sec)x40 cycles; 95 oC 15sec.   
4.3.2 siRNA assay 
Pre-designed human SMC1A and GAPDH siRNA were order from 
Dharmacon (Thermo Fisher Scientific, Lafayette, CO). The transient SMC1A 
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knock down assay was performed in 6 wells plate with the manufacturer’s 
protocol. Each siRNA treatment was duplicated. After 48 hours treatment, one of 
the duplicated siRNA samples was use for RT-PCR analysis to measure the knock 
down efficiency, another one was expended and use for the AIG assay to measure 
the tumorigenicity.  
Smc05: 5’-GGACAGCUCUAUUUGAAGAUU 
Smc08: 5’-GAACUGGCCUCAAAGAACAUU   
4.3.3 shRNA assay 
The shRNA assay was performed with BLOC-iTTM Lentiviral Pol II miR 
RNAi Exression System (Life Technologies, Carlsbad, CA). Two targets of the 
mouse SMC1A gene were designed and synthesized for cloning, as well as a no-
target sequence:  
SMC38: 
TGCTGAGGAGCTACACAGTTGTAGTTGTTTTGGCCACTGACTGACAAC
TACAAGTGTAGCTCCT;  
SMC75: 
TGCTGAGCCTTGGTGTAGAATTCCTCGTTTTGGCCACTGACTGACGAG
GAATTACACCAAGGCT; 
Neg: 
TGCTGAAATGTACTGCGCGTGGAGACGTTTTGGCCACTGACTGACGTC
TCCACGCAGTACATTT  
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Briefly, the synthesized oligos were cloned into Gateway vector system 
and finally constructed into pLenti6/V5 Expression vector and sequence 
confirmed. Co-transfect the pLenti6/V5 Expression vector with ViraPower Pawer 
Packaging Mix into 293FT cells and produces the lentivirus. Transduce the 
lentivirus into BALB-3T3 and select transfected cells with blasticidin. After the 
selection, expand the cells and then use part for sorting single clones and keep 
some as a population. The SMC1A knock down was measured in the population 
cells with RT-PCR analysis.  
4.3.4 Anchorage independent growth assay 
Prepare the plate 
Prepare 2x DMEM with 5% FBS and pen/strep and keep in a 37°C water 
bath.  Make a 2X 0.8% agarose stock in sterile water and autoclave. When the 
agarose cools to 50°C, mix with equal volume of the 2x medium. Quickly add 
2.5ml mixed medium to 60mm plate. Keep plates at 4°C.  
Prepare the assay 
Make 0.75% agarose stock in sterile water and autoclave. Then put in a 
45oC water bath. Pre-heat the 2x medium and plate at 37°C. Prepare cells and 
adjust to 2x104/ml in 1xDMEM medium and keep at 37°C. Mix 5ml 2X 
DMEM+4ml 0.75% agrose+1ml cells and quickly pour 3ml of the mixed over the 
bottom layer of the plate. Duplicate the plate. It will be 0.3% aragose with 5,000 
cells in each plate. After the top layer cools, add 1ml complete 1x DMEM on the 
top. Culture for 3-4 weeks and count the colonies.  
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4.3.5 Enzymatic deglycolyzation assay  
Follow the manufacturer’s protocol with the Protein Deglycosylation Mix 
(NEB, Ipswich, MA). Dissolve in 100ug desalted B16F10 lysate into 18ul water 
and add 2ul denaturing buffer and heat to 100°C for 10 minutes for the denaturing 
reaction. Then add 5ul G7 reaction buffer, 5ul 10% NP40, 15ul water and 5ul 
deglycosylation enzyme cocktail and mix gently. Incubate the reaction at 37 °C 
for 4 hours and 8 hours. Store the treated samples at -80°C.   
4.3.4 Chemical Deglycosylation with Trifluoromethanesulfonic Acid (TFMS) 
The salt free and lyophilized B16F10 cell lysate was prepared. Add 150ul 
pre-cooled TFMS into the 1mg lyophilized cell lysate. Gently shake the sample to 
dissolve the lysate. Incubate the sample on ice for 25 minutes. Then add pre-
cooled 60% Pyridine Solution drop by drop up to the 300ul. Check the pH with 
pH paper until it reachs around 6. Use the desalt column to remove the TFMS 
salt. Store the samples at -80°C. 
4.4 Discussion 
Genome instability is a fundamental hallmark of the molecular 
alternations of the tumor. It could drive the tumor initiation and progression [106]. 
Mutations of the genes involved in genome integrity increase the risk of the 
cancer. For example, mutation of the mismatch repair gene hMSH2 is related with 
colon cancer. People with the inherited mutation of hMSH2 gene have a high risk 
of the colorectal cancer because of the microsatellite instability [230, 231].  
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SMC1A gene has multiple important functions to maintain genome 
integrity.  The deficiency of SMC1A in tumors was observed in pancreatic cancer 
by genetic mutation and in AML patients by decreasing protein expression. Both 
the mutations and knock-down of the WT SMC1A could induce spontaneous 
genetic instability [210, 227]. These previous studies indicate that SMC1A could 
be involved in tumor initiation and progression. However, the genetic mutations 
of SMC1A are rarely identified in different cancers [232]. Most identified 
SMC1A mutations in cancer were mis-sense mutations, which still could keep 
some the primary function of SMC1A [225]. Missense mutations and small in-
frame deletions were also identified in CdLS, a developmental disorder. A severe 
mutation of SMC1A could reduce the fitness of the cell and even cause cell death 
[210, 211]. This may be the major cause of low frequency mutations of SMC1A 
identified in tumors. There was also no published evidence about the low SMC1A 
expression in tumors based on mRNA quantification. This indicated that the 
deficiency of SMC1A in tumor cells, such as lower SMC1A protein detection in 
AML patients, may be caused by some other pathway than genetic mutations.  
Our findings in this study suggested that the deficiency of the SMC1A 
RNA in tumor cells is mainly caused by the mis-regulated splicing and this is 
common in different type of tumors. The mis-regulated splicing in cancers has 
been well documented. Splicing errors promote tumorigenicity either by splicing 
an isoform with oncogenetic activity or by simply decreasing the tumor 
suppressor isoform through consuming the pre-mRNA with nonfunctional 
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isoforms, or both [200, 208]. We found that there was mis-regulated splicing of 
the SMC1A in different tumor cells. Different splicing isoforms of the entire 
SMC1A were detected in tumor cells. Most of them were in frame deletions, 
which could encode proteins with residual functions and affect the WT protein 
function or even have negative functions.  
We also found a unique FS isoform in different tumors. This was caused 
by exon2 and exon3 skipping. The SMC1A FS isoform and its relative WT 
isoform were deeply studied. I found that the FS isoform was frequently increased 
in pancreatic tumors, while the relative WT isoform was frequently decreased. 
The increasing of the FS isoform was also detected in multiple tumor types. This 
was the first evidence of decreasing SMC1A WT mRNA isoform in tumor cells 
and this may be due to splice switching to the SMC1A FS isoform. There have 
been no other studies that have shown the decrease of SMC1A mRNA in tumors 
[226]. And there was no correlation found between SMC1A mRNA levels, and 
the lower SMC1A protein level. This may be caused by using different target 
fragments of the SMC1A mRNA for quantification.  
It has been published that the deficiency of the SMC1A, either caused by 
mutation or siRNA treatment, could spontaneously induce the genetic instability 
and aneuploidy of normal cells [227]. There was no direct evidence of the 
correlation between the deficiency of the SMC1A and tumor development. The 
transient SMC1A knock down by siRNA did not efficiently induce tumorigenicity 
in HPED6 cells, which was consistent with the previously published study. 
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However, the stable SMC1A knock down in BALB-3T3 cells successfully 
induced significant tumorigenicity. This was the first evidence that directly 
showed tumor initiation by deficiency of SMC1A. Our previous study looking at 
the different stages of tumor development in FVB/N-NeuT, demonstrated that the 
mis-regulated splicing of SMC1A happened at early stages of tumor development 
along with the expression of the tumor driven gene, Rat Her2. All of our findings 
indicate that the constant deficiency of SMC1A by mis-regulated splicing 
promotes the initiation and progression of different type of tumors.   
The increase of SMC1A FS isoform was detected in multiple tumors. This 
FS transcript contains a PTC, and is a classical target of the NMD. The selective 
protection of this FS isoform from the NMD indicates this FS isoform may have 
unique functions to promote tumor development, aside from the side product of 
the mis-regulated splicing. It was interesting that the truncated protein encoded by 
the SMC1A FS isoform was detected in both normal tissues and tumors and was 
sumoylated with SUMO2/3 by WB analysis. The IHC assay and IF assay with the 
anti SMC1A FS peptide antiserum also showed the expression of the truncated 
protein in tumor and normal cells. These two assays also revealed that most of the 
truncated protein was located at the nucleolus of both tumor and normal cells. The 
SUMOylation has a variety functions for protein stability maintenance, protein 
cellular localization and transcription [233, 234]. The SUMOylation of the target 
could stabilize the protein by preventing the ubiquitination [235]. That may cause 
the accumulation of the SMC1A truncated protein in normal cells, although the 
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transcript level of the FS isoform are low in normal cells. The SUMOylation also 
could regulate protein cellular localization [236, 237]. Both mammalian SUMO2 
and SUMO3 were detected at the cell nucleolus, where the SMC1A truncated 
protein localized. This indicates that the SMC1A truncated proteins are stabilized 
and localized at the nucleolus by SUMOylation. The evolutionary analysis of the 
exon4-fs showed that the FS peptide encoded by this fragment is highly conserved 
across five eukaryote species. This indicates that the SMC1A FS truncated protein 
may have cellular function in normal cells. 
In summary, this study supports the concept that the WT SMC1A acts as a 
tumor suppressor gene, and also suggests that SMC1A FS isoforms are expressed 
and produce their effects within the cell nucleolus. The mis-regulated SMC1A FS 
isoform is common in a variety of cancer types and could have oncogenetic 
function to promote tumor development. However, further characterization of 
both WT and FS isoforms is still necessary to provide solid evidence of the 
isoforms’ function in tumor development.   
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CHAPTER 5  
SUMMARY 
Cancer is one of the most serious global diseases that affects human 
society in both health and economy. Although we have achieved dramatic 
developments against cancer over the last hundreds years, we still can not 
efficiently control this disease. The development in cancer prevention, especially 
in the cancer immunoprevention, has shown this is the most cost-effective long 
term aspect for global cancer control. However, research on cancer 
immunotherapy needs much more efforts to further develop.  
Our center has focused on cancer immunoprevention for years. In this 
thesis I described our systematic strategy for general cancer prevention through 
variety of immunological methods.  
Prophylactic primary and metastatic cancer vaccines based on the tumor 
specific and related FS antigens is one of the most important concepts we 
developed for the cancer immuneprevention. The goal of this concept is to 
develop a general cancer vaccine that could prevent healthy people from 
developing different types of cancer. Our center has identified a list of tumor 
specific and related FS antigens that are frequently presented in different human 
cancers and mouse tumor models. In silica analysis demonstrated that the list of 
the FS antigens is sufficient to cover major cancer types and most HLA types in 
the population (Lee and Johnston, in preparation).  I tested the concept with FS 
antigens in a variety of mouse tumor models, including transplant mouse tumor 
 
182
models: 4T1/BALC/c and B16F10/C57BL6; and transgenic mouse tumor models: 
BALB-NeuT and FVB/N-NeuT. Although there is no qualified epitope base on 
the in silica prediction of these FS antigens, the prophylactic cancer vaccines with 
different FS antigens, especially the SMC1A FS antigen, have shown significant 
inhibition of the development primary tumors in all of four mouse models, and it 
also has shown the potential to inhibit the tumor metastasis incidence in the 
4T1/BALB/c model.  
The concept of innate stimulation to prevent tumor onset adds another 
layer of the cancer immunoprevention. The clinical applications of this concept 
have been tried for years; however it has been limited by use of poorly defined 
components or the toxicity. I tested this concept with a viral immune modulator 
B2L, which was identified in our Center recently [162]. Compared with the 
control group and the group vaccinated with a known immune adjuvant CpG and 
GMCSF, the vaccination of B2L significantly inhibited tumor development in the 
BALB-NeuT model. All of the B2L treated mice behaved the same as other two 
groups and did not showed severe side affects. The significant efficacy of the B2L 
vaccination in tumor inhibition suggests the promise of the innate stimulation for 
the cancer prevention by identifying more components in future investigations.  
Besides the immunoprevention, early cancer detection is also an important 
component in our systematic strategy of cancer prevention. Based on the studies 
of the tumor related FS antigen, SMC1A FS peptide, I discovered two types of 
cancer biomarkers: circulating FS transcripts and FS specific antibody. I also 
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developed two unique methods to improve the sensitivity and specificity of these 
two biomarkers.  
The SMC1A FS transcript was frequently increased in the tumor cells by 
abnormal splicing. Using regular RT-PCR with the flanking primers, both WT 
and FS transcripts of SMC1A could be amplified and detected from the plasma of 
tumor bearing mice, while only the WT transcript was detected from plasma of 
the non-tumor bearing mice. Based on the electrophoresis analysis of the PCR 
products, the intensity ratio of the FS verses the WT was significantly correlated 
with the tumor size in the 4T1/BALB/c mouse tumor models. This indicated that 
the ratio of the two splicing isoforms not only could be used for early cancer 
detection, but also could be a unique biomarker for tumor progression. All kinds 
of tumor related alternative splicings with similar patterns are suitable for this 
unique detection method, including those tumor related FS splicings and in frame 
splicings. The ratio of the two splicing isoforms was amplified both in vivo and in 
vitro because of the size difference; therefore this method is more sensitive than 
other detection methods for cNA biomarkers. This detection method does not 
need an extra reference for quantification; therefore it is more robust and simple 
for large cancer screen.  
The SMC1A FS antibody was detected by a set of mimotopes of SMC1A 
FS peptide. The epitope of the original SMC1A FS peptide was represented by a 
set of mimotopes on the peptide array. The sensitivity of the FS antibody 
detection was increased about 50 fold by using the set of the mimotopes. The 
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positive rate of the SMC1A FS antibody was 53.8% and 56.5% in breast cancer 
patients and pancreas cancer patients respectively. This was about 2 fold higher 
than currently reported positive rates of a single cancer related auto-antibody, 
such as anti-P53 auto-antibody, in cancer patients. The high sensitivity of SMC1A 
FS antibody detection is mainly contributed by efficient epitopes representation 
with the mimotopes. This method of using mimotopes could increase the 
detection sensitivity of all current antibody biomarkers of different diseases.  
Based on the antibody biomarker, I also developed a concept of novel 
diagnosis for immune response based biomarkers; we name the “amplified 
diagnosis”. The concept is straightforward: set up efficient memory immune 
response to disease specific antigens in disease free people through immunization. 
The adaptive memory immune response is more sensitive and reactive than the 
endogenous immune response to the exposure of the disease specific antigens. 
Therefore the immune response based biomarkers can be efficiently detected even 
by current detection methods.  
Cancer is a complex and systematic disease. Efficient cancer control can 
not be accomplished by a simple method. The different concepts we developed 
are focused on tumor specific and related FS antigens. However, these strategies 
are also suitable for some of current tumor antigens and other related diseases. 
Based on different concepts I described in this thesis, we developed a systematic 
strategy of cancer immunoprevention: apply the innate stimulation and 
prophylactic cancer vaccine to generally prevent the tumor onset; apply the 
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amplified immune diagnosis and circulating RNA detection to early detect 
specific cancers for different early cancer treatment. Further development of this 
systematic strategy should make an important contribution to global cancer 
control.  
Besides the development of applications for cancer control, my 
investigation of SMC1A also indicated that the wild type SMC1A may be down 
regulated in tumor cells by mis-regulated splicing which could induce the 
tumorigenicity of normal cells. On the other hand, the SMC1A FS truncated 
protein may be SUMOylated and accumulated in nucleolus of normal cells. Mis-
regulated SUMOylated SMC1AFS protein may cause tumorigenicity in normal 
cells as well.  Therefore, mis-regulation of both WT SMC1A and FS SMC1A 
may be the one of the early events of the process of normal cell transformation. 
Further investigation is necessary to confirm the hypothesis.        
In summary, this thesis discussed the developments and tests of different 
concepts in cancer immunoprevention. And this thesis also suggested the tumor 
related FS antigens are a non-fully explored field which has important value for 
both translational and basic research of cancer control.  
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APPENDIX 1 
FS ANTIGEN DISCOVERY BY PROTEOMICS ANALYSIS 
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We are focusing on FS antigens for a prophylactic cancer vaccine. To 
discover tumor specific and related FS antigens, we systematically used 
bioinformatics, genetics, proteomics approaches to screen different tumor cells. 
Lee et.al. has described the strategy of using bioinformatics analysis to discover 
FS antigens (Lee and Johnston, in preparation). We also tried to use proteomics 
analysis to directly identify tumor related FS antigens from tumor cell surface and 
chaperone-rich cell lysate (CRCL).  
The major function of molecular chaperones is in preventing protein 
aggregation. People also found that, in the case of cellular stress, chaperone 
proteins can recognize and bind to non-native structured proteins [239]. It has 
been shown that the CRCL purified from the 12BL tumor cell, a BCR-ABL+ 
mouse leukemia cell line, could induce anti-tumor immune response in mouse and 
inhibit tumor growth [240]. Since the FS antigens we focused on are not correctly 
folded, truncated proteins and could accumulate in tumor cells, we hypothesized 
that CRCL could enrich the tumor related FS antigens and those antigens are 
potential candidates for a prophylactic cancer vaccine.  
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To identify the FS peptide in CRCL from 12B1 cell (CRCL and 12B1 
cells were offered by Dr. Emmanuel Katsanis, University of Arizona), we used 
acid to dissociate the protein interactions and enriched the small peptides through 
10KD or 3KD filters. The peptides fractions were analyzed by liquid 
chromatography-mass spectrometry. The potential FS peptides were identified by 
analyzing the MS data with our FS peptides database. A total 11 FS peptides were 
identified from CRCL of 12B1 (Johnston, Lake and Antwi, unpublished data).  
I analyzed the potential T cell epitopes of list of FS peptides. Three of 
them have predicted T cell epitopes (Table AP1-1). These three FS peptides 
encoding sequences were constructed into pCMIVi-US and pCMVi-LS to test if 
they could inhibit the 12B1 tumor growth. Immunization of the pooled FS 
antigens showed the potential tumor inhibition in 12B1/BALB/c mouse tumor 
model (Figure AP1.1). However, both antibody and T cell response were 
undetectable in these mice. The genetic immunization methods and adjuvant were 
not optimized at the time I tested these three FS antigens. Further experiments 
with optimized immunization are necessary to verify the anti-tumor efficacy of 
these three FS antigens.  
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I did not detect the transcripts corresponding to these three FS peptide in 
12B1 cells. As I discussed in chapter 2, these FS transcripts may be degraded by 
NMD. Inhibition of NMD in 12B1 cell can increase the possibility to detect these 
FS transcripts. Analysis the specific immune response to these FS peptides in 
mice immunized with CRCL of 12B1 cell also can confirm the exhibition of these 
FS peptides in 12B1 cells.  
This experiment demonstrated the potential value of using proteomics 
analysis to screen the tumor FS antigens.  
 
 
 
           
Table AP1. 1 FS peptides identify from LC/MS analysis of CRLC of 12B1 
cell. (By Johnston, Lake and Antwi) 
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Table AP1. 2 T cell epitope prediction of three FS peptides 
 
 
 
Figure AP1. 1 Protection analysis in 12B1/BALB/c mouse model. A. 
Experimental plan. 5x103 12B1 were inoculated into four to five weeks old 
BALB/C mice. The 12B1 group (n=15) was immunized with three pooled FS 
antigens; the HPV group (n=12) was immunized with HPV225a generated in our 
Center as the negative control). B. Tumor growth curve. Tumor sizes were 
measured daily after detecting palpable tumors. The data represents three 
individal experiments. *: t-test P<0.01   
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APPENDIX 2 
RT-PCR ANALYSIS OF FS TRANSCRIPTS 
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Figure AP2. 1 RT-PCR screen SMC1A FS transcript in human tumor cell 
lines. 33 human breast tumor cell lines and non-tumorigenitic epithelial cell line 
MCF-10A and normal pancreatic epithelial cell line HPDE6. The experiment was 
performed by Dr. Buendia Jose Cano, CIM.   
 
 
 
Figure AP2. 2  RT-PCR detection SMC1A FS transcript in normal BALB/C 
splenocytes. Splenocytes were separated by mouse CD8+ T cell enrichment kit 
(Stemcell Technologies Inc, Vancouver, Canada). 1. CD8+ splenocytes; 2. CD8- 
splenocytes; 3. B16F10 melanoma cell. 
 
smc1a WT
smc1a FS
b-actin
1 MDA-MB-468 6 HCC1395 11 HCC70 16 HCC1937 21 MB157 26 ZR-75-1 31 Hs 605.T
2 SW 527 7 MDA-MB-453 12 UACC-893 17 HCC1428 22 Hs739.T 27 HS-362.T 32 BT474
3 HS 606T 8 HCC 1143 13 AU565 18 MCF-7 23 DU4475 28 BT-20 33 Hs 343.T
4 HCC1187 9 M4A4 14 HCC 1954 19 Hs-578.T 24 MDA-MB-231 29 HCC 2218 34 MCF-10-A
5 HCC1806 10 HCC1419 15 ZR-75-30 20 HCC1500 25 Cama-1 30 HCC 1599 35 HPDE6
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35
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Figure AP2. 3  RT-PCR detection of SMC1A, 6-21 and 1-78 FS transcripts in 
four dog melanoma cDNAs.   
 
 
Figure AP2. 4 RT-PCR screen 6-21 FS transcript in C57BL6 mouse normal 
and B16F10 melanoma cell 
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Figure AP2. 5  RT-PCR screen 6-21 and 1-78 FS transcript in spontaneous 
breast tumors from FVB/N-NeuT mice. 
 
 
Figure AP2. 6  RT-PCR detection of 6-21 transcript in human breast tumors 
tumor cell lines and MCF-10A cell   
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Figure AP2. 7  RT-PCR detection of 6-21 transcript in human primary 
breast tumors tumors and normal mammary tissues. 1-8: primary breast 
tumor cDNA, 9 and 10: normal mammary cDNA. 
 
 
 
Figure AP2. 8 RT-PCR detection of 6-21 FS transcript in dog tumor cDNAs 
and normal tissues. A. Detection of 6-21 FS transcripts in dog tumor cDNAs. 1: 
Melanoma; 2: Osteosarcoma; 3. Lymphosarcoma; 4: Hemangiosarcoma; 5: Breast 
tumor; 6: Mast Cell Tumor; 7: Transitional cell carcinoma; 8: Thyroid 
adenocarcinoma. B. Detection of 6-21 FS transcripts in dog normal tissues.  
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APPENDIX 3 
INSTITUTIONAL REVIEW BOARD (IRB) 
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APPENDIX 4 
INSTITUTIONAL ANIMAL CARE & USE COMMITTEE 
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